# EDGAR Filing Document

**Accession Number:** 0001679363
**File Stem:** 0001104659-23-019132
**Filing Date:** 2023-2
**Character Count:** 296845
**Document Hash:** 2bc1cdaaa181cb4a079746e767ba2871
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-23-019132.hdr.sgml**: 20230213

**ACCESSION NUMBER**: 0001104659-23-019132

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20230212

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Unregistered Sales of Equity Securities

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230213

**DATE AS OF CHANGE**: 20230213

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Morphic Holding, Inc.
- **CENTRAL INDEX KEY:** 0001679363
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 473878772
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38940
- **FILM NUMBER:** 23615047

**BUSINESS ADDRESS:**
- **STREET 1:** 35 GATEHOUSE DRIVE A2
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 9787296480

**MAIL ADDRESS:**
- **STREET 1:** 35 GATEHOUSE DRIVE A2
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Morphic Holding, LLC
- **DATE OF NAME CHANGE:** 20160712

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 12, 2023**

**Morphic Holding, Inc.**

**(Exact Name of Registrant as Specified in its Charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38940** | **47-3878772** |
| **(State or other jurisdiction of** | **(Commission** | **(I.R.S. Employer** |
| **incorporation or organization)** | **File Number)** | **Identification No.)** |

---

---

| | |
|:---|:---|
| **35 Gatehouse Drive, A2<br> Waltham, Massachusetts** | **02451** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (781) 996-0955**

**Not Applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

◻ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

◻ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

◻ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

◻ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading<br> Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.0001 par value per share | MORF | Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ◻

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

**Item 1.01 Entry into a Material Definitive Agreement** 

*Securities Purchase Agreement*

On February 13, 2023, Morphic Holding, Inc., a Delaware corporation (the "Company"), entered into a securities purchase agreement (the "Securities Purchase Agreement") with certain investors listed on the signature pages thereto (the "Investors"), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the "Private Placement") an aggregate of (i) 848,655 shares (the "Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock"), at a purchase price of $35.35 per share and (ii) 1,980,198 pre-funded warrants (the "Pre-Funded Warrants") to purchase up to an aggregate of 1,980,198 shares of Common Stock (the "Warrant Shares" and, together with the Shares and the Pre-Funded Warrants, the "Securities") at a purchase price of $35.3499 per Pre-Funded Warrant. Each Pre-Funded Warrant has an exercise price of $0.0001 per Warrant Share. The Pre-Funded Warrants are exercisable at any time after their original issuance and will not expire.

The Private Placement is anticipated to close on or about February 15, 2023, subject to the satisfaction of customary closing conditions. The Company anticipates receiving gross proceeds from the Private Placement of approximately $100.0 million, before deducting costs and expenses. The Company intends to use the net proceeds from the Private Placement for working capital general corporate purposes, including clinical development.

The Pre-Funded Warrants to be issued in the Private Placement will provide that the holder of the Pre-Funded Warrants will not have the right to exercise any portion of its Pre-Funded Warrants if such holder, together with its affiliates, would beneficially own in excess of 9.99% of the number of shares of the Company's Common Stock outstanding immediately after giving effect to such exercise (the "Beneficial Ownership Limitation").

The foregoing descriptions of the Securities Purchase Agreement and Pre-Funded Warrants do not purport to be complete and are qualified in their entirety by reference to the full text of such agreements, which are filed as Exhibit 10.1 and 4.01, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

*Registration Rights Agreement*

In connection with the Private Placement, the Company and the Investors also entered into a Registration Rights Agreement, dated as of February 13, 2023 (the "Registration Rights Agreement"), providing for the registration for resale of the Shares and the Warrant Shares (the "Registerable Securities"). The Company has agreed to prepare and file a registration statement (the "Registration Statement") with the Securities and Exchange Commission (the "SEC") promptly, and in any event within 30 days of the closing of the Private Placement, and to use commercially reasonable efforts to have the Registration Statement declared effective within 30 days (provided that if the Registration Statement is an automatically effective shelf registration statement, or a prospectus supplement to an automatically effective shelf registration statement, it shall become effective upon filing with the SEC pursuant to Rule 462(e)) of the Securities Act of 1933, as amended (the "Securities Act").

The Company has granted the Investors customary indemnification rights in connection with the Registration Rights Agreement. The Investors have also granted the Company customary indemnification rights in connection with the Registration Statement.

The foregoing description of the Registration Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of such agreement, which is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated by reference herein.

**Item 3.02 Unregistered Sales of Equity Securities** 

The information contained above under Item 1.01, to the extent required by Item 3.02 of Form 8-K, is hereby incorporated by reference herein. Based in part upon the representations of the Investors in the Securities Purchase Agreement, the offering and sale of the Securities was made in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D under the Securities Act and corresponding provisions of state securities or "blue sky" laws. The Securities have not been registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements. The sale of the Securities did not involve a public offering and was made without general solicitation or general advertising. The Investors represented that they are accredited investors, as such term is defined in Rule 501(a) of Regulation D under the Securities Act, and that they are acquiring the securities for investment purposes only and not with a view to any resale, distribution or other disposition of the securities in violation of the U.S. federal securities laws.

Neither this Current Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy shares of Common Stock or other securities of the Company

**Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year**

On February 12, 2023, in connection with the effectiveness of new SEC rules regarding universal proxy cards, certain recent changes to the Delaware General Corporation Law (the "DGCL"), and a periodic review of the bylaws of the Company, the Company's board of directors (the "Board") approved and adopted the Company's amended and restated bylaws (the "Amended and Restated Bylaws"), which became immediately effective.

Among other things, the amendments effected by the Amended and Restated Bylaws:

&nbsp;&nbsp;&nbsp;&nbsp;· revise certain provisions relating to adjournment procedures and lists of stockholders entitled to vote at stockholder meetings, in
each case to conform to recent amendments to the DGCL;

· update certain provisions related to the conduct of stockholder meetings, including clarifying that the presiding person of a stockholder
meeting may set additional attendance or other procedures for meeting attendees and Rule 14a-8 proponents;

· revise the procedures and disclosure requirements set forth in the advance notice bylaw provisions, including (1) requiring additional
information, representations and disclosures from proposing stockholders, proposed nominees and other persons related to a stockholder's
solicitation of proxies, (2) restricting the number of nominees a stockholder may nominate for election at a meeting to the number of
directors to be elected at such meeting, (3) requiring that proposed nominees be available for interviews by the Board or any Board committee
thereof;

· address matters relating to Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the "Universal Proxy Rules")
(e.g., providing that stockholders delivering a notice of nomination certify to the Company in writing that they have complied with the
Universal Proxy Rules requirements, providing the Company a remedy if a stockholder fails to satisfy the Universal Proxy Rules requirements,
requiring that a stockholder providing notice pursuant to the advance notice bylaws to inform the Company if a stockholder no longer plans
to solicit proxies in accordance with the Universal Proxy Rules, and requiring stockholders intending to use the Universal Proxy Rules
to provide reasonable evidence of the satisfaction of the requirements under the Universal Proxy Rules at least five business days before
the meeting, etc.);

· require that a stockholder directly or indirectly soliciting proxies from other stockholders use a proxy card color other than white;

&nbsp;&nbsp;&nbsp;&nbsp;· require that a stockholder intending to authorize a qualified representative to act for such stockholder as a proxy to present a nomination
or proposal at such meeting to give notice of such authorization to the Company at least three business days before the applicable meeting;

· amend the notice provisions to reflect amendments to the DGCL relating to electronic transmission of notices to stockholders; and

· add an emergency bylaw provision to provide clarity and authority to directors and certain officers during an emergency situation
that would otherwise prevent a quorum of the Board or a Board committee from being achieved.

The Amended and Restated Bylaws also incorporate ministerial, clarifying and conforming changes, including changes to align with the language used in certain provisions of the DGCL and the Universal Proxy Rules.

The foregoing summary does not purport to be complete and is qualified in its entirety by reference to the full text of the Amended and Restated Bylaws, a copy of which is attached hereto as Exhibit 3.1 and is incorporated herein by reference.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

(d) Exhibits:

---

| | |
|:---|:---|
| **Exhibit<br> No.** | **Description** |
| [3.1](tm236505d1_ex3-1.htm) | [Amended and Restated Bylaws of Morphic Holding, Inc. (as amended and restated on February 12, 2023)](tm236505d1_ex3-1.htm) |
| [4.1](tm236505d1_ex4-1.htm) | [Form of Pre-Funded Warrant](tm236505d1_ex4-1.htm) |
| [10.1\*](tm236505d1_ex10-1.htm) | [Securities Purchase Agreement, dated February 13, 2023, by and among Morphic Holding, Inc. and the investors listed on the signature pages thereto](tm236505d1_ex10-1.htm) |
| [10.2](tm236505d1_ex10-2.htm) | [Registration Rights Agreement, dated February 13, 2023, by and among Morphic Holding, Inc. and the investors listed on the signature pages thereto](tm236505d1_ex10-2.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

\* Schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule and/or exhibit will be furnished to the SEC upon request.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **MORPHIC HOLDING, INC.** | **MORPHIC HOLDING, INC.** |
| Date: February 13, 2023 | By: | /s/ Marc Schegerin |
|  |  | Marc Schegerin, M.D. |
|  |  | Chief Financial Officer and Chief Operating Officer |

---

## Exhibit 3.1

**Exhibit 3.1**

------

**MORPHIC HOLDING, INC.**

(a Delaware corporation)

**AMENDED AND RESTATED BYLAWS**

As Amended and Restated on February 12, 2023

------

**MORPHIC HOLDING, INC.**

(a Delaware corporation)

**AMENDED AND RESTATED BYLAWS**

**TABLE OF CONTENTS**

---

| | | |
|:---|:---|:---|
| **<u>Article I:</u>** STOCKHOLDERS | **<u>Article I:</u>** STOCKHOLDERS | 1 |
| &nbsp;&nbsp;**Section 1.1:** | <u>Annual Meetings</u> | 1 |
| &nbsp;&nbsp;**Section 1.2:** | <u>Special Meetings</u> | 1 |
| &nbsp;&nbsp;**Section 1.3:** | <u>Notice of Meetings</u> | 1 |
| &nbsp;&nbsp;**Section 1.4:** | <u>Adjournments</u> | 1 |
| &nbsp;&nbsp;**Section 1.5:** | <u>Quorum</u> | 2 |
| &nbsp;&nbsp;**Section 1.6:** | <u>Organization</u> | 2 |
| &nbsp;&nbsp;**Section 1.7:** | <u>Voting; Proxies</u> | 2 |
| &nbsp;&nbsp;**Section 1.8:** | <u>Fixing Date for Determination of Stockholders of Record</u> | 2 |
| &nbsp;&nbsp;**Section 1.9:** | <u>List of Stockholders Entitled to Vote</u> | 3 |
| &nbsp;&nbsp;**Section 1.10:** | <u>Inspectors of Elections</u> | 3 |
| &nbsp;&nbsp;**Section 1.11:** | <u>Notice of Stockholder Business; Nominations.</u> | 4 |
| &nbsp;&nbsp;**Section 1.12** | <u>Emergency Bylaws</u> | 7 |
| **<u>Article II:</u>** BOARD OF DIRECTORS | **<u>Article II:</u>** BOARD OF DIRECTORS | 8 |
| &nbsp;&nbsp;**Section 2.1:** | <u>Number; Qualifications</u> | 8 |
| &nbsp;&nbsp;**Section 2.2:** | <u>Election; Resignation; Removal; Vacancies</u> | 8 |
| &nbsp;&nbsp;**Section 2.3:** | <u>Regular Meetings</u> | 8 |
| &nbsp;&nbsp;**Section 2.4:** | <u>Special Meetings</u> | 8 |
| &nbsp;&nbsp;**Section 2.5:** | <u>Remote Meetings Permitted</u> | 8 |
| &nbsp;&nbsp;**Section 2.6:** | <u>Quorum; Vote Required for Action</u> | 9 |
| &nbsp;&nbsp;**Section 2.7:** | <u>Organization</u> | 9 |
| &nbsp;&nbsp;**Section 2.8:** | <u>Unanimous Action by Directors in Lieu of a Meeting</u> | 9 |
| &nbsp;&nbsp;**Section 2.9:** | <u>Powers</u> | 9 |
| &nbsp;&nbsp;**Section 2.10:** | <u>Compensation of Directors</u> | 9 |
| **<u>Article III:</u>** COMMITTEES | **<u>Article III:</u>** COMMITTEES | 9 |
| &nbsp;&nbsp;**Section 3.1:** | <u>Committees</u> | 9 |
| &nbsp;&nbsp;**Section 3.2:** | <u>Committee Rules</u> | 10 |
| **<u>Article IV:</u>** OFFICERS; CHAIRPERSON; LEAD INDEPENDENT DIRECTOR | **<u>Article IV:</u>** OFFICERS; CHAIRPERSON; LEAD INDEPENDENT DIRECTOR | 10 |
| &nbsp;&nbsp;**Section 4.1:** | <u>Generally</u> | 10 |
| &nbsp;&nbsp;**Section 4.2:** | <u>Chief Executive Officer</u> | 10 |
| &nbsp;&nbsp;**Section 4.3:** | <u>Chairperson of the Board</u> | 11 |
| &nbsp;&nbsp;**Section 4.4:** | <u>Lead Independent Director</u> | 11 |
| &nbsp;&nbsp;**Section 4.5:** | <u>President</u> | 11 |
| &nbsp;&nbsp;**Section 4.6:** | <u>Chief Financial Officer</u> | 11 |
| &nbsp;&nbsp;**Section 4.7:** | <u>Treasurer</u> | 11 |
| &nbsp;&nbsp;**Section 4.8:** | <u>Vice President</u> | 12 |
| &nbsp;&nbsp;**Section 4.9:** | <u>Secretary</u> | 12 |
| &nbsp;&nbsp;**Section 4.10:** | <u>Delegation of Authority</u> | 12 |
| &nbsp;&nbsp;**Section 4.11:** | <u>Removal</u> | 12 |
| **<u>Article V:</u>** STOCK | **<u>Article V:</u>** STOCK | 12 |
| &nbsp;&nbsp;**Section 5.1:** | <u>Certificates</u> | 12 |
| &nbsp;&nbsp;**Section 5.2:** | <u>Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificates or Uncertificated Shares</u> | 12 |
| &nbsp;&nbsp;**Section 5.3:** | <u>Other Regulations</u> | 12 |

---

---

| | | |
|:---|:---|:---|
| **<u>Article VI:</u>** INDEMNIFICATION | **<u>Article VI:</u>** INDEMNIFICATION | 13.0 |
| &nbsp;&nbsp;**Section 6.1:** | <u>Indemnification of Officers and Directors</u> | 13.0 |
| &nbsp;&nbsp;**Section 6.2:** | <u>Advancement of Expenses</u> | 13.0 |
| &nbsp;&nbsp;**Section 6.3:** | <u>Non-Exclusivity of Rights</u> | 13.0 |
| &nbsp;&nbsp;**Section 6.4:** | <u>Indemnification Contracts</u> | 14.0 |
| &nbsp;&nbsp;**Section 6.5:** | <u>Right of Indemnitee to Bring Suit</u> | 14.0 |
| &nbsp;&nbsp;**Section 6.6:** | <u>Nature of Rights</u> | 14.0 |
| &nbsp;&nbsp;**Section 6.7:** | <u>Insurance</u> | 14.0 |
| &nbsp;&nbsp;**Section 6.8:** | <u>Indemnification for Successful Defense</u> | 15.0 |
| **<u>Article VII:</u>** NOTICES | **<u>Article VII:</u>** NOTICES | 15.0 |
| &nbsp;&nbsp;**Section 7.1:** | <u>Notice</u> | 15.0 |
| &nbsp;&nbsp;**Section 7.2:** | <u>Waiver of Notice</u> | 15.0 |
| **<u>Article VIII:</u>** INTERESTED DIRECTORS | **<u>Article VIII:</u>** INTERESTED DIRECTORS | 15.0 |
| &nbsp;&nbsp;**Section 8.1:** | <u>Interested Directors</u> | 15.0 |
| &nbsp;&nbsp;**Section 8.2:** | <u>Quorum</u> | 16.0 |
| **<u>Article IX:</u>** MISCELLANEOUS | **<u>Article IX:</u>** MISCELLANEOUS | 16.0 |
| &nbsp;&nbsp;**Section 9.1:** | <u>Fiscal Year</u> | 16.0 |
| &nbsp;&nbsp;**Section 9.2:** | <u>Seal</u> | 16.0 |
| &nbsp;&nbsp;**Section 9.3:** | <u>Form of Records</u> | 16.0 |
| &nbsp;&nbsp;**Section 9.4:** | <u>Reliance upon Books, Records and Experts</u> | 16.0 |
| &nbsp;&nbsp;**Section 9.5:** | <u>Certificate of Incorporation Governs</u> | 16.0 |
| &nbsp;&nbsp;**Section 9.6:** | <u>Severability</u> | 16.0 |
| &nbsp;&nbsp;**Section 9.7:** | <u>Time Periods</u> | 17.0 |
| **<u>Article X:</u>** AMENDMENT | **<u>Article X:</u>** AMENDMENT | 17.0 |
| <br> **<u>Article XI:</u>** EXCLUSIVE FORUM | <br> **<u>Article XI:</u>** EXCLUSIVE FORUM | 17.0 |

---

**MORPHIC HOLDING, INC.**

(a Delaware corporation)

**AMENDED AND RESTATED BYLAWS**

As Adopted February 12, 2023 and

As Effective February 12, 2023

**ARTICLE I: STOCKHOLDERS**

**Section 1.1:** <u>Annual Meetings</u>

An annual meeting of stockholders shall be held for the election of directors at such date and time as the Board of Directors (the "***Board***") of Morphic Holding, Inc. (the "***Corporation***") shall each year fix. The meeting may be held either at a place, within or without the State of Delaware as permitted by the Delaware General Corporation Law (the "***DGCL***"), or by means of remote communication as the Board in its sole discretion may determine. Any proper business may be transacted at the annual meeting.

**Section 1.2:** <u>Special Meetings</u>

Special meetings of stockholders for any purpose or purposes may be called at any time by the Chairperson of the Board, the Chief Executive Officer, the President or the Board acting pursuant to a resolution adopted by a majority of the "***Whole Board***," which shall mean the total number of authorized directors, whether or not there exist any vacancies in previously authorized directorships. Special meetings may not be called by any other person or persons. The special meeting may be held either at a place, within or without the State of Delaware, or by means of remote communication as the Board in its sole discretion may determine. Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the notice of the meeting.

**Section 1.3:** <u>Notice of Meetings</u>

Notice of all meetings of stockholders shall be given in accordance with applicable law (including, without limitation, as set forth in Section 7.1 of these Bylaws) stating the date, time and place, if any, of the meeting and the means of remote communication, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting. In the case of a special meeting, such notice shall also set forth the purpose or purposes for which the meeting is called. Unless otherwise required by applicable law or the Restated Certificate of Incorporation of the Corporation (as the same may be amended and/or restated from time to time, the "***Certificate of Incorporation***"), notice of any meeting of stockholders shall be given not less than ten (10), nor more than sixty (60), days before the date of the meeting to each stockholder of record entitled to vote at such meeting.

**Section 1.4:** <u>Adjournments</u>

The chairperson of the meeting shall have the power to adjourn the meeting to another time, date and place (if any). Any meeting of stockholders may be adjourned from time to time (including an adjournment taken to address a technical failure to convene or continue a meeting using remote communication), and notice need not be given of any such adjourned meeting if the time, date and place (if any) thereof and the means of remote communication (if any) by which stockholders and proxy holders may be deemed to be present in person and vote at such adjourned meeting are (i) announced at the meeting at which the adjournment is taken, (ii) displayed, during the time scheduled for the meeting, on the same electronic network used to enable stockholders and proxy holders to participate in the meeting by means of remote communication or (iii) set forth in the notice of meeting given in accordance with Section 222(a) of the DGCL; *<u>provided</u>*,*<u>however</u>*, that if the adjournment is for more than thirty (30) days, or if a new record date is fixed for the adjourned meeting, then a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. At the adjourned meeting, the Corporation may transact any business that might have been transacted at the original meeting. To the fullest extent permitted by law, the Board may postpone, reschedule or cancel any previously scheduled special or annual meeting of stockholders before it is to be held, in which case notice shall be provided to the stockholders of the new date, time and place, if any, of the meeting as provided in Section 1.3 above.

**Section 1.5:** <u>Quorum</u>

At each meeting of stockholders the holders of a majority of the voting power of the shares of stock entitled to vote at the meeting, present in person or represented by proxy, shall constitute a quorum for the transaction of business, unless otherwise required by applicable law. Where a separate vote by a class or classes or series is required, a majority of the voting power of the shares of such class or classes or series present in person or represented by proxy shall constitute a quorum entitled to take action with respect to that vote on that matter. If a quorum shall fail to attend any meeting, the chairperson of the meeting or the holders of a majority of the shares entitled to vote who are present, in person or by proxy, at the meeting may adjourn the meeting.

**Section 1.6:** <u>Organization</u>

Meetings of stockholders shall be presided over by (a) such person as the Board may designate, or (b) in the absence of such a person, the Chairperson of the Board, or (c) in the absence of such person, the Lead Independent Director, or, (d) in the absence of such person, the Chief Executive Officer of the Corporation, or (e) in the absence of such person, the President of the Corporation, or (f) in the absence of such person, such person as may be chosen by the holders of a majority of the voting power of the shares entitled to vote who are present, in person or by proxy, at the meeting. Such person shall be chairperson of the meeting and, subject to Section 1.10 hereof, shall determine the order of business and the procedure at the meeting, including such regulation of the manner of voting and the conduct of discussion as seems to him or her to be in order. The Secretary of the Corporation shall act as secretary of the meeting, but in such person's absence the chairperson of the meeting may appoint any person to act as secretary of the meeting.

**Section 1.7:** <u>Voting; Proxies</u>

Each stockholder entitled to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy. Such a proxy may be prepared, transmitted and delivered in any manner permitted by applicable law. Except as may be required in the Certificate of Incorporation, directors shall be elected by a plurality of the votes cast. Unless otherwise provided by applicable law, the rules of any stock exchange upon which the Corporation's securities are listed, the Certificate of Incorporation or these Bylaws, every matter other than the election of directors shall be decided by a majority of the votes cast for or against the matter.

Any stockholder directly or indirectly soliciting proxies from other stockholders must use a proxy card color other than white, which shall be reserved for exclusive use by the Board.

**Section 1.8:** <u>Fixing Date for Determination of Stockholders of Record</u>

In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, unless otherwise required by law, the Board may fix, in advance, a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board and which shall not be more than sixty (60), nor less than ten (10), days before the date of such meeting, nor more than sixty (60) days prior to any other action. If no record date is fixed by the Board, then the record date shall be as provided by applicable law. To the fullest extent permitted by law, a determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment of the meeting; *<u>provided</u>, <u>however</u>*, that the Board may fix a new record date for the adjourned meeting.

In order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights, or entitled to exercise any rights in respect of any change, conversion or exchange of stock or for the purpose of any other lawful action, the Board may fix, in advance, a record date, which shall not precede the date upon which the resolution fixing the record date is adopted by the Board and which shall not be more than sixty (60) days prior to such action. If no such record date is fixed by the Board, then the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board adopts the resolution relating thereto.

**Section 1.9:** <u>List of Stockholders Entitled to Vote</u>

A complete list of stockholders entitled to vote at any meeting of stockholders, arranged in alphabetical order and showing the address of each stockholder and the number of shares registered in the name of each stockholder, shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10) days ending on the day prior to the meeting date, either on a reasonably accessible electronic network as permitted by law (provided that the information required to gain access to the list is provided with the notice of the meeting) or during ordinary business hours at the principal place of business of the Corporation. Nothing in this Section 1.9 shall require the Corporation to include electronic mail addresses or other electronic contact information on such list. In the event that the Corporation determines to make the list available on an electronic network, the Corporation may take reasonable steps to ensure that such information is available only to the stockholders of the Corporation. Notwithstanding the foregoing, the Corporation may maintain and authorize examination of the list of stockholders in any manner expressly permitted by the DGCL at the time.

**Section 1.10:** <u>Inspectors of Elections</u>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10.1 <u>Applicability</u>. Unless otherwise required by the Certificate of Incorporation or by the DGCL, the following provisions of this Section 1.10 shall apply only if and when the Corporation has a class of voting stock that is: (a) listed on a national securities exchange; (b) authorized for quotation on an interdealer quotation system of a registered national securities association; or (c) held of record by more than two thousand (2,000) stockholders. In all other cases, observance of the provisions of this Section 1.10 shall be optional, and at the discretion of the Board.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10.2 <u>Appointment</u>. The Corporation shall, in advance of any meeting of stockholders, appoint one or more inspectors of election to act at the meeting and make a written report thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of stockholders, the person presiding at the meeting shall appoint one or more inspectors to act at the meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10.3 <u>Inspector's Oath</u>. Each inspector of election, before entering upon the discharge of his or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the best of such inspector's ability.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10.4 <u>Duties of Inspectors</u>. At a meeting of stockholders, the inspectors of election shall (a) ascertain the number of shares outstanding and the voting power of each share, (b) determine the shares represented at a meeting and the validity of proxies and ballots, (c) count all votes and ballots, (d) determine and retain for a reasonable period of time a record of the disposition of any challenges made to any determination by the inspectors, and (e) certify their determination of the number of shares represented at the meeting, and their count of all votes and ballots. The inspectors may appoint or retain other persons or entities to assist the inspectors in the performance of the duties of the inspectors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10.5 <u>Opening and Closing of Polls</u>. The date and time of the opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting. No ballot, proxies or votes, nor any revocations thereof or changes thereto, shall be accepted by the inspectors after the closing of the polls unless the Court of Chancery of the State of Delaware upon application by a stockholder shall determine otherwise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.10.6 <u>Determinations</u>. In determining the validity and counting of proxies and ballots, the inspectors shall be limited to an examination of the proxies, any envelopes submitted with those proxies, any information provided pursuant to Section 211(a)(2)b.(i) or (iii) of the DGCL, or in accordance with Sections 211(e) or 212(c)(2) of the DGCL, ballots and the regular books and records of the Corporation, except that the inspectors may consider other reliable information for the limited purpose of reconciling proxies and ballots submitted by or on behalf of banks, brokers, their nominees or similar persons which represent more votes than the holder of a proxy is authorized by the record owner to cast or more votes than the stockholder holds of record. If the inspectors consider other reliable information for the limited purpose permitted herein, the inspectors at the time they make their certification of their determinations pursuant to this Section 1.10 shall specify the precise information considered by them, including the person or persons from whom they obtained the information, when the information was obtained, the means by which the information was obtained and the basis for the inspectors' belief that such information is accurate and reliable.

**Section 1.11: <u>Notice of Stockholder Business; Nominations.</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.11.1 <u>Annual Meeting of Stockholders</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Nominations of persons for election to the Board and the proposal of business to be considered by the stockholders shall be made at an annual meeting of stockholders (i) pursuant to the Corporation's notice of such meeting, (ii) by or at the direction of the Board or (iii) by any stockholder of the Corporation who was a stockholder of record at the time of giving of the notice provided for in this Section 1.11, who is entitled to vote at such meeting and who complies with the notice procedures set forth in this Section 1.11. For the avoidance of doubt, the foregoing clause (iii) shall be the exclusive means for a stockholder to make nominations or propose business (other than business included in the Corporation's proxy materials pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (such act, and the rules and regulations promulgated thereunder, the "***Exchange Act***")), at an annual meeting of stockholders.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) For nominations or other business to be properly brought before an annual meeting by a stockholder pursuant to Section 1.11.1(a):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the stockholder must have given timely notice thereof in writing to the Secretary of the Corporation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) such other business must otherwise be a proper matter for stockholder action;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) (A) if the stockholder, or the beneficial owner on whose behalf any such proposal or nomination is made, has provided the Corporation with a Solicitation Notice, as that term is defined in this Section, in the case of a proposal other than the nomination of persons for election to the Board, such stockholder or beneficial owner must have delivered a proxy statement and form of proxy to holders of at least the percentage of the Corporation's voting shares required under applicable law to carry any such proposal and must have included in such materials the Solicitation Notice, or (B) if the stockholder, or the beneficial owner on whose behalf any such proposal or nomination is made, has delivered a notice of nomination or nominations, such stockholder or beneficial owner must certify to the Corporation in writing, that it has complied with and will comply with the requirements of Rule 14a-19 promulgated under the Exchange Act, if applicable, and the stockholder or beneficial owner shall deliver, no later than five (5) business days prior to the annual meeting or any adjournment, rescheduling, postponement or other delay thereof, reasonable evidence that it has complied with such requirements; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) in the case of a proposal other than the nomination of persons for election to the Board, if no Solicitation Notice relating thereto has been timely provided pursuant to this Section, the stockholder or beneficial owner proposing such business must not have solicited a number of proxies sufficient to have required the delivery of such a Solicitation Notice under this Section.

To be timely, (i) a stockholder's notice must be delivered to the Secretary at the principal executive offices of the Corporation not later than the close of business on the seventy-fifth (75th) day nor earlier than the close of business on the one hundred and fifth (105th) day prior to the first anniversary of the preceding year's annual meeting; *<u>provided</u>, <u>however</u>*, that in the event that the date of the annual meeting is more than thirty (30) days before or more than sixty (60) days after such anniversary date, or if no annual meeting was held in the preceding year, notice by the stockholder to be timely must be so delivered (A) no earlier than the close of business on the one hundred and fifth (105th) day prior to currently proposed annual meeting and (B) no later than the close of business on the later of the seventy-fifth (75th) day prior to such annual meeting or the close of business on the tenth (10th) day following the day on which Public Announcement of the date of such meeting is first made by the Corporation, (ii) in the case of a proposal for the nomination of persons for election to the Board, the stockholder shall have complied in all respects with the requirements of Section 14 of the Exchange Act, including, without limitation, if applicable, the requirements of Rule 14a-19 (as such rule and regulations may be amended from time to time by the Securities and Exchange Commission, including any Securities and Exchange Commission Staff interpretations relating thereto) and (iii) in the case of a proposal for the nomination of persons for election to the Board, the Board or an executive officer designated thereby shall have determined that the stockholder has satisfied the requirements of this Section. Such stockholder's notice shall set forth:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) as to each person whom the stockholder proposes to nominate for election or reelection as a director (i) all information relating to such person that would be required to be disclosed in solicitations of proxies for election of directors, or would be otherwise required, in each case pursuant to Regulation 14A under the Exchange Act, including such person's written consent to being named as a nominee in any proxy materials relating to the Corporation's next meeting and to serving as a director if elected; (ii) a description of any position of such person as an officer or director of any Competitor (as defined below) within the three years preceding the submission of the notice; a description of any business or personal interests that could place such person in a potential conflict of interest with the Corporation or any of its subsidiaries; such other information as the Corporation may reasonably require to determine the eligibility of such proposed nominee to serve as a director of the Corporation and to determine the independence of such director under the Exchange Act and rules and regulations thereunder and applicable stock exchange rules; (y) as to any other business that the stockholder proposes to bring before the meeting, a brief description of the business desired to be brought before the meeting, the reasons for conducting such business at the meeting and any material interest in such business of such stockholder and the beneficial owner, if any, on whose behalf the proposal is made; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(z) as to the stockholder giving the notice and the beneficial owner, if any, on whose behalf the nomination or proposal is made, (aa) the name and address of such stockholder, as they appear on the Corporation's books, and of such beneficial owner, (bb) the class and number of shares of the Corporation that are owned beneficially and held of record by such stockholder and such beneficial owner, and a certification regarding whether such stockholder and beneficial owner, if any, have complied with all applicable federal, state and other legal requirements in connection with such stockholder's and beneficial owner's acquisition of shares of capital stock or other securities of the Corporation and/or such stockholder's and beneficial owner's acts or omissions as a stockholder or beneficial owner of the Corporation, (cc) a description of any agreement, arrangement or understanding with respect to the nomination or proposal between or among such stockholder and such beneficial owner, any of their respective affiliates or associates, and any others acting in concert with any of the foregoing, (dd) a description of any agreement, arrangement or understanding (including any derivative or short positions, profit interests, options, warrants, stock appreciation or similar rights, hedging transactions, and borrowed or loaned shares) that has been entered into as of the date of the stockholder's notice by, or on behalf of, such stockholder and such beneficial owners, the effect or intent of which is to mitigate loss to, manage risk or benefit of share price changes for, or increase or decrease the voting power of, such stockholder or such beneficial owner, with respect to shares of stock of the Corporation, (ee) a representation that the stockholder is a holder of record of stock of the Corporation entitled to vote at such meeting and intends to appear in person (including virtually in the case of a meeting conducted solely by means of remote communication) or by proxy at the meeting to propose such business or nomination, (ff) in the case of a proposal other than the nomination of persons for election to the Board, a representation whether either such stockholder or beneficial owner intends to deliver a proxy statement and form of proxy to holders of, in the case of a proposal, at least the percentage of the Corporation's voting shares required under applicable law to carry the proposal (an affirmative statement of such intent being a "***Solicitation Notice***"), (gg) in the case of a nomination or nominations, a representation whether either such stockholder or beneficial owner intends to solicit the holders of shares representing at least 67% of the voting power of the shares entitled to vote on the election of directors in support of director nominees other than the Corporation's nominees in accordance with Rule 14a-19, and the name of each participant (as defined in Item 4 of Exchange Act Schedule 14A) in such solicitation, and (hh) a complete and accurate description of any pending or, to such stockholder's and beneficial owner's knowledge, threatened legal proceeding in which such stockholder and beneficial owner, if any, is a party or participant involving the Corporation or, to such stockholder's and beneficial owner's knowledge, any current or former officer, director, affiliate or associate of the Corporation. If requested by the Corporation, the information required under clauses (bb), (cc) and (dd) of this subparagraph (z) shall be supplemented by such stockholder and beneficial owner, if any, not later than 10 days after the record date for the meeting to disclose such information as of the record date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Notwithstanding the foregoing, if a stockholder or beneficial owner no longer plans to solicit proxies in accordance with its representation pursuant to Section 1.11.1(b)(z)(gg), such stockholder or beneficial owner shall inform the Corporation of this change by delivering a writing to the Secretary at the principal executive offices of the Corporation no later than two (2) business days after the occurrence of such change. For the avoidance of doubt, the obligation to update as set forth in this paragraph shall not limit the Corporation's rights with respect to any deficiencies in any notice provided by a Record Stockholder, extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend or update any proposal or nomination or to submit any new proposal, including by changing or adding nominees, matters, business and/or resolutions proposed to be brought before a meeting of the stockholders. If a Record Stockholder providing written notice required by this Section 1.12 fails to provide any written update in accordance with this Section 1.12, the information as to which such written update relates may be deemed not to have been provided in accordance with these Bylaws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) If any information submitted pursuant to this Section 1.11 is inaccurate or incomplete in any material respect (as determined by the Board or a committee thereof), such information shall be deemed not to have been provided in accordance with these Bylaws. A stockholder shall notify the Secretary in writing at the principal executive offices of the Corporation of any inaccuracy or change in any information submitted within two (2) business days after becoming aware of such inaccuracy or change, and any such notification shall clearly identify the inaccuracy or change, it being understood that no such notification will cure any deficiencies or inaccuracies with respect to any prior submission by such stockholder. Upon written request of the Secretary on behalf of the Board (or a duly authorized committee thereof), the stockholder shall provide, within seven (7) business days after delivery of such request (or such longer period as may be specified in such request), (1) written verification, reasonably satisfactory to the Board, any committee thereof, or any authorized officer of the Corporation, to demonstrate the accuracy of any information submitted and (2) a written affirmation of any information submitted as of an earlier date. If the stockholder fails to provide such written verification or affirmation within such period, the information as to which written verification or affirmation was requested may be deemed not to have been provided in accordance with these Bylaws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.11.2 <u>Special Meetings of Stockholders</u>. Only such business shall be conducted at a special meeting of stockholders as shall have been brought before the meeting pursuant to the Corporation's notice of such meeting. Nominations of persons for election to the Board may be made at a special meeting of stockholders at which directors are to be elected pursuant to the Corporation's notice of such meeting (a) by or at the direction of the Board or (b) provided that the Board has determined that directors shall be elected at such meeting, by any stockholder of the Corporation who is a stockholder of record at the time of giving of notice of the special meeting, who shall be entitled to vote at the meeting and who complies with the notice procedures set forth in this Section 1.11. In the event the Corporation calls a special meeting of stockholders for the purpose of electing one or more directors to the Board, any such stockholder may nominate a person or persons (as the case may be), for election to such position(s) as specified in the Corporation's notice of meeting, if (A) the stockholder's notice required by Section 1.11.1(b) shall be delivered to the Secretary of the Corporation at the principal executive offices of the Corporation (i) no earlier than the one hundred fifth (105th) day prior to such special meeting and (ii) no later than the close of business on the later of the seventy fifth (75th) day prior to such special meeting or the tenth (10th) day following the day on which Public Announcement is first made of the date of the special meeting and of the nominees proposed by the Board to be elected at such meeting, (B) the stockholder has complied in all respects with the requirements of Section 14 of the Exchange Act, including, without limitation, if applicable, the requirements of Rule 14a-19 (as such rule and regulations may be amended from time to time by the Securities and Exchange Commission, including any Securities and Exchange Staff interpretations relating thereto) and (C) the Board or an executive officer designated thereby has determined that the stockholder has satisfied the requirements of Section 1.12. In no event shall an adjournment or, postponement or rescheduling (or the Public Announcement thereof) of a special meeting commence a new time period (or extend any time period) for providing such notice.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.11.3 <u>General</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Only such persons who are nominated in accordance with the procedures set forth in this Section 1.11 shall be eligible to serve as directors and only such business shall be conducted at a meeting of stockholders as shall have been brought before the meeting in accordance with the procedures set forth in this Section 1.11. The number of nominees a stockholder may nominate for election at a meeting of stockholders (or in the case of a stockholder giving the notice on behalf of a beneficial owner, the number of nominees a stockholder may nominate for election at the meeting on behalf of such beneficial owner) shall not exceed the number of directors to be elected at such meeting. Except as otherwise provided by law or these Bylaws, the chairperson of the meeting shall have the power and duty to determine whether a nomination or any business proposed to be brought before the meeting was made or proposed, as the case may be, in accordance with the procedures set forth in this Section 1.11 (including satisfying the information requirements set forth herein with accurate and complete information) and, if any proposed nomination or business is not in compliance herewith, to declare that such defective proposal or nomination shall be disregarded (and any such nominee shall be disqualified), including that if a stockholder provides notice pursuant to Rule 14a-19(b) promulgated under the Exchange Act and subsequently fails to comply with the requirements of Rule 14a-19(a)(2) and Rule 14a-19(a)(3) promulgated under the Exchange Act, including the provision to the Corporation of notices required thereunder in a timely manner, then the Corporation shall disregard any proxies or votes solicited for such stockholder's director nominees (and any such nominee shall be disqualified).. Notwithstanding the foregoing provisions of Section 1.11, unless otherwise required by law, no stockholder shall solicit proxies in support of director nominees other than the Corporation's nominees unless such stockholder has complied with Rule 14a-19 promulgated under the Exchange Act in connection with the solicitation of such proxies, including the provision to the Corporation of notices required thereunder in a timely manner.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Board may request that any stockholder that gives notice of a nomination, any beneficial owner on whose behalf such nomination is made and any proposed nominee thereof furnish such additional information as may be reasonably required by the Board. Such stockholder, beneficial owner and/or proposed nominee thereof shall provide such additional information within ten (10) days after it has been requested by the Board. The Board may require any such proposed nominee to submit to interviews with the Board or any committee thereof, and such proposed nominee shall make themself available for any such interviews within no less than ten (10) business days following the date of such request.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) For purposes of this Section 1.11, the term "***Public Announcement***" shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or comparable national news service or in a document publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Exchange Act. For purposes of this Section 1.11, the term "***Competitor***" shall mean any entity that provides products or services that compete with or are alternatives to the principal products produced or services provided by the Corporation or its affiliates. For purposes of this Section 1.11, the terms "***affiliate***" and "***associate***" shall have the meanings ascribed thereto in Rule 405 under the Securities Act of 1933, as amended (the "Securities Act"); provided, however, that the term "partner" as used in the definition of "associate" shall not include any limited partner that is not involved in the management of the relevant partnership.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Notwithstanding the foregoing provisions of this Section 1.11, a stockholder shall also comply with all applicable requirements of the Exchange Act and the rules and regulations thereunder with respect to the matters set forth herein. Nothing in this Section 1.11 shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation's proxy statement pursuant to Rule 14a-8 under the Exchange Act.

**Section 1.12: <u>Emergency Bylaws</u>**

This Section 1.12 shall be operative during any emergency condition as contemplated by Section 110 of the DGCL (an "***Emergency***"), notwithstanding any different or conflicting provisions in these Bylaws, the Certificate of Incorporation or the DGCL. In the event of any Emergency the director or directors in attendance at a meeting of the Board or a standing committee thereof shall constitute a quorum. Such director or directors in attendance may further take action to appoint one or more of themselves or other directors to membership on any standing or temporary committees of the Board as they shall deem necessary and appropriate. In the event that no directors are able to attend a meeting of the Board or any committee thereof in an Emergency, then the Designated Officers in attendance shall serve as directors, or committee members, as the case may be, for the meeting and will have full powers to act as directors, or committee members, as the case may be, of the Corporation. Except as the Board may otherwise determine, during any Emergency, the Corporation and its directors and officers, may exercise any authority and take any action or measure contemplated by Section 110 of the DGCL. For purposes of this Section 1.13, the term "***Designated Officer***" means an officer identified on a numbered list of officers of the Corporation who shall be deemed to be, in the order in which they appear on the list up until a quorum is obtained, directors of the Corporation, or members of a committee of the Board, as the case may be, for purposes of obtaining a quorum during an Emergency, if a quorum of directors or committee members, as the case may be, cannot otherwise be obtained during such Emergency, which list of Designated Officers shall be approved by the Board from time to time but in any event prior to such time or times as an Emergency may have occurred.

**ARTICLE II: BOARD OF DIRECTORS**

**Section 2.1:** **<u>Number; Qualifications</u>**

The total number of authorized directors constituting the Board (the "***Whole Board***") shall be fixed from time to time in the manner set forth in the Certificate of Incorporation. No decrease in the authorized number of directors constituting the Whole Board shall shorten the term of any incumbent director. Directors need not be stockholders of the Corporation.

**Section 2.2:** **<u>Election; Resignation; Removal; Vacancies</u>**

The directors shall be divided, with respect to the time for which they severally hold office, into classes as provided in the Certificate of Incorporation, and vacancies occurring in the Board and any newly created directorships resulting from any increase in the authorized number of directors shall be filled, as provided in the Certificate of Incorporation.

**Section 2.3:** **<u>Regular Meetings</u>**

Regular meetings of the Board may be held at such places, within or without the State of Delaware, and at such times as the Board may from time to time determine. Notice of regular meetings need not be given if the date, times and places thereof are fixed by resolution of the Board.

**Section 2.4:** **<u>Special Meetings</u>**

Special meetings of the Board may be called by the Chairperson of the Board, the Chief Executive Officer, the Lead Independent Director or a majority of the members of the Board then in office and may be held at any time, date or place, within or without the State of Delaware, as the person or persons calling the meeting shall fix. Notice of the time, date and place of such meeting shall be given, orally, in writing or by electronic transmission (including electronic mail), by the person or persons calling the meeting to all directors at least four (4) days before the meeting if the notice is mailed, or at least twenty-four (24) hours before the meeting if such notice is given by telephone, hand delivery or electronic transmission. Unless otherwise indicated in the notice, any and all business may be transacted at a special meeting.

**Section 2.5:** **<u>Remote Meetings Permitted</u>**

Members of the Board, or any committee of the Board, may participate in a meeting of the Board or such committee by means of conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to conference telephone or other communications equipment shall constitute presence in person at such meeting.

**Section 2.6:** **<u>Quorum; Vote Required for Action</u>**

Subject to the Certificate of Incorporation regarding the ability of members of the Board to fill a vacancy occurring in the Board, a majority of the Whole Board shall constitute a quorum for the transaction of business. If a quorum shall fail to attend any meeting, a majority of those present may adjourn the meeting to another place, date or time with further notice thereof. Except as otherwise provided herein or in the Certificate of Incorporation, or required by law, the vote of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board.

**Section 2.7:** **<u>Organization</u>**

Meetings of the Board shall be presided over by (a) the Chairperson of the Board, or (b) in the absence of such person, the Lead Independent Director, or (c) in such person's absence, by the Chief Executive Officer, or (d) in such person's absence, by a chairperson chosen at the meeting. The Secretary shall act as secretary of the meeting, but in such person's absence the chairperson of the meeting may appoint any person to act as secretary of the meeting.

**Section 2.8: <u>Unanimous Action by Directors in Lieu of a Meeting</u>**

Any action required or permitted to be taken at any meeting of the Board, or of any committee thereof, may be taken without a meeting if all members of the Board or such committee, as the case may be, consent thereto in writing or by electronic transmission. After an action is taken, the writing or writings or electronic transmission or transmissions shall be filed with the minutes of proceedings of the Board or committee, as applicable. Such filing shall be in paper form if the minutes are maintained in paper form and shall be in electronic form if the minutes are maintained in electronic form.

**Section 2.9:** **<u>Powers</u>**

The Board may, except as otherwise required by law or the Certificate of Incorporation, exercise all such powers and manage and direct all such acts and things as may be exercised or done by the Corporation.

**Section 2.10:** **<u>Compensation of Directors</u>**

Members of the Board, as such, may receive, pursuant to a resolution of the Board, fees and other compensation for their services as directors, including without limitation their services as members of committees of the Board.

**ARTICLE III: COMMITTEES**

**Section 3.1:** **<u>Committees</u>**

The Board may designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the committee. In the absence or disqualification of a member of the committee, the member or members thereof present at any meeting of such committee who are not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board to act at the meeting in place of any such absent or disqualified member. Any such committee, to the extent provided in a resolution of the Board, shall have and may exercise all the powers and authority of the Board in the management of the business and affairs of the Corporation and may authorize the seal of the Corporation to be affixed to all papers that may require it; but no such committee shall have the power or authority in reference to the following matters: (a) approving, adopting, or recommending to the stockholders any action or matter (other than the election or removal of members of the Board) expressly required by the DGCL to be submitted to stockholders for approval or (b) adopting, amending or repealing any bylaw of the Corporation.

**Section 3.2:** **<u>Committee Rules</u>**

Each committee shall keep records of its proceedings and make such reports as the Board may from time to time request. Unless the Board otherwise provides, each committee designated by the Board may make, alter and repeal rules for the conduct of its business. In the absence of such rules, each committee shall conduct its business in the same manner as the Board conducts its business pursuant to Article II of these Bylaws. Except as otherwise provided in the Certificate of Incorporation, these Bylaws or the resolution of the Board designating the committee, any committee may create one or more subcommittees, each subcommittee to consist of one or more members of the committee, and may delegate to any such subcommittee any or all of the powers and authority of the committee.

**ARTICLE IV: OFFICERS; CHAIRPERSON; LEAD INDEPENDENT DIRECTOR**

**Section 4.1: <u>Generally</u>**

The officers of the Corporation shall consist of a Chief Executive Officer (who may be the Chairperson of the Board or the President), a President, a Secretary and a Treasurer and may consist of such other officers, including, without limitation, a Chief Financial Officer, and one or more Vice Presidents, as may from time to time be appointed by the Board. All officers shall be elected by the Board; *provided*, *however*, that the Board may empower the Chief Executive Officer of the Corporation to appoint any officer other than the Chief Executive Officer, the President, the Chief Financial Officer or the Treasurer. Except as otherwise provided by law, by the Certificate of Incorporation or these Bylaws, each officer shall hold office until such officer's successor is duly elected and qualified or until such officer's earlier resignation, death, disqualification or removal. Any number of offices may be held by the same person. Any officer may resign by delivering a resignation in writing or by electronic transmission to the Corporation at its principal office or to the Chairperson of the Board, the Chief Executive Officer, or the Secretary. Such resignation shall be effective upon delivery unless it is specified to be effective at some later time or upon the happening of some later event. Any vacancy occurring in any office of the Corporation by death, resignation, removal or otherwise may be filled by the Board and the Board may, in its discretion, leave unfilled, for such period as it may determine, any offices.

**Section 4.2:** **<u>Chief Executive Officer</u>**

Subject to the control of the Board and such supervisory powers, if any, as may be given by the Board, the powers and duties of the Chief Executive Officer of the Corporation are:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) to act as the general manager and, subject to the control of the Board, to have general supervision, direction and control of the business and affairs of the Corporation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) subject to Article I, Section 1.6 of these Bylaws, to preside at all meetings of the stockholders;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) subject to Article I, Section 1.2 of these Bylaws, to call special meetings of the stockholders to be held at such times and, subject to the limitations prescribed by law or by these Bylaws, at such places as he or she shall deem proper;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) to affix the signature of the Corporation to all deeds, conveyances, mortgages, guarantees, leases, obligations, bonds, certificates and other papers and instruments in writing which have been authorized by the Board or which, in the judgment of the Chief Executive Officer, should be executed on behalf of the Corporation; to sign certificates for shares of stock of the Corporation (if any); and, subject to the direction of the Board, to have general charge of the property of the Corporation and to supervise and control all officers, agents and employees of the Corporation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) to vote and otherwise act on, or to authorize any officer to vote or otherwise act on, on behalf of the Corporation, in person or by proxy, at any meeting of stockholders of or with respect to any action of stockholders of any other corporation in which this Corporation may hold securities and otherwise to exercise, or authorize any officer otherwise to exercise, any and all rights and powers which this Corporation may possess by reason of its ownership of securities in such other corporation.

The person holding the office of President shall be the Chief Executive Officer of the Corporation unless the Board shall designate another officer to be the Chief Executive Officer. If there is no President, and the Board has not designated any other officer to be the Chief Executive Officer, then the Chairperson of the Board shall be the Chief Executive Officer.

**Section 4.3:** **<u>Chairperson of the Board</u>**

Subject to the provisions of Section 2.7 of these Bylaws, the Chairperson of the Board shall have the power to preside at all meetings of the Board and shall have such other powers and duties as provided in these Bylaws and as the Board may from time to time prescribe.

**Section 4.4:** **<u>Lead Independent Director</u>**

The Board may, in its discretion, elect a lead independent director from among its members that are Independent Directors (as defined below) (such director, the "***Lead Independent Director***"). The Lead Independent Director shall preside at all meetings at which the Chairperson of the Board is not present and shall exercise such other powers and duties as may from time to time be assigned to him or her by the Board or as prescribed by these Bylaws. For purposes of these Bylaws, "***Independent Director***" has the meaning ascribed to such term under the rules of the exchange upon which the Corporation's Common Stock is primarily traded.

**Section 4.5:** **<u>President</u>**

The person holding the office of Chief Executive Officer shall be the President of the Corporation unless the Board shall have designated one individual as the President and a different individual as the Chief Executive Officer of the Corporation. Subject to the provisions of these Bylaws and to the direction of the Board, and subject to the supervisory powers of the Chief Executive Officer (if the Chief Executive Officer is an officer other than the President), and subject to such supervisory powers and authority as may be given by the Board to the Chairperson of the Board, and/or to any other officer, the President shall have the responsibility for the general management and control of the business and affairs of the Corporation and the general supervision and direction of all of the officers, employees and agents of the Corporation (other than the Chief Executive Officer, if the Chief Executive Officer is an officer other than the President) and shall perform all duties and have all powers that are commonly incident to the office of President or that are delegated to the President by the Board.

**Section 4.6:** **<u>Chief Financial Officer</u>**

The person holding the office of Chief Financial Officer shall be the Treasurer of the Corporation unless the Board shall have designated another officer as the Treasurer of the Corporation. Subject to the direction of the Board and the Chief Executive Officer, the Chief Financial Officer shall perform all duties and have all powers that are commonly incident to the office of Chief Financial Officer.

**Section 4.7:** **<u>Treasurer</u>**

The person holding the office of Treasurer shall have custody of all monies and securities of the Corporation. The Treasurer shall make such disbursements of the funds of the Corporation as are authorized and shall render from time to time an account of all such transactions. The Treasurer shall also perform such other duties and have such other powers as are commonly incident to the office of Treasurer, or as the Board or the Chief Executive Officer may from time to time prescribe.

**Section 4.8:** **<u>Vice Presidents</u>**

Any Vice President shall perform such duties and possess such powers as the Board of Directors or the President may from time to time prescribe. In the event of the absence, inability or refusal to act of the President, the Vice President (or if there shall be more than one, the Vice Presidents in the order determined by the Board of Directors) shall perform the duties of the President and when so performing shall have at the powers of and be subject to all the restrictions upon the President. The Board of Directors may assign to any Vice President the title of Executive Vice President, Senior Vice President or any other title selected by the Board of Directors.

**Section 4.9:** **<u>Secretary</u>**

The Secretary shall issue or cause to be issued all authorized notices for, and shall keep, or cause to be kept, minutes of all meetings of the stockholders and the Board. The Secretary shall have charge of the corporate minute books and similar records and shall perform such other duties and have such other powers as are commonly incident to the office of Secretary, or as the Board or the Chief Executive Officer may from time to time prescribe.

**Section 4.10:** **<u>Delegation of Authority</u>**

The Board may from time to time delegate the powers or duties of any officer of the Corporation to any other officers or agents of the Corporation, notwithstanding any provision hereof.

**Section 4.11:** **<u>Removal</u>**

Any officer of the Corporation shall serve at the pleasure of the Board and may be removed at any time, with or without cause, by the Board; *provided* that if the Board has empowered the Chief Executive Officer to appoint any officer of the Corporation, then such officer may also be removed by the Chief Executive Officer. Such removal shall be without prejudice to the contractual rights of such officer, if any, with the Corporation.

**ARTICLE V: STOCK**

**Section 5.1:** **<u>Certificates</u>**

The shares of capital stock of the Corporation shall be represented by certificates; provided, however, that the Board may provide by resolution or resolutions that some or all of any or all classes or series of its stock may be uncertificated shares. Notwithstanding the adoption of such resolution by the Board, each holder of stock represented by certificates shall be entitled to have a certificate signed by or in the name of the Corporation by the Chairperson or Vice-Chairperson of the Board, or the President or a Vice President, and by the Treasurer or an Assistant Treasurer, or the Secretary or an Assistant Secretary, of the Corporation, certifying the number of shares owned by such stockholder in the Corporation. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were an officer, transfer agent or registrar at the date of issue.

**Section 5.2:** **<u>Lost, Stolen or Destroyed Stock Certificates; Issuance of New Certificates or Uncertificated Shares</u>**

The Corporation may issue a new certificate of stock or uncertificated shares in the place of any certificate previously issued by it, alleged to have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate, or such owner's legal representative, to agree to indemnify the Corporation and/or to give the Corporation a bond sufficient to indemnify it, against any claim that may be made against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate.

**Section 5.3:** **<u>Other Regulations</u>**

Subject to applicable law, the Certificate of Incorporation and these Bylaws, the issue, transfer, conversion and registration of shares represented by certificates and of uncertificated shares shall be governed by such other regulations as the Board may establish.

**ARTICLE VI: INDEMNIFICATION**

**Section 6.1:** **<u>Indemnification of Officers and Directors</u>**

Each person who was or is made a party to, or is threatened to be made a party to, or is involved in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a "***Proceeding***"), by reason of the fact that such person (or a person of whom such person is the legal representative), is or was a member of the Board or officer of the Corporation or a Reincorporated Predecessor (as defined below) or is or was serving at the request of the Corporation or a Reincorporated Predecessor as a member of the board of directors, officer or trustee of another corporation, or of a partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans (for purposes of this Article VI, an "***Indemnitee***"), shall be indemnified and held harmless by the Corporation to the fullest extent permitted by the DGCL as the same exists or may hereafter be amended (but, in the case of any such amendment, only to the extent that such amendment permits the Corporation to provide broader indemnification rights than such law permitted the Corporation to provide prior to such amendment), against all expenses, liability and loss (including attorneys' fees, judgments, fines, ERISA excise taxes and penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by such Indemnitee in connection therewith, provided such Indemnitee acted in good faith and in a manner that the Indemnitee reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or Proceeding, had no reasonable cause to believe the Indemnitee's conduct was unlawful. Such indemnification shall continue as to an Indemnitee who has ceased to be a director or officer and shall inure to the benefit of such Indemnitees' heirs, executors and administrators. Notwithstanding the foregoing, the Corporation shall indemnify any such Indemnitee seeking indemnity in connection with a Proceeding (or part thereof) initiated by such Indemnitee only if such Proceeding (or part thereof) was authorized by the Board or such indemnification is authorized by an agreement approved by the Board. As used herein, the term the "***Reincorporated Predecessor***" means a corporation that is merged with and into the Corporation in a statutory merger where (a) the Corporation is the surviving corporation of such merger; (b) the primary purpose of such merger is to change the corporate domicile of the Reincorporated Predecessor to Delaware.

**Section 6.2:** **<u>Advancement of Expenses</u>**

Except as otherwise provided in a written indemnification agreement between the Corporation and an Indemnitee upon written request, the Corporation shall pay all expenses (including attorneys' fees) incurred by such an Indemnitee in defending any such Proceeding as they are incurred in advance of its final disposition; *<u>provided</u>, <u>however</u>*, that if the DGCL then so requires, the payment of such expenses incurred by such Indemnitee in advance of the final disposition of such Proceeding shall be made only upon delivery to the Corporation of an undertaking, by or on behalf of such Indemnitee, to repay all amounts so advanced if it should be determined ultimately by final judicial decision from which there is no appeal that such Indemnitee is not entitled to be indemnified under this Article VI or otherwise. Such expenses (including attorneys' fees) incurred by former directors and officers or other employees and agents of the Corporation or by persons serving at the request of the Corporation as directors, officers, employees or agents of another corporation, partnership, joint venture, trust or other enterprise may be so paid upon such terms and conditions, if any, as the Corporation deems appropriate. The right to advancement of expenses shall not apply to any claim for which indemnity is excluded pursuant to these bylaws, but shall apply to any Proceeding referenced in Section 6.1 prior to a determination that the person is not entitled to be indemnified by the Corporation.

**Section 6.3:** **<u>Non-Exclusivity of Rights</u>**

The rights conferred on any person in this Article VI shall not be exclusive of any other right that such person may have or hereafter acquire under any statute, provision of the Certificate of Incorporation, Bylaws, agreement, vote or consent of stockholders or disinterested directors, or otherwise. Additionally, nothing in this Article VI shall limit the ability of the Corporation, in its discretion, to indemnify or advance expenses to persons whom the Corporation is not obligated to indemnify or advance expenses pursuant to this Article VI.

**Section 6.4:** **<u>Indemnification Contracts</u>**

The Board is authorized to cause the Corporation to enter into indemnification contracts with any director, officer, employee or agent of the Corporation, or any person serving at the request of the Corporation as a director, officer, employee, agent or trustee of another corporation, partnership, joint venture, trust or other enterprise, including employee benefit plans, providing indemnification or advancement rights to such person. Such rights may be greater than those provided in this Article VI.

**Section 6.5:** **<u>Right of Indemnitee to Bring Suit</u>**

The following shall apply to the extent not in conflict with any indemnification contract provided for in Section 6.4 of these Bylaws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5.1 <u>Right to Bring Suit</u>. If a claim under Section 6.1 or 6.2 of these Bylaws is not paid in full by the Corporation within sixty (60) days after a written claim has been received by the Corporation, the Indemnitee may at any time thereafter bring suit against the Corporation to recover the unpaid amount of the claim. If successful in whole or in part in any such suit, or in a suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Indemnitee shall be entitled to be paid, to the fullest extent permitted by law, the expense of prosecuting or defending such suit. In (a) any suit brought by the Indemnitee to enforce a right to indemnification hereunder (but not in a suit brought by the Indemnitee to enforce a right to an advancement of expenses) it shall be a defense that, and (b) in any suit brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the Corporation shall be entitled to recover such expenses upon a final adjudication that, the Indemnitee has not met any applicable standard for indemnification set forth in applicable law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5.2 <u>Effect of Determination</u>. Neither the failure of the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) to have made a determination prior to the commencement of such suit that indemnification of the Indemnitee is proper in the circumstances because the Indemnitee has met the applicable standard of conduct set forth in applicable law, nor an actual determination by the Corporation (including its directors who are not parties to such action, a committee of such directors, independent legal counsel or its stockholders) that the Indemnitee has not met such applicable standard of conduct, shall create a presumption that the Indemnitee has not met the applicable standard of conduct or, in the case of such a suit brought by the Indemnitee, be a defense to such suit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5.3 <u>Burden of Proof</u>. In any suit brought by the Indemnitee to enforce a right to indemnification or to an advancement of expenses hereunder, or brought by the Corporation to recover an advancement of expenses pursuant to the terms of an undertaking, the burden of proving that the Indemnitee is not entitled to be indemnified, or to such advancement of expenses, under this Article VI, or otherwise, shall be on the Corporation.

**Section 6.6:** **<u>Nature of Rights</u>**

The rights conferred upon Indemnitees in this Article VI shall be contract rights and such rights shall continue as to an Indemnitee who has ceased to be a director, officer or trustee and shall inure to the benefit of the Indemnitee's heirs, executors and administrators. Any amendment, repeal or modification of any provision of this Article VI that adversely affects any right of an Indemnitee or an Indemnitee's successors shall be prospective only, and shall not adversely affect any right or protection conferred on a person pursuant to this Article VI and existing at the time of such amendment, repeal or modification.

**Section 6.7: <u>Insurance</u>**

The Corporation may purchase and maintain insurance, at its expense, on behalf of any person who is or was a director, officer, employee or agent of the Corporation, or is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any expense, liability or loss asserted against such person and incurred by such person in any such capacity, or arising out of such person's status as such, whether or not the Corporation would have the power to indemnify such person against such expense, liability or loss under the provisions of the DGCL.

**Section 6.8: <u>Indemnification for Successful Defense</u>**

To the extent that a present or former director or officer has been successful on the merits or otherwise in defense of any Proceeding (or in defense of any claim, issue or matter therein), such present or former director or officer shall be indemnified under this Section 6.8 against expenses (including attorneys' fees) actually and reasonably incurred in connection with such defense. Indemnification under this Section 6.8 shall not be subject to satisfaction of a standard of conduct, and the Corporation may not assert the failure to satisfy a standard of conduct as a basis to deny indemnification or recover amounts advanced, including in a suit brought pursuant to Section 6.5 (notwithstanding anything to the contrary therein).

**ARTICLE VII: NOTICES**

**Section 7.1: <u>Notice</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1.1 <u>Form and Delivery</u>. Except as otherwise required by law, notice may be given in writing directed to a stockholder's mailing address as it appears on the records of the Corporation and shall be given: (a) if mailed, when notice is deposited in the U.S. mail, postage prepaid; and (b) if delivered by courier service, the earlier of when the notice is received or left at such stockholder's address. So long as the Corporation is subject to the Securities and Exchange Commission's proxy rules set forth in Regulation 14A under the Exchange Act, notice shall be given in the manner required by such rules. To the extent permitted by such rules, or if the Corporation is not subject to Regulation 14A, notice may be given by electronic transmission directed to the stockholder's electronic mail address, and if so given, shall be given when directed to such stockholder's electronic mail address unless the stockholder has notified the Corporation in writing or by electronic transmission of an objection to receiving notice by electronic mail or such notice is prohibited by Section 232(e) of the DGCL. If notice is given by electronic mail, such notice shall comply with the applicable provisions of Sections 232(a) and 232(d) of the DGCL. Notice may be given by other forms of electronic transmission with the consent of a stockholder in the manner permitted by Section 232(b) of the DGCL and shall be deemed given as provided therein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1.2 <u>Affidavit of Giving Notice</u>. An affidavit of the Secretary or an Assistant Secretary or of the transfer agent or other agent of the Corporation that the notice has been given shall, in the absence of fraud, be prima facie evidence of the facts stated therein.

**Section 7.2:** **<u>Waiver of Notice</u>**

Whenever notice is required to be given under any provision of the DGCL, the Certificate of Incorporation or these Bylaws, a written waiver of notice, signed by the person entitled to notice, or waiver by electronic transmission by such person, whether before or after the time stated therein, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any regular or special meeting of the stockholders, directors or members of a committee of directors need be specified in any waiver of notice.

**ARTICLE VIII: INTERESTED DIRECTORS**

**Section 8.1:** **<u>Interested Directors</u>**

No contract or transaction between the Corporation and one or more of its members of the Board or officers, or between the Corporation and any other corporation, partnership, association or other organization in which one or more of its directors or officers are members of the board of directors or officers, or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board or committee thereof that authorizes the contract or transaction, or solely because his, her or their votes are counted for such purpose, if: (a) the material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known to the Board or the committee, and the Board or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; (b) the material facts as to his, her or their relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders; or (c) the contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified by the Board, a committee thereof, or the stockholders.

**Section 8.2:** **<u>Quorum</u>**

Interested directors may be counted in determining the presence of a quorum at a meeting of the Board or of a committee which authorizes the contract or transaction.

**ARTICLE IX: MISCELLANEOUS**

**Section 9.1:** **<u>Fiscal Year</u>**

The fiscal year of the Corporation shall be determined by resolution of the Board.

**Section 9.2:** **<u>Seal</u>**

The Board may provide for a corporate seal, which may have the name of the Corporation inscribed thereon and shall otherwise be in such form as may be approved from time to time by the Board.

**Section 9.3:** **<u>Form of Records</u>**

Any records administered by or on behalf of the Corporation in the regular course of its business, including its stock ledger, books of account and minute books, may be kept on or by means of, or be in the form of, any other information storage device, method or one or more electronic networks or databases (including one or more distributed electronic networks or databases), electronic or otherwise, *provided* that the records so kept can be converted into clearly legible paper form within a reasonable time and otherwise comply with the DGCL. The Corporation shall so convert any records so kept upon the request of any person entitled to inspect such records pursuant to any provision of the DGCL.

**Section 9.4:** **<u>Reliance upon Books, Records and Experts</u>**

A member of the Board, or a member of any committee designated by the Board shall, in the performance of such person's duties, be fully protected in relying in good faith upon the books and records of the Corporation and upon such information, opinions, reports or statements presented to the Corporation by any of the Corporation's officers or employees, or committees of the Board, or by any other person as to matters the member reasonably believes are within such other person's professional or expert competence and who has been selected with reasonable care by or on behalf of the Corporation.

**Section 9.5:** **<u>Certificate of Incorporation Governs</u>**

In the event of any conflict between the provisions of the Certificate of Incorporation and Bylaws, the provisions of the Certificate of Incorporation shall govern.

**Section 9.6:** **<u>Severability</u>**

If any provision of these Bylaws shall be held to be invalid, illegal, unenforceable or in conflict with the provisions of the Certificate of Incorporation, then such provision shall nonetheless be enforced to the maximum extent possible consistent with such holding and the remaining provisions of these Bylaws (including without limitation, all portions of any section of these Bylaws containing any such provision held to be invalid, illegal, unenforceable or in conflict with the Certificate of Incorporation, that are not themselves invalid, illegal, unenforceable or in conflict with the Certificate of Incorporation) shall remain in full force and effect.

**Section 9.7:** **<u>Time Periods</u>**

In applying any provision of these Bylaws which requires that an act be done or not be done a specified number of days prior to an event or that an act be done during a period of a specified number of days prior to an event, calendar days shall be used, the day of the doing of the act shall be excluded, and the day of the event shall be included.

**ARTICLE X: AMENDMENT**

Notwithstanding any other provision of these Bylaws, any alteration, amendment or repeal of these Bylaws, and any adoption of new Bylaws, shall require the approval of the Board or the stockholders of the Corporation as expressly provided in the Certificate of Incorporation.

**ARTICLE XI: EXCLUSIVE FORUM**

Unless the Corporation consents in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act, including all causes of action asserted against any defendant named in such complaint.

Any person or entity purchasing or otherwise acquiring or holding any interest in any security of the Corporation shall be deemed to have notice of and consented to the provisions of this Article XI.

## Exhibit 4.1

**Exhibit 4.1**

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, OR (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED.

<br> WARRANT NO. 2023-[·] NUMBER OF SHARES: [·] <br> (subject to adjustment hereunder)

DATE OF ISSUANCE: February 15, 2022

EXPIRATION DATE: The first date on which no shares of Common Stock are issuable upon a cash exercise of this Warrant

PRE-FUNDED WARRANT TO PURCHASE SHARES OF

COMMON STOCK OF

MORPHIC HOLDING, INC.

This Warrant (the "<u>Warrant</u>") is issued by Morphic Holding, Inc., a Delaware corporation (the "<u>Company</u>"), to [·], or its registered assigns (including any successors or assigns, the "<u>Holder</u>"), and is subject to the terms and conditions set forth below. The Warrant is being issued pursuant to that certain Securities Purchase Agreement, dated as of February 13, 2023, among the Company and the investors signatory thereto (as amended and/or restated from time to time, the "<u>Purchase Agreement</u>"). Capitalized terms used and not otherwise defined herein shall have the meanings set forth in the Purchase Agreement.

1) EXERCISE OF WARRANT.

&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Number and Exercise Price of Warrant Shares; Expiration Date</u>. Subject to the terms and conditions set forth herein, the Holder
is entitled to purchase from the Company up to [ · ]
shares (the " <u>Warrant Shares</u> ") of the Company's Common Stock, $0.0001 par value per share (the " <u>Common Stock</u> ") (as adjusted from time to time pursuant to the provisions of this Warrant) until this Warrant is exercised in full.
The aggregate exercise price of this Warrant of $[ · ],
except for a nominal exercise price of $0.0001 per Warrant Share, was paid to the Company on or prior to the Date of Issuance of this
Warrant, and, consequently, no additional consideration (other than the nominal exercise price of $0.0001 per Warrant Share) shall be
required to be paid by the Holder to effect any exercise of this Warrant. The Holder shall not be entitled to return or refund of all,
or any portion, of such pre-paid aggregate exercise price under any circumstance or for any reason whatsoever, including in the event
this Warrant shall not have been exercised prior to the Expiration Date. The remaining unpaid exercise price per share of Common Stock
under this Warrant shall be $0.0001, subject to adjustment as provided herein (the " <u>Exercise Price</u> ").

&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Method of Exercise</u>. While this Warrant remains outstanding and exercisable in accordance with Section 1(a) above,
the Holder may exercise this Warrant in whole or in part in accordance with Section 5 by either:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) wire transfer to the Company or cashier ' s check drawn on a United States bank made payable
to the order of the Company, or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) exercising of the right to credit the Exercise Price against the Fair Market Value (as defined below) of the Warrant Shares at the
time of exercise (the " <u>Net Exercise</u> ") pursuant to Section 1(c).

&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Net Exercise</u>. At any time the Holder may elect to exercise this Warrant by Net Exercise pursuant to this Section 1(c).
At any time that this Warrant may be exercised by Net Exercise pursuant to this Section 1(c), if the Company shall receive written
notice from the Holder at the time of exercise of this Warrant that the Holder elects to Net Exercise the Warrant, the Company shall deliver
to such Holder (without payment by the Holder of any exercise price in cash) that number of Warrant Shares computed using the following
formula:

<br> X= <u>Y (A - B)</u> <br> A

Where

X = The number of Warrant Shares to be issued to the Holder.

Y = The number of Warrant Shares purchasable under this Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being cancelled (at the date of such calculation).

A = The Fair Market Value of one share of Common Stock (at the date of such calculation).

B = The Exercise Price (as adjusted to the date of such calculations).

The "<u>Fair Market Value</u>" of one share of Common Stock shall mean (x) the last reported sale price and, if there are no sales, the last reported bid price, of the Common Stock on the last trading day prior to the date of exercise on the trading market on which the Common Stock is listed as reported by Bloomberg Financial Markets (or a comparable reporting service of national reputation selected by the Company and reasonably acceptable to the Holder if Bloomberg Financial Markets is not then reporting sales prices of the Common Stock) (collectively, "<u>Bloomberg</u>"), or (y) if the foregoing does not apply, the last sales price of such security in the over-the-counter market on the pink sheets by Pink Sheets LLC (formerly the National Quotation Bureau, Inc.) or bulletin board for such security as reported by Bloomberg, or if no sales price is so reported, the last bid price of the Common Stock as reported by Bloomberg or (z) if the fair market value cannot be calculated on any of the foregoing bases, the fair market value determined by the Company's Board of Directors in good faith.

&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Disputes</u>. In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant
Shares, the Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed.

&nbsp;&nbsp;&nbsp;&nbsp;e) <u>Deemed Exercise</u>. In the event that immediately prior to the close of business on the Expiration Date, the Fair Market Value
of one share of Common Stock (as determined in accordance with Section 1(c) above) is greater than the then applicable Exercise
Price, this Warrant shall be deemed to be automatically exercised on a net exercise issue basis pursuant to Section 1(c) above,
and the Company shall deliver the applicable number of shares of Common Stock to the Holder pursuant to the provisions of Section 1(c) above
and this Section 1(e). Notwithstanding anything to the contrary contained in this Section 1(e), to the extent that the Holder's
right to receive shares of Common Stock upon such a net exercise would result in the Holder and its affiliates exceeding the Beneficial
Ownership Limitation (as defined below), if applicable pursuant to Section 5(c) herein, then the Holder shall not be entitled
to such shares of Common Stock to the extent of the Beneficial Ownership Limitation (and shall not be entitled to beneficial ownership
of such shares of Common Stock (and beneficial ownership) to the extent of any such excess) and the portion of such shares of Common Stock
shall be held in abeyance for the benefit of the Holder until such time or times, if ever, as its right thereto would not result in the
Holder and its affiliates exceeding the Beneficial Ownership Limitation, at which time or times the Holder shall be granted such shares
of Common Stock to the same extent as if there had been no such limitation).

2) CERTAIN ADJUSTMENTS.

&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Adjustment of Number of Warrant Shares and Exercise Price</u>. The number and kind of Warrant Shares purchasable upon exercise
of this Warrant and the Exercise Price shall be subject to adjustment from time to time as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) <u>Subdivisions, Combinations and Other Issuances</u>. If the Company shall at any time after the Date of Issuance but prior to the
Expiration Date subdivide its shares of capital stock of the same class as the Warrant Shares, by split-up or otherwise, or combine such
shares of capital stock, or issue additional shares of capital stock as a dividend with respect to any shares of such capital stock, the
number of Warrant Shares issuable on the exercise of this Warrant shall forthwith be proportionately increased in the case of a subdivision
or stock dividend, or proportionately decreased in the case of a combination. Appropriate adjustments shall also be made to the Exercise
Price payable per share, but the aggregate Exercise Price payable for the total number of Warrant Shares purchasable under this Warrant
(as adjusted) shall remain the same. Any adjustment under this Section 2(a)(1) shall become effective at the close of business
on the date the subdivision or combination becomes effective, or as of the record date of such dividend, or in the event that no record
date is fixed, upon the making of such dividend.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) <u>Reorganizations or Mergers</u>. In case of any reclassification, capital reorganization or change in the capital stock of the Company
(other than as a result of a subdivision, combination or stock dividend provided for in Section 2(a)(1) above) that occurs after
the Date of Issuance, then as a condition of such reclassification, reorganization or change, lawful provision shall be made, and duly
executed documents evidencing the same from the Company or its successor shall be delivered to the Holder, so that the Holder shall thereafter
have the right at any time prior to the expiration of this Warrant to purchase, at a total price equal to that payable upon the exercise
of this Warrant, the kind and amount of shares of stock and/or other securities or property (including, if applicable, cash) receivable
in connection with such reclassification, reorganization or change by a holder of the same number and type of securities as were purchasable
as Warrant Shares by the Holder immediately prior to such reclassification, reorganization or change. In any such case, appropriate provisions
shall be made with respect to the rights and interest of the Holder so that the provisions hereof shall thereafter be applicable with
respect to any shares of stock or other securities or property deliverable upon exercise hereof, and appropriate adjustments shall be
made to the Exercise Price payable hereunder, provided the aggregate Exercise Price shall remain the same (and, for the avoidance of doubt,
this Warrant shall be exclusively exercisable for such shares of stock and/or other securities or property from and after the consummation
of such reclassification or other change in the capital stock of the Company).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) <u>Rights Upon Distribution of Assets</u>. If the Company shall declare or make any dividend, other distribution of its assets (or
rights to acquire its assets) or evidences of its indebtedness to holders of shares of Common Stock generally (which dividend or other
distribution has not already been given to the Holder with respect to the Warrant Shares), by way of return of capital or otherwise not
addressed by this Section 2 above (including, without limitation, any distribution of cash, stock or other securities, property or
options by way of a dividend, spin off, subdivision, reclassification, corporate rearrangement, scheme of arrangement or other similar
transaction) (a " <u>Distribution</u> "), at any time after the issuance of this Warrant and prior to the Expiration Date, then
in each such case the Holder shall be entitled (subject to the following proviso) to participate in such Distribution to the same extent
that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise
of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including, without limitation, the Beneficial
Ownership Limitation) immediately before the date on which a record is taken for such Distribution, or, if no such record is taken, the
date as of winch the record holders of shares of Common Stock are to be determined for the participation in such Distribution. Notwithstanding
anything to the contrary contained herein, to the extent that the Holder s right to participate in any such Distribution would result
in the Holder and its affiliates exceeding the Beneficial Ownership Limitation, if applicable pursuant to Section 5(c) herein,
then the Holder shall not be entitled to participate in such Distribution to the extent of the Beneficial Ownership Limitation (and shall
not be entitled to beneficial ownership of such shares of Common Stock as a result of such Distribution (and beneficial ownership) to
the extent of any such excess) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such
time or times, if ever, as its right thereto would not result in the Holder and its affiliates exceeding the Beneficial Ownership Limitation,
at which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution
or on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such limitation).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(4) <u>Purchase Rights</u>. If at any time the Company grants, issues or sells any options, convertible securities or rights to purchase
stock, warrants, securities or other property pro rata to the record holders of any class of Common Stock (the " <u>Purchase Rights</u> "),
then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the
Holder could have acquired if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant
(without regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Beneficial Ownership
Limitation) immediately before the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no
such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale
of such Purchase Rights (provided, however, that to the extent that the Holder's right to participate in any such Purchase Right
would result in the Holder and the other Attribution Parties (as defined in Section 5(c)) exceeding the Beneficial Ownership Limitation,
then the Holder shall not be entitled to participate in such Purchase Right to such extent (and shall not be entitled to beneficial ownership
of such shares of Common Stock as a result of such Purchase Right (and beneficial ownership) to such extent) and such Purchase Right to
such extent shall be held in abeyance for the benefit of the Holder until such time or times as its right thereto would not result in
the Holder and the other Attribution Parties exceeding the Beneficial Ownership Limitation, at which time or times the Holder shall be
granted such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right
held similarly in abeyance) to the same extent as if there had been no such limitation).

&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Notice of Adjustment</u>. When any adjustment is required to be made in the number or kind of shares purchasable upon exercise
of the Warrant or in the Exercise Price, the Company shall promptly notify the Holder of such event and of the number of Warrant Shares
or other securities or property thereafter purchasable upon exercise of this Warrant.

&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Calculations</u>. No adjustment in the Exercise Price shall be required unless such adjustment would require an increase or decrease
of at least $0.01 in such price; <u>provided</u>, <u>however</u>, that any adjustment which by reason of this Section 2(c) is
not required to be made shall be carried forward and taken into account in any subsequent adjustments under this Section 2. All calculations
under this Section 2 shall be made by the Company in good faith and shall be made to the nearest cent or to the nearest one hundredth
of a share, as applicable. No adjustment need be made for a change in the par value or no par value of the Company's Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Treatment of Warrant upon a Change of Control</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) If, at any time while this Warrant is outstanding, there is a Change of Control (as defined below), then the Holder shall have the
right thereafter to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have
been entitled to receive upon the occurrence of such Change of Control if it had been, immediately prior to such Change of Control, the
holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant (the " <u>Alternate Consideration</u> ").
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Change of Control,
and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value
of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash
or property to be received in a Change of Control, then the Holder shall be given the same choice as to the Alternate Consideration it
receives upon any exercise of this Warrant following such Change of Control. Any successor to the Company or surviving entity in such
Change of Control shall issue to the Holder a new warrant substantially in the form of this Warrant and consistent with the foregoing
provisions and evidencing the Holder's right to purchase the Alternate Consideration for the aggregate Exercise Price upon exercise
thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) <u>Notice of a Change of Control</u>. The Company shall provide written notice to the Holder of a Change of Control reasonably promptly
after public announcement thereof (and, in any event, not less than twenty (20) trading days prior to the consummation of such Change
of Control) and such notice shall include (i) the projected date of consummation of the Change of Control to the extent known at
the time such notice is delivered and (ii) the expected consideration to be received by the Company's stockholders in such
Change of Control.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) As used in this Warrant, a " <u>Change of Control</u> " shall mean (i) a merger or consolidation of the Company with
another entity, in which the Company is not the survivor or the stockholders of the Company immediately prior to such merger or consolidation
do not own, directly or indirectly, at least 50% of the voting securities of the surviving entity, (ii) the consummation of a stock
purchase agreement or other business combination of the Company with another Person whereby such other Person acquires more than 50% of
the outstanding shares of Common Stock (not including any shares of Common Stock held by the other Person or other Persons making or party
to, or associated or affiliated with the other Persons making or party to, such stock purchase agreement or other business combination),
(iii) the sale, assignment, transfer, conveyance or other disposal of all or substantially all of the properties or assets or all
or a majority of the outstanding voting securities of the Company, (iv) a purchase, tender or exchange offer accepted by the holders
of a majority of the outstanding voting shares of capital stock of the Company directly or indirectly, in one or more related transactions,
(v) a "person" or "group" (as these terms are used for purposes of Section 13(d) and 14(d) of
the Securities Exchange Act of 1934, as amended (the " <u>Exchange Act</u> ")) is or shall become the "beneficial owner"
(as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of at least a majority of the outstanding shares of Common
Stock of the Company through a stock purchase agreement or other business combination (including, without limitation, a reorganization,
reclassification, spin off or scheme of arrangement) with another person, or (vi) the Company has elected to reorganize, recapitalize
or reclassify its Common Stock (other than to change domicile).

3) NO STOCKHOLDER RIGHTS. Until the exercise of this Warrant, the Holder shall not have, nor exercise, any rights as a stockholder of the Company (including without limitation the right to notification of stockholder meetings or the right to receive any notice or other communication concerning the business and affairs of the Company), except as expressly provided in this Warrant.

4) COVENANT TO PERFORM; NON-CIRCUMVENTION. The Company hereby covenants and agrees that the Company will at all times in good faith carry out all the provisions of this Warrant and will not by amendment of its certificate of incorporation, bylaws or other organizational documents or through a Change of Control, dissolution, sale of assets or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant. Without limiting the generality of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this Warrant above the Exercise Price then in effect, (ii) shall take such actions as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and nonassessable shares of Common Stock upon the exercise of this Warrant, and (iii) shall, so long as this Warrant is outstanding, take action necessary to reserve and keep available out of its authorized and unissued shares of Common Stock solely for the purpose of effecting the exercise of this Warrant, 100% of the number of shares of Common Stock issuable upon exercise of this Warrant then outstanding.

5) MECHANICS OF EXERCISE.

&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Delivery of Warrant Shares Upon Exercise</u>. This Warrant may be exercised by the Holder hereof upon the delivery of a Notice
of Exercise (the " <u>Exercise Notice</u> ") attached hereto as <u>Exhibit A</u> properly completed and duly executed by
the Holder hereof, at the office of the Company designated for such purpose together with this Warrant and payment in full of the Exercise
Price (unless the Holder has elected to Net Exercise) then in effect with respect to the number of Warrant Shares as to which the Warrant
is being exercised. This Warrant shall be deemed to have been exercised immediately prior to the close of business on the date of its
surrender for exercise as provided above, and the person entitled to receive the Warrant Shares issuable upon such exercise shall be treated
for all purposes as the holder of such shares of record as of the close of business on such date. Notwithstanding anything herein to the
contrary (although the Holder may surrender the Warrant to, and receive a replacement Warrant from, the Company), the Holder shall not
be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder
and the Warrant has been exercised in full, in which case, the Holder shall surrender this Warrant to the Company for cancellation within
three (3) trading days of the date the final Exercise Notice is delivered to the Company. Execution and delivery of the Exercise
Notice with respect to less than all of the Warrant Shares available hereunder shall have the effect of lowering the outstanding number
of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. On or before the second
(2 nd) trading day following the date on which the Company has received each of the Exercise Notice
and the aggregate Exercise Price (or confirmation from the Company of the number of shares of Warrant Shares issuable in connection with
a duly executed and delivered notice of Net Exercise), the Company shall transmit by facsimile an acknowledgment of confirmation of receipt
of the Exercise Notice to the Company's transfer agent (" <u>Transfer Agent</u> "). The Company shall deliver any objection
to the Exercise Notice on or before the second trading day following the date on which the Company has received the Exercise Notice. On
or before the second (2 nd) trading day following the date on which the Company has received the Exercise
Notice and the aggregate Exercise Price (the " <u>Share Delivery Date</u> "), the Company shall (X) provided that the Transfer
Agent is participating in The Depository Trust Company (" <u>DTC</u> ") Fast Automated Securities Transfer Program and either
(i) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares
by the Holder or (ii) this Warrant is being exercised via cashless exercise and Rule 144 is available, upon the request of the
Holder, credit such aggregate number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the Holder is or its
designee's balance account with DTC through its Deposit Withdrawal Agent Commission system, or (Y) if the Transfer Agent is
not participating in the DTC Fast Automated Securities Transfer Program, or (i) there is not an effective registration statement
permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder and (ii) this Warrant is being exercised
via cashless exercise and Rule 144 is not available, upon the request of the Holder, issue and dispatch by first class mail, postage
prepaid, to the address as specified in the Exercise Notice, a certificate, registered in the Company's share register in the name
of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. Upon
delivery of the Exercise Notice and the payment of the aggregate Exercise Price (or a duly executed and delivered notice of Net Exercise),
the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which
this Warrant has been exercised, irrespective of the date such Warrant Shares are credited to the Holder ' s
DTC account or the date of delivery of the certificates or book-entry position evidencing such Warrant Shares, as the case may be. The
Company shall pay any and all taxes (other than taxes based upon the income of the Holder) which may be payable with respect to the issuance
and delivery of Warrant Shares upon exercise of this Warrant; provided, that the Company shall not be required to pay any tax that may
be payable in respect of any transfer involved in the issue and delivery of shares of Common Stock in any name other than that of the
Holder, in either case with respect to any income or transfer tax due by the Holder with respect to such shares of Common Stock issued
upon exercise of this Warrant. The Company shall not have any duty or obligation to take any action under any section of this Agreement
that requires the payment of taxes and/or charges unless and until it is satisfied that all such payments have been made.

&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Company's Failure to Timely Deliver Securities</u>. If the Company shall fail for any reason or for no reason to issue to
the Holder by the Share Delivery Date in compliance with the terms of this Section 5, a certificate or book entry position for the
number of shares of Common Stock to which the Holder is entitled and register such shares of Common Stock on the Company's share
register or to credit the Holder's balance account with DTC for such number of shares of Common Stock to which the Holder is entitled
upon the Holder ' s exercise of this Warrant, and if on or after such trading day the Holder
purchases (in an open market transaction or otherwise, provided such purchases shall be made in a commercially reasonable manner at prevailing
market prices) shares of Common Stock to deliver in satisfaction of a sale by the Holder of shares of Common Stock issuable upon such
exercise that the Holder anticipated receiving from the Company, then the Company shall, within two (2) trading days after the Holder ' s
request and in the Holder ' s discretion, either (i) pay cash to the Holder in an amount
equal to the Holder ' s total purchase price (including commercially reasonable brokerage commissions,
if any) for the shares of Common Stock so purchased (the " <u>Buy-In Price</u> "), at which point the Company ' s
obligation to deliver such certificate or evidence of book entry position (and to issue such Warrant Shares) shall terminate, or (ii) pay
cash to the Holder in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of
Common Stock, times (B) the price at which the sell order giving rise to such purchase obligation was executed (assuming such sale
was executed on commercially reasonable terms at prevailing market prices) and, at the option of the holder, either (x) promptly
honor its obligation to deliver to the Holder a certificate or certificates or evidence of book entry position representing such Warrant
Shares or (y) reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored
(in which case such exercise shall be deemed rescinded).

&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Holder ' s Exercise Limitation</u>. Notwithstanding anything to the contrary contained
in this Warrant, this Warrant shall not be exercisable by the Holder pursuant to Section 1 or otherwise, and any such exercise shall
be void ab initio, to the extent (but only to the extent) that after giving effect to such issuance after exercise as set forth on the
applicable Exercise Notice, the Holder (together with the Holder ' s affiliates, and any other
persons acting as a group together with the Holder or any of the Holder's affiliates (such person " <u>Attribution Parties</u> ")),
would beneficially own in excess of 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance
of shares of Common Stock issued upon exercise of this Warrant (the " <u>Beneficial Ownership Limitation</u> "). Notwithstanding
the foregoing, the Holder shall have the right to increase or decrease the Beneficial Ownership Limitation (to an amount not to exceed
9.9% of the number of shares of Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable
upon exercise of this Warrant, with any increase to be effective only upon the Holder providing the Company with prior written notice
of such increase, which shall be effective 61 days after delivery of such notice to the Company. To the extent the above limitation applies,
the determination of whether this Warrant shall be exercisable (vis-à-vis other convertible, exercisable or exchangeable securities
owned by the Holder or any of its Attribution Parties) and of which such securities shall be exercisable (as among all such securities
owned by the Holder or any of its Attribution Parties) shall, subject to such Beneficial Ownership Limitation, be determined by the Holder,
and the Company shall have no responsibility for determining the accuracy of the Holder ' s determination.
No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of
this paragraph with respect to any subsequent determination of exercisability. For purposes of the calculation of the Beneficial Ownership
Limitation, the aggregate number of shares of Common Stock beneficially owned by the Holder and its Attribution Parties shall include
the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but
shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining nonexercised portion
of this Warrant beneficially owned by the Holder or any of its Attribution Parties and (ii) exercise or conversion of the unexercised
or nonconverted portion of any other securities of the Company (including, without limitation, any other convertible notes or convertible
preferred stock or warrants) subject to a limitation on conversion or exercise analogous to the limitation contained herein beneficially
owned by the Holder or any of its Attribution Parties. Except as set forth in the preceding sentence, for purposes of this section, beneficial
ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance
with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance
therewith. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of
the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 5(c), in determining the
number of outstanding shares of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in
(A) the Company's most recent periodic or annual report filed with the Securities and Exchange Commission, as the case may
be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Company's
transfer agent setting forth the number of shares of Common Stock outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Holder or its Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The provisions
of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 5(c) to
correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation
herein contained or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations
contained in this paragraph shall apply to a successor holder of this Warrant. Upon the written request of the Holder, the Company shall
within three (3) trading days confirm orally or in writing to the Holder the number of shares of Common Stock then outstanding, including
by virtue of any prior conversion or exercise of convertible or exercisable securities into Common Stock, including, without limitation,
pursuant to this Warrant or securities issued pursuant to the Purchase Agreement.

6) CERTIFICATE OF ADJUSTMENT. Whenever the Exercise Price or number or type of securities issuable upon exercise of this Warrant is adjusted, as herein provided, the Company shall, at its expense, promptly deliver to the Holder a certificate of an officer of the Company setting forth the nature of such adjustment and showing in detail the facts upon which such adjustment is based.

7) NOTICES. In the event of:

&nbsp;&nbsp;&nbsp;&nbsp;a) any taking by the Company of a record of the holders of any class of securities for the purpose of determining the holders thereof
who are entitled to receive any dividend (other than a cash dividend payable out of earned surplus of the Company) or other distribution,
or any right to subscribe for, purchase or otherwise acquire any shares of stock of any class or any other securities or property, or
to receive any other right; or

&nbsp;&nbsp;&nbsp;&nbsp;b) any voluntary or involuntary dissolution, liquidation or winding-up of the Company, then and in each such event the Company will promptly
mail or cause to be delivered to the Holder (or a permitted transferee) a notice specifying (i) the date on which any such record
is to be taken for the purpose of such dividend, distribution or right, and stating the amount and character of such dividend, distribution
or right, and (ii) the date on which any such dissolution, liquidation or winding-up is to take place, and the time, if any, as of
which the holders of record of Common Stock (or other securities) shall be entitled to exchange their shares of Common Stock (or other
securities) for securities or other property deliverable upon such dissolution, liquidation or winding-up. Such notice shall be delivered
at least twenty (20) days prior to the date therein specified.

&nbsp;&nbsp;&nbsp;&nbsp;c) Whenever any other notice is required to be given under this Warrant, unless otherwise provided herein, the Company shall provide
prompt written notice of all actions taken pursuant to this Warrant, including in reasonable detail a description of such action and the
reason therefore.

8) REPLACEMENT OF WARRANTS. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of any such loss, theft or destruction of this Warrant, on delivery of an indemnity agreement reasonably satisfactory in form and amount to the Company or, in the case of any such mutilation, on surrender and cancellation of such Warrant, the Company at its expense will execute and deliver, in lieu thereof, a new Warrant of like tenor.

9) ISSUANCE OF NEW WARRANTS. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant (i) shall be of like tenor with this Warrant, (ii) shall represent, as indicated on the face of such new Warrant, the right to purchase the Warrant Shares then underlying this Warrant (or in the case of a new Warrant being issued pursuant to Sections 8 or 9, the Warrant Shares designated by the Holder which, when added to the number of shares of Common Stock underlying the other new Warrants issued in connection with such issuance, does not exceed the number of Warrant Shares then underlying this Warrant), (iii) shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date, and (iv) shall have the same rights and conditions as this Warrant.

10) NO FRACTIONAL SHARES. No fractional Warrant Shares or scrip representing fractional shares will be issued upon exercise of this Warrant. In lieu of any fractional shares which would otherwise be issued, the Company shall pay cash equal to the product of such fraction multiplied by the Fair Market Value of one Warrant Share.

11) AMENDMENT AND WAIVER. Except as otherwise provided herein, the provisions of this Warrant may be amended and the Company may take any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder.

12) TRADING DAYS. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall be other than a day on which the Common Stock is traded (which for the avoidance of doubt includes a Saturday, Sunday or a legal U.S. holiday) on the Nasdaq Global Select Market, or, if the Nasdaq Global Select Market is not the principal trading market for the Common Stock or other such securities, as applicable, then on the principal securities exchange or securities market on which the Common Stock is then traded then such action may be taken or such right may be exercised on the next succeeding day on which the Common Stock is so traded.

13) TRANSFERS; EXCHANGES.

&nbsp;&nbsp;&nbsp;&nbsp;a) Subject to compliance with applicable federal and state securities laws and Section 7 hereof, this Warrant may be transferred
by the Holder with respect to all of the Warrant Shares purchasable hereunder. For a transfer of this Warrant, as an entirety by Holder,
upon surrender of this Warrant to the Company, together with the Notice of Assignment in the form attached hereto as <u>Exhibit B</u> properly completed and duly executed by the Holder, the Company shall issue a new Warrant of the same denomination to the assignee. Upon
surrender of this Warrant to the Company, together with the Notice of Assignment in the form attached hereto as <u>Exhibit B</u> properly completed and duly executed by the Holder, for transfer of this Warrant with respect to a portion of the Warrant Shares purchasable
hereunder, the Company will forthwith issue and deliver upon the order of the Holder a new Warrant (in accordance with Section 9),
registered as the Holder may request, representing the right to purchase the number of Warrant Shares being transferred by the Holder
and, if less than the total number of Warrant Shares then underlying this Warrant is being transferred, a new Warrant (in accordance with
Section 9) to the Holder representing the right to purchase the number of Warrant Shares not being transferred.

&nbsp;&nbsp;&nbsp;&nbsp;b) This Warrant is exchangeable, without expense, at the option of the Holder, upon presentation and surrender hereof to the Company
for other warrants of different denominations entitling the holder thereof to purchase in the aggregate the same number of shares of Common
Stock purchasable hereunder. This Warrant may be combined with other warrants that carry the same rights upon presentation hereof at the
office of the Company designated for such purpose together with a written notice specifying the denominations in which new warrants are
to be issued to the Holder and signed by the Holder hereof. The term "Warrants" as used herein includes any warrants into
which this Warrant may be divided or exchanged.

&nbsp;&nbsp;&nbsp;&nbsp;c) If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall
not be either (i) registered pursuant to an effective registration statement under the Securities Act of 1933, as amended (the " <u>Securities Act</u> ") and under applicable state securities or blue sky laws or (ii) eligible for resale pursuant to Rule 144, the
Company may require, as a condition of allowing such transfer; that the Holder or transferee of this Warrant, as the case may be, provide
to the Company an opinion of counsel selected by the Holder and reasonably acceptable to the Company, the form and substance of which
opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred
Warrant under the Securities Act.

&nbsp;&nbsp;&nbsp;&nbsp;d) The Holder, by the acceptance hereof, represents and warrants that, except when it exercises this Warrant pursuant to a Net Exercise,
it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account
and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities Act or
any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act.

14) GOVERNING LAW; VENUE. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. With respect to any disputes arising out of or related to this Warrant, the parties consent to the exclusive jurisdiction of, and venue in, the state courts in the State of New York (or in the event of exclusive federal jurisdiction, the courts of the District of New York). Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS WARRANT OR THE TRANSACTIONS CONTEMPLATED HEREBY.

15) DISPUTE RESOLUTION. In the case of a dispute as to the determination of the Exercise Price, the arithmetic calculation of the Warrant Shares or under Sections 2 or 6, the disputing party shall submit the disputed determinations or arithmetic calculations to the other party. If the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price or the Warrant Shares within three (3) trading days of such disputed determination or arithmetic calculation being submitted to the non-disputing party, then the Company shall, within two (2) trading days submit the dispute to an independent, reputable accountant. The Company shall cause, at the expense of the prevailing party, the accountant to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten (10) trading days from the time it receives the disputed determinations or calculations. Such accountant's determination or calculation shall be binding upon all parties absent demonstrable error.

16) REMEDIES, OTHER OBLIGATIONS, BREACHES AND INJUNCTIVE RELIEF. The remedies provided in this Warrant shall be cumulative and in addition to all other remedies available under this Warrant, at law or in equity (including a decree of specific performance and/or other injunctive relief), and nothing herein shall limit the right of the Holder to pursue actual damages for any failure by the Company to comply with the terms of this Warrant.

17) CONSTRUCTION; HEADINGS. This Warrant shall be deemed to be jointly drafted by the Company and the Holder and shall not be construed against any person as the drafter hereof. The headings of this Warrant are for convenience of reference and shall not form part of, or affect the interpretation of, this Warrant.

18) SUCCESSORS AND ASSIGNS. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of the Holder. The provisions of this Warrant are intended to be for and the benefit of any Holder from time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares.

19) RESTRICTIONS. The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, must comply with the applicable restrictions upon resale imposed by state and federal securities laws.

20) MISCELLANEOUS. All notices, requests, consents and other communications hereunder shall be in writing, shall be sent by confirmed electronic mail, or mailed by first-class registered or certified airmail, or nationally recognized overnight express courier, postage prepaid, and shall be deemed given when so sent in the case of electronic mail transmission, or when so received in the case of mail or courier, and addressed as follows: (a) if to the Company, at Morphic Holding, Inc., 35 Gatehouse Drive, A2, Waltham, Massachusetts, 02451, Attention: Chief Executive Officer; General Counsel; with a copy to (which shall not constitute notice) Fenwick & West LLP, 555 California Street, 12th Floor San Francisco, California, 94104, Attention: Effie Toshav, Robert Freedman, Julia Forbess, and (b) if to the Holder, at such address or addresses (including copies to counsel) as may have been furnished by the Holder to the Company in writing. The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provisions.

[Signature Page Follows]

IN WITNESS WHEREOF, this Warrant is issued effective as of the date first set forth above.

---

| |
|:---|
| MORPHIC HOLDING, INC. |
| By: |
| Name: |
| Title: |

---

**EXHIBIT A**

**NOTICE OF INTENT TO EXERCISE**

(To be signed only upon exercise of Warrant)

To: Morphic Holding, Inc.

The undersigned, the Holder of the attached Warrant, hereby irrevocably elects to exercise the purchase right represented by such Warrant for, and to purchase thereunder, [·] shares of Common Stock of Morphic Holding, Inc., a Delaware corporation (the "<u>Company</u>"), and (choose one)

[·] herewith makes payment of USD [·] thereof

or

[·] elects to Net Exercise the Warrant pursuant to Section 1(b)(2) thereof.

The undersigned requests that the certificates or book entry position evidencing the shares to be acquired pursuant to such exercise be issued in the name of, and delivered to [·], whose address is [·].

By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section 5(c) of the Warrant to which this notice relates.

By its signature below the undersigned hereby represents and warrants that it is an "accredited investor" as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended, and agrees to be bound by the terms and conditions of the attached Warrant as of the date hereof, including Section 5 thereof.

---

| | |
|:---|:---|
| DATED: |  |
|  | (Signature must conform in all respects to name of the Holder as specified on the face of the Warrant) |
|  | [Holder Name] |
|  | Address: |

---

**<u>EXHIBIT B</u>**

**NOTICE OF ASSIGNMENT FORM**

FOR VALUE RECEIVED, [Holder Name] (the "<u>Assignor</u>") hereby sells, assigns and transfers all of the rights of the undersigned Assignor under the attached Warrant with respect to the number of shares of common stock of Morphic Holding, Inc., a Delaware corporation (the "<u>Company</u>"), covered thereby set forth below, to the following "<u>Assignee</u>" and, in connection with such transfer, represents and warrants to the Company that the transfer is in compliance with Section 5 of the Warrant and applicable federal and state securities laws:

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NAME OF ASSIGNEE | ADDRESS |
| Number of shares: |  |
| Dated: | Signature: |

---

**ASSIGNEE ACKNOWLEDGMENT**

The undersigned Assignee acknowledges that it has reviewed the attached Warrant and by its signature below it hereby represents and warrants that it is an "accredited investor" as defined in Rule 501(a) of Regulation D promulgated under the Securities Act of 1933, as amended, and agrees to be bound by the terms and conditions of the Warrant as of the date hereof, including Section 5 thereof.

---

| |
|:---|
| Signature: |
| By: |
| Its: |

---

Address:

## Exhibit 10.1

**Exhibit 10.1** 

**<u>SECURITIES PURCHASE AGREEMENT</u>**

This SECURITIES PURCHASE AGREEMENT (this "<u>Agreement</u>") is made and entered into as of February 13, 2023 by and among Morphic Holding, Inc., a Delaware corporation (the "<u>Company</u>"), and the Investors identified on <u>Exhibit A</u> attached hereto (each an "Investor" and collectively the "<u>Investors</u>").

**RECITALS** 

WHEREAS, the Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by the provisions of Section 4(a)(2) of the Securities Act of 1933, as amended (the "<u>1933 Act</u>"), and Rule 506 of Regulation D ("<u>Regulation D</u>"), as promulgated by the U.S. Securities and Exchange Commission (the "<u>SEC</u>") under the 1933 Act; and

WHEREAS, the Investors wish to purchase from the Company, and the Company wishes to sell and issue to the Investors, upon the terms and subject to the conditions stated in this Agreement, that aggregate number of (i) shares (the "<u>Shares</u>") of the Company's common stock, par value $0.0001 per share (the "<u>Common Stock</u>"), and (ii) pre-funded warrants, in substantially the form attached as <u>Exhibit B</u> hereto (the "<u>Pre-Funded Warrants</u>"), to purchase shares of Common Stock, as set forth next to such Investor's name on <u>Exhibit A</u> hereto;

WHEREAS, the shares of Common Stock issuable upon exercise of, or otherwise pursuant to, the Pre-Funded Warrants are referred to herein as the "<u>Warrant Shares</u>";

WHEREAS, the Shares and the Pre-Funded Warrants to be sold pursuant to the terms of this Agreement are sometimes referred to herein as the "<u>Securities</u>"; and

WHEREAS, contemporaneously with the sale of the Securities, the parties hereto will execute and deliver a Registration Rights Agreement, in the form attached hereto as <u>Exhibit C</u> (the "<u>Registration Rights Agreement</u>"), pursuant to which the Company will agree to provide certain registration rights in respect of the Shares and Warrant Shares under the 1933 Act, and the rules and regulations promulgated thereunder, and applicable state securities laws.

NOW, THEREFORE, IN CONSIDERATION of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

1. <u>Definitions</u>. For the purposes of this Agreement, the following terms shall have the meanings set forth below:

"<u>Affiliate</u>" means, with respect to any Person, any other Person which directly or indirectly through one or more intermediaries Controls, is controlled by, or is under common Control with, such Person.

"<u>Applicable Laws</u>" means all statutes, rules or regulations of the U.S. Food and Drug Administration ("<u>FDA</u>") and other comparable governmental entities applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the Company.

"<u>Authorizations</u>" means any Applicable Laws or any licenses, certificates, approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws.

"<u>Business Day</u>" means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business.

"<u>Bylaws</u>" has the meaning set forth in Section 4.4.

"<u>Certificate of Incorporation</u>" has the meaning set forth in Section 4.4.

"<u>Closing</u>" has the meaning set forth in Section 3.1.

"<u>Closing Date</u>" has the meaning set forth in Section 3.1.

"<u>Common Stock</u>" has the meaning set forth in the recitals to this Agreement.

"<u>Company</u>" means Morphic Holding, Inc., a Delaware corporation.

"<u>Company's Knowledge</u>" means the actual knowledge, after reasonable inquiry, of the executive officers (as defined in Rule 405 under the 1933 Act) of the Company.

"<u>Control</u>" (including the terms "controlling", "controlled by" or "under common control with") means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

"<u>Disclosure Date</u>" has the meaning set forth in Section 9.7.

"<u>EcoR1</u>" means EcoR1 Capital, LLC. and its affiliates.

"<u>Financial Statements</u>" has the meaning set forth in Section 4.9.

"<u>GAAP</u>" has the meaning set forth in Section 4.24.

"<u>Governmental Entity</u>" means any arbitrator, court, governmental body, regulatory body, administrative agency or other authority, body or agency having jurisdiction over the Company or any of its subsidiaries or any of their respective properties, assets or operations.

"<u>HIPAA</u>" has the meaning set forth in Section 4.30.

"<u>Intellectual Property</u>" has the meaning set forth in Section 4.15.

"<u>Investor Questionnaire</u>" has the meaning set forth in Section 5.8.

"<u>Investors</u>" has the meaning set forth in the recitals to this Agreement.

"<u>IT Systems</u>" has the meaning set forth in 4.33.

"<u>Losses</u>" has the meaning set forth in Section 8.2.

"<u>Material Adverse Effect</u>" means a material adverse effect on (i) the assets, liabilities, results of operations, prospects, condition (financial or otherwise) or business of the Company and its subsidiaries taken as a whole, (ii) the legality or enforceability of any of the Transaction Documents or (iii) the ability of the Company to perform its obligations under the Transaction Documents.

"<u>Material Contract</u>" means any contract, instrument or other agreement to which the Company is a party or by which it is bound which is material to the business of the Company, including those that have been filed or were required to have been filed as an exhibit to the SEC Filings pursuant to Item 601(b)(10) of Regulation S-K.

"<u>Money Laundering Laws</u>" has the meaning set forth in Section 4.31.

"<u>Nasdaq</u>" means the Nasdaq Global Market.

"<u>Permits</u>" has the meaning set forth in Section 4.12.

"<u>Personal Data</u>" has the meaning set forth in Section 4.33.

"<u>Person</u>" means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein.

"<u>Pre-Funded Warrants</u>" has the meaning set forth in the recitals to this Agreement.

"<u>Registration Rights Agreement</u>" has the meaning set forth in the recitals to this Agreement.

"<u>Regulation D</u>" has the meaning set forth in the recitals to this Agreement.

"<u>Sanctions</u>" has the meaning set forth in Section 4.32.

"<u>SEC Filings</u>" means the Company's filings made pursuant to the 1934 Act.

"<u>Securities</u>" has the meaning set forth in the recitals to this Agreement.

"<u>Short Sales</u>" means all "short sales" as defined in Rule 200 of Regulation SHO under the 1934 Act (but shall not be deemed to include the location and/or reservation of borrowable shares of Common Stock).

"<u>Subscription Amount</u>" means, as to an Investor, the aggregate amount to be paid for the Securities purchased hereunder as specified opposite such Investor's name on <u>Exhibit A</u> attached hereto, under the column entitled "Aggregate Purchase Price of Securities Purchased," in U.S. Dollars and in immediately available funds.

"<u>Transfer Agent</u>" has the meaning set forth in Section 7.2.

"<u>Transaction Documents</u>" means this Agreement and the Registration Rights Agreement.

"<u>Warrant Shares</u>" has the meaning set forth in the recitals to this Agreement.

"<u>1933 Act</u>" has the meaning set forth in the recitals to this Agreement.

"<u>1934 Act</u>" means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

"<u>1934 Act Regulations</u>" means the rules and regulations promulgated under the 1934 Act.

2. <u>Purchase and Sale of the Securities</u>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the
Company will issue and sell, and each Investor will purchase, severally and not jointly, the number of Securities set forth opposite the
name of such Investor under the heading "Number of Securities Purchased" on <u>Exhibit A</u> attached hereto. The purchase
price of Common Stock shall be $35.35 per share and the purchase price of the Pre-Funded Warrants shall be $35.3499 per Pre-Funded Warrant.

3. <u>Closing</u>.

&nbsp;&nbsp;&nbsp;&nbsp;3.1. Upon the satisfaction of the conditions set forth in Section 6, the completion of the purchase and sale of the Securities (the " <u>Closing</u> ")
shall occur remotely via exchange of documents and signatures (the " <u>Closing Date</u> ") on the second trading day after
the date hereof.

&nbsp;&nbsp;&nbsp;&nbsp;3.2. On the Closing Date, each Investor shall deliver or cause to be delivered to the Company the Subscription Amount via wire transfer
of immediately available funds pursuant to the wire instructions delivered to such Investor by the Company on or prior to the Closing
Date, provided that where requested in writing by an Investor, such funds may follow the receipt by such Investor of a copy of the records
of the Transfer Agent showing the Investor as the owner of the number of Securities indicated on <u>Exhibit A</u> attached hereto as of
the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;3.3. At or before the Closing, the Company shall deliver or cause to be delivered to each Investor (i) the number of Shares, registered
in the name of the Investor (or its nominee in accordance with such Investor's delivery instructions), equal to the number of Shares
indicated under the heading "Number of Shares Purchased" on <u>Exhibit A</u> attached hereto and (ii) the number of Pre-Funded
Warrants, executed by the Company and registered in the name of such Investor (or its nominee in accordance with such Investor's
delivery instructions), equal to the number of Pre-Funded Warrants indicated under the heading "Number of Pre-Funded Warrants Purchased"
on <u>Exhibit A</u> attached hereto. The Shares shall be delivered via a book-entry record through the Transfer Agent, and the Company
shall cause the Transfer Agent to deliver to the Investor, at or prior to the Closing, a copy of the records of the Transfer Agent showing
the Investor as the owner of the number of Shares indicated on <u>Exhibit A</u> attached hereto as of the Closing Date. The Pre-Funded
Warrants shall be delivered as an electronic copy, with the original Pre-Funded Warrants delivered within five Business Days of the Closing
Date.

4. <u>Representations and Warranties of the Company</u>. The Company hereby represents and warrants to the Investors that, except as
otherwise described in the SEC Filings made prior to the date hereof, which qualify these representations and warranties in their entirety:

&nbsp;&nbsp;&nbsp;&nbsp;4.1. <u>Organization, Good Standing and Qualification</u>. The Company and each of its subsidiaries have been duly organized and are validly
existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and
are in good standing in each jurisdiction in which their respective ownership or lease of property or the conduct of their respective
businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct
the businesses in which they are engaged, except where the failure to be so qualified or in good standing or have such power or authority
would not, individually or in the aggregate, have a Material Adverse Effect. The Company does not have any significant subsidiary as defined
in Rule 1-20(w) of Regulation S-X other than the subsidiaries listed in Exhibit 21.1 to the Company's Annual Report on Form 10-K
for the most recently ended fiscal year.

&nbsp;&nbsp;&nbsp;&nbsp;4.2. <u>Authorization</u>. The Company has the requisite corporate power and authority and has taken all requisite corporate action necessary
for, and no further action on the part of the Company, its officers, directors and stockholders is necessary for, (i) the authorization,
execution and delivery of the Transaction Documents, (ii) the authorization of the performance of all obligations of the Company hereunder
or thereunder, and (iii) the authorization for issuance and delivery of the Securities. The Transaction Documents constitute the legal,
valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors' rights
generally and to general equitable principles.

&nbsp;&nbsp;&nbsp;&nbsp;4.3. <u>Capitalization</u>. As set forth in the SEC Filings as of the date set forth therein, all of the Company's outstanding shares
of capital stock have been duly authorized and validly issued and are fully paid and nonassessable, have been issued in compliance with
all federal and state securities laws, and were not issued in violation of or subject to any preemptive right or other rights to subscribe
for or purchase securities. Except as disclosed in the SEC Filings, there are no existing options, warrants, calls, subscriptions or other
rights, agreements, arrangements or commitments of any character, relating to the issued or unissued capital stock of the Company, obligating
the Company to issue, transfer, sell, redeem, purchase, repurchase or otherwise acquire or cause to be issued, transferred, sold, redeemed,
purchased, repurchased or otherwise acquired any capital stock or voting debt of, or other equity interest in, the Company or securities
or rights convertible into or exchangeable for such shares or equity interests or obligations of the Company to grant, extend or enter
into any such option, warrant, call, subscription or other right, agreement, arrangement or commitment. Neither the execution of this
Agreement nor the issuance of Securities pursuant to any provision of this Agreement will give rise to any preemptive rights or rights
of first refusal on behalf of any Person or result in the triggering of any anti-dilution or other similar rights. Other than the Common
Stock, there are no other shares of any other class or series of capital stock of the Company issued or outstanding. The Company's
Certificate of Incorporation, as amended and as in effect on the date hereof (the " <u>Certificate of Incorporation</u> "),
and the Company's Bylaws, as amended and as in effect on the date hereof (the " <u>Bylaws</u> "), are included in the
SEC Filings except as otherwise disclosed to the Investors, and the Company shall not amend or otherwise modify the Certificate of Incorporation
or Bylaws prior to the Closing.

&nbsp;&nbsp;&nbsp;&nbsp;4.4. <u>Valid Issuance</u>. The Securities being purchased hereunder have been duly authorized and, when issued, delivered and paid for
in the manner set forth in this Agreement will be validly issued, fully paid and nonassessable and will be free and clear of all encumbrances

or imposed by applicable securities laws. The Shares conform, in all material respects, to all statements relating thereto contained in
the SEC Filings and such description conforms in all material respects to the rights set forth in the instruments defining the same. The
Warrant Shares issuable upon exercise of the Pre-Funded Warrants have been duly authorized and, when issued and paid for in accordance
with the terms of the Transaction Documents, will be duly and validly issued, fully paid and nonassessable, other than restrictions on
transfer provided for in the Transaction Documents or imposed by applicable securities laws, and shall not be subject to preemptive rights,
rights of first refusal or other similar rights. Assuming the accuracy of the representations and warranties of each Investor in Section
5 hereof, the Securities will be issued in compliance with applicable federal and state securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;4.5. <u>Consents</u>. Subject to the accuracy of the representations and warranties of each Investor set forth in Section 5 hereof, the
execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale of the Purchased Shares
require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official other than filings
that have been made pursuant to applicable state securities laws and post-sale filings pursuant to applicable state and federal securities
laws and the rules and regulations of Nasdaq which the Company undertakes to file within the applicable time periods and other than the
registration statement required to be filed by the Registration Rights Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;4.6. <u>Use of Proceeds</u>. The net proceeds of the sale of the Securities hereunder shall be used by the Company for working capital
and general corporate purposes, including clinical development.

&nbsp;&nbsp;&nbsp;&nbsp;4.7. <u>No Material Adverse Change</u>. Since September 30, 2022, except as specifically disclosed in the SEC Filings, there have been
no events, occurrences or developments that have had or would reasonably be expected to have, either individually or in the aggregate,
a Material Adverse Effect. Except for the transactions contemplated by this Agreement, no event, liability or development has occurred
or exists with respect to the Company or any of its subsidiaries or their respective businesses, properties, operations or financial conditions
that would be required to be disclosed by the Company under applicable securities laws at the date of this Agreement that has not been
publicly disclosed at least one trading day prior to the date of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;4.8. <u>No Conflict, Breach, Violation or Default</u>. The execution, delivery and performance of the Transaction Documents by the Company
and the issuance and sale of the Securities in accordance with the provisions hereof and thereof will not, (i) conflict with or result
in a breach or violation of (a) any of the terms and provisions of, or constitute a default under, the Company's Certificate of
Incorporation or Bylaws, both as in effect on the date hereof (true and complete copies of which have been made available to the Investors
through the EDGAR system, except as otherwise disclosed to the Investors), or (b) assuming the accuracy of the representations and warranties
in Section 5, any applicable statute, rule, regulation or order of any governmental agency or body or any court, domestic or foreign,
having jurisdiction over the Company, or any of its assets or properties, or (ii) conflict with, or constitute a default (or an event
that with notice or lapse of time or both would become a default) under, result in the creation of any lien, encumbrance or other adverse
claim upon any of the properties or assets of the Company or give to others any rights of termination, amendment, acceleration or cancellation
(with or without notice, lapse of time or both) of, any Material Contract except, with respect to clauses (i)(b) and (ii), for such violations,
conflicts or defaults as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. This Section
does not relate to matters with respect to tax status, which are the subject of Section 4.11 and employee relations and labor matters,
which are the subject of Section 4.14.

&nbsp;&nbsp;&nbsp;&nbsp;4.9. <u>SEC Filings; Financial Statements; Independent Accountants</u>. The Company is not an "ineligible issuer" (as defined
in Rule 405 promulgated under the 1933 Act). The Company is subject to the reporting requirements of the 1934 Act, and has filed or will
file in a timely manner all documents that the Company was or is required to file with the SEC under Sections 13, 14(a) and 15(d) of the
1934 Act, since becoming subject to the requirements of the 1934 Act. As of their respective filing dates (or, if amended prior to the
date of this Agreement, when amended), all SEC Filings complied in all material respects with the requirements of the 1934 Act and the
rules and regulations of the SEC promulgated thereunder. None of the SEC Filings as of their respective filing dates contained any untrue
statement of material fact or omitted to state a material fact required to be stated therein or necessary to make the statements made
therein, in light of the circumstances under which they were made, not misleading. Each prospectus filed by the Company pursuant to Rule
424(b) under the 1933 Act, as of its issue date and as of the closing of any sale of securities pursuant thereto, did not contain any
untrue statement of a material fact or omit to state any material fact required to be stated therein or necessary in order to make the
statements made therein, in the light of the circumstances under which they were made, not misleading. The financial statements of the
Company set forth in the SEC Filings, together with the related schedules and notes (the " <u>Financial Statements</u> ") comply
in all material respects with applicable accounting requirements and with the published rules and regulations of the SEC with respect
thereto. The Financial Statements have been prepared in accordance with United States generally accepted accounting principles consistently
applied and fairly present the financial position of the Company at the dates thereof and the results of its operations and cash flows
for the periods then ended (subject, in the case of unaudited statements, to normal, recurring adjustments). The accountants who certified
the Financial Statements are independent public accountants as required by the 1933 Act and the 1934 Act and the regulations thereunder
and the Public Company Accounting Oversight Board.

&nbsp;&nbsp;&nbsp;&nbsp;4.10. <u>Tax Matters</u>. All United States federal income tax returns of the Company and its subsidiaries required by law to be filed by
them (taking into account any timely requested extensions thereof) have been filed and all taxes shown by such returns or otherwise assessed,
which are due and payable, have been paid, except assessments against which appeals have been or will be promptly taken and as to which
adequate reserves have been provided. The Company and its subsidiaries have filed all other tax returns that are required to have been
filed by them pursuant to applicable foreign, state, local or other law except insofar as the failure to file such returns would not reasonably
be expected to result in a Material Adverse Effect, and has paid all material taxes due pursuant to such returns or pursuant to any assessment
received by the Company and its subsidiaries, except for such taxes, if any, as are being contested in good faith and as to which adequate
reserves have been established by the Company. The charges, accruals and reserves on the books of the Company in respect of any income
and corporation tax liability for any years not finally determined are adequate to meet any assessments or re-assessments for additional
income tax for any years not finally determined, except to the extent of any inadequacy that would not reasonably be expected to result
in a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;4.11. <u>Title to Properties</u>. The Company and its subsidiaries have good and marketable title in fee simple to, or have valid rights
to lease or otherwise use, all items of real and personal property that are material to the respective businesses of the Company and its
subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that
(i) do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries or (ii)
would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;4.12. <u>Licenses and Permits</u>. The Company and its subsidiaries have all franchises, licenses, permits, certificates and other authorizations
from such federal, state or local government or governmental agency, department or body that are currently necessary for the operation
of their respective businesses as currently conducted, including, without limitation, all such certificates, approvals, authorizations,
exemptions, licenses and permits required by the FDA or any other comparable Governmental Entities (collectively, " <u>Permits</u> "),
except where the failure to possess such Permits would not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect. Neither the Company nor any of its subsidiaries has received any written notice requiring or threatening any revocation
or modification of any such Permits, where such revocation or modification would reasonably be expected to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;4.13. <u>Labor Matters</u>. No labor dispute with the employees of the Company or any of its subsidiaries exists or, to the Company's
Knowledge, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or any
subsidiary's principal suppliers, manufacturers, customers or contractors, which, in either case, would reasonably be expected to
result in a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;4.14. <u>Intellectual Property</u>. To the Company's Knowledge, the Company and its subsidiaries own, have valid and enforceable license
to, or otherwise have the right to use, all material patents, patent applications, trademarks, service marks, trade names, trademark registrations,
service mark registrations, trade dress, designs, data, database rights, Internet domain names, copyrights, works of authorship,
licenses, proprietary information and know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential
information, systems or procedures), and all other intellectual property and proprietary rights, including registrations and applications
for registration thereof (collectively, " <u>Intellectual Property</u> ") necessary for the conduct of their respective businesses
as currently conducted and as proposed to be conducted, or which are described in the SEC Filings as being owned by or licensed to the
Company or its subsidiaries. To the Company's Knowledge, the Company and its subsidiaries' conduct of their respective businesses
does not infringe, misappropriate or otherwise violate in any material respect with any Intellectual Property of any third party. The
Intellectual Property of the Company has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole
or in part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. To the Company's
Knowledge, the Company and its subsidiaries have not received any notice of any claim of infringement, misappropriation or conflict with
any intellectual property rights of another, and the Company is unaware of any facts which would form a reasonable basis for any such
notice or claim. To the Company's Knowledge, there are no third parties who have rights to any Intellectual Property, except for
customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the SEC Filings as owned
by or licensed to the Company or its subsidiaries. Except as disclosed in the SEC Filings, there is no pending or, to the Company's
Knowledge, threatened action, suit, proceeding or claim by others: (A) challenging the Company's rights in or to any Intellectual
Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim;
(B) challenging the validity, enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which
would form a reasonable basis for any such action, suit, proceeding or claim; or (C) asserting that the Company or its subsidiaries
infringe, misappropriate, or otherwise violate, or would, upon the commercialization of any product or service described in the SEC Filings
as under development, infringe, misappropriate, or otherwise violate, any intellectual property rights of others, and the Company is unaware
of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. The Company and its subsidiaries have
complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or its subsidiaries,
and all such agreements are in full force and effect. To the Company's Knowledge, there are no material defects in any of the patents
or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken all reasonable steps to protect,
maintain and safeguard their Intellectual Property, including the execution of appropriate nondisclosure, confidentiality agreements and
invention assignment agreements and invention assignments with their employees. To the Company's Knowledge, no employee of the Company
is in or has been in violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition
agreement, non-solicitation agreement, nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis
of such violation relates to such employee's employment with the Company. The duty of candor and good faith as required by the United
States Patent and Trademark Office during the prosecution of the United States patents and patent applications within the Intellectual
Property have been complied with; and in all foreign offices having similar requirements, all such requirements have been complied with.
None of the Company owned Intellectual Property or technology (including information technology and outsourced arrangements) employed
by the Company or its subsidiaries has been obtained or is being used by the Company or its subsidiary in violation of any contractual
obligation binding on the Company or its subsidiaries or any of their respective officers, directors or employees or otherwise in violation
of the rights of any persons.

&nbsp;&nbsp;&nbsp;&nbsp;4.15. <u>Legal Proceedings</u>. Except as disclosed in the SEC Filings, there is no action, suit, proceeding, inquiry or investigation before
or brought by any Governmental Entity now pending or, to the Company's Knowledge, threatened, against or affecting the Company or
any of its subsidiaries, which would reasonably be expected to result in a Material Adverse Effect, or which would reasonably be expected
to materially and adversely affect their respective properties or assets or the consummation of the transactions contemplated in the Transaction
Documents or the performance by the Company of its obligations thereunder; and the aggregate of all pending legal or governmental proceedings
to which the Company or any such subsidiary is a party or of which any of their respective properties or assets is the subject which are
not described in the SEC Filings, including ordinary routine litigation incidental to the business, would not reasonably be expected to
result in a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;4.16. <u>Insurance Coverage</u>. The Company maintains insurance underwritten by insurers of recognized financial responsibility, of the
types and in the amounts that the Company reasonably believes is adequate for businesses of the Company and its subsidiaries, including
directors' and officers' liability insurance and insurance covering all real and personal property owned or leased by the
Company or any of its subsidiaries against theft, damage, destruction, acts of vandalism and all other risks customarily insured against
and against such risks which the Company believes it is prudent to insure against, with such deductibles as are customary for companies
in the same or similar business, all of which insurance is in full force and effect. To the Company's Knowledge, neither the Company
nor any of its subsidiaries has (i) received notice from any insurer or agent of such insurer that capital improvements or other expenditures
are required or necessary to be made in order to continue such insurance or (ii) knowledge of any events that have occurred, or circumstances
that exist, with respect to the Company that would cause it to be unable to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business.

&nbsp;&nbsp;&nbsp;&nbsp;4.17. <u>Compliance with Nasdaq Continued Listing Requirements</u>. The Company is in compliance with applicable Nasdaq continued listing
requirements. There are no proceedings pending or, to the Company's Knowledge, threatened against the Company relating to the continued
listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company's Knowledge is there any
reasonable basis for, the delisting of the Common Stock from Nasdaq.

&nbsp;&nbsp;&nbsp;&nbsp;4.18. <u>Brokers and Finders</u>. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid
right, interest or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement,
arrangement or understanding entered into by or on behalf of the Company. No Investor shall have any obligation with respect to any fees,
or with respect to any claims made by or on behalf of other Persons for fees, in each case of the type contemplated by this Section 4.19
that may be due in connection with the transactions contemplated by this Agreement or the Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;4.19. <u>No Directed Selling Efforts or General Solicitation</u>. Neither the Company nor any Person acting on its behalf has conducted
any general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer or sale of the
Securities.

&nbsp;&nbsp;&nbsp;&nbsp;4.20. <u>No Integrated Offering</u>. Neither the Company nor any Person acting on its behalf has, directly or indirectly, made any offers
or sales of any Company security or solicited any offers to buy any Company security, under circumstances that would adversely affect
reliance by the Company on Section 4(a)(2) for the exemption from registration for the transactions contemplated hereby or would require
registration of the Securities under the 1933 Act.

&nbsp;&nbsp;&nbsp;&nbsp;4.21. <u>Private Placement</u>. Assuming the accuracy of the representations and warranties of the Investors set forth in Section 5, the
offer and sale of the Securities to the Investors as contemplated hereby are exempt from the registration requirements of the 1933 Act.

&nbsp;&nbsp;&nbsp;&nbsp;4.22. <u>Questionable Payments</u>  *.*** Neither the Company nor, to the Company's Knowledge, any of the Company's
directors, officers, employees, agents or other Persons acting on behalf of the Company, has on behalf of the Company: (a) used any corporate
funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity; (b) made any direct
or indirect unlawful payments to any governmental officials or employees from corporate funds; (c) established or maintained any unlawful
or unrecorded fund of corporate monies or other assets which is in violation of law; (d) made any false or fictitious entries on the books
and records of the Company; or (e) made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment of any
nature.

&nbsp;&nbsp;&nbsp;&nbsp;4.23. <u>Transactions with Affiliates</u>. None of the executive officers or directors of the Company and, to the Company's Knowledge,
none of the employees of the Company is presently a party to any transaction with the Company (other than as holders of stock options,
and for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing
of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments to or from any officer,
director or such employee or, to the Company's Knowledge, any entity in which any officer, director, or any such employee has a
substantial interest or is an officer, director, trustee or partner.

&nbsp;&nbsp;&nbsp;&nbsp;4.24. <u>Internal Controls</u>. The Company and its subsidiaries maintain systems of "internal control over financial reporting"
(as defined in Rule 13a-15(f) of the 1934 Act) designed to comply with the applicable requirements of the 1934 Act and have
been designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing
similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with U.S. generally accepted accounting principles (" <u>GAAP</u> "), including internal
accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management's
general or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in
conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management's
general or specific authorization; (iv) the recorded accountability for assets is compared with the existing assets at reasonable
intervals and appropriate action is taken with respect to any differences; and (v) the interactive data in eXtensible Business Reporting
Language included or incorporated by reference in the SEC Filings fairly presents the information called for in all material respects
and is prepared in accordance with the SEC's rules and guidelines applicable thereto. There are no material weaknesses in the
Company's internal controls. The Company's auditors and the Audit Committee of the Board of Directors of the Company have
been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial
reporting which have adversely affected or are reasonably likely to adversely affect the Company's ability to record, process, summarize
and report financial information; and (ii) to the best knowledge of the Company, any fraud, whether or not material, that involves
management or other employees who have a significant role in the Company's internal controls over financial reporting.

&nbsp;&nbsp;&nbsp;&nbsp;4.25. <u>Investment Company</u>. The Company is not required to be registered as, and is not an Affiliate of, and immediately following
the Closing will not be required to register as, an "investment company" within the meaning of the Investment Company Act
of 1940, as amended.

&nbsp;&nbsp;&nbsp;&nbsp;4.26. <u>Tests and Preclinical and Clinical Trials</u>. The studies, tests and preclinical and clinical trials conducted by or, to the Company's
Knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental
protocols, procedures and controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws,
including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and current
Good Clinical Practices and Good Laboratory Practices and any applicable rules, regulations and policies of the jurisdiction in which
such trials and studies are being conducted; the descriptions of the results of such studies, tests and trials contained or incorporated
by reference in the SEC Filings are, to the Company's knowledge, accurate and complete in all material respects and fairly present
the data derived from such studies, tests and trials; except to the extent disclosed in the SEC Filings, the Company is not aware of any
studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described
or referred to in the SEC Filings when viewed in the context in which such results are described and the clinical state of development;
and, except to the extent disclosed in the SEC Filings, the Company has not received any notices or correspondence from the FDA or any
governmental entity requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on
behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation
of such trials, copies of which communications have been made available to you.

&nbsp;&nbsp;&nbsp;&nbsp;4.27. <u>Manipulation of Price</u>. The Company has not, and, to the Company's Knowledge, no Person acting on its behalf has taken,
directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of any of the Securities.

&nbsp;&nbsp;&nbsp;&nbsp;4.28. <u>Bad Actor Disqualification</u>. None of the Company, any predecessor or affiliated issuer of the Company nor, to the Company's
Knowledge, any director or executive officer of the Company or any promoter connected with the Company in any capacity, is subject to
any of the "bad actor" disqualifications within the meaning of Rule 506(d) under the 1933 Act, except for a disqualification
event covered by Rule 506(d)(2) or (d)(3).

&nbsp;&nbsp;&nbsp;&nbsp;4.29. <u>Absence of Violations, Defaults and Conflicts</u>. Neither the Company nor any of its subsidiaries is (i) in violation of its charter,
by-laws or similar organizational document, (ii) in default in the performance or observance of any obligation, agreement, covenant or
condition contained in any Material Contract, except for such defaults that would not, singly or in the aggregate, result in a Material
Adverse Effect, or (iii) in violation of any law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity,
except for such violations that would not, singly or in the aggregate, result in a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;4.30. <u>Healthcare Laws</u>. The Company and its subsidiaries are, and at all times have been, in compliance in all material respects with
all Health Care Laws. For purposes of this Agreement, " <u>Health Care Laws</u> " means: (i) the Federal Food, Drug, and
Cosmetic Act and the regulations promulgated thereunder; (ii) all applicable federal, state, local and foreign health care fraud
and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. Section 1320a-7b(b)), the U.S. Civil False
Claims Act (31 U.S.C. Section 3729 et seq.), the criminal False Statements Law (42 U.S.C. Section 1320a-7b(a)), 18 U.S.C. Sections
286, 287, 1035, 1347, and 1349 the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability
Act of 1996 (" <u>HIPAA</u> ") (42 U.S.C. Section 1320d et seq.), the civil monetary penalties law (42 U.S.C. Section 1320a-7a),
the exclusions law (42 U.S.C. Section 1320a-7), laws governing government funded or sponsored healthcare programs; (iii) HIPAA,
as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. Section 17921 et seq.); (iv) the
Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010; (v) licensure,
quality, safety and accreditation requirements under applicable federal, state, local or foreign laws or regulatory bodies; and (vi) all
other local, state, federal, national, supranational and foreign laws, relating to the regulation of the Company or its subsidiaries,
and (vii) the directives and regulations promulgated pursuant to such statutes and any state or non-U.S. counterpart thereof. Neither
the Company, any of its subsidiaries, nor any of their respective officers, directors, employees or agents have engaged in activities
which are, as applicable, cause for liability under a Health Care Law. Neither the Company nor any of its subsidiaries has received written
notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator
or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care
Laws nor, to the Company's Knowledge, is any such claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration
or other action threatened. The Company, and to the Company's knowledge, its subsidiaries have filed, maintained or submitted all
material reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any
Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments
were complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission).
Neither the Company, any of its subsidiaries, nor, to the Company's Knowledge, any of their respective employees, officers, directors,
or agents is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements
with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor any of their
respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health
care program or human clinical research or, to the Company's Knowledge, is subject to a governmental inquiry, investigation, proceeding,
or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion.

&nbsp;&nbsp;&nbsp;&nbsp;4.31. <u>Money Laundering Laws</u>. The operations of the Company and its subsidiaries are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as
amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related or similar rules, regulations
or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the " <u>Money Laundering Laws</u> ");
and no action, suit or proceeding by or before any Governmental Entity involving the Company or any of its subsidiaries with respect to
the Money Laundering Laws is pending or, to the Company's Knowledge, threatened.

&nbsp;&nbsp;&nbsp;&nbsp;4.32. <u>OFAC</u>. None of the Company, any of its subsidiaries or, to the Company's Knowledge, any director, officer, agent, employee,
affiliate or representative of the Company or any of its subsidiaries is a Person currently the subject or target of any sanctions administered
or enforced by the United States Government, including, without limitation, the U.S. Department of the Treasury's Office of Foreign
Assets Control, the United Nations Security Council, the European Union, Her Majesty's Treasury, or other relevant sanctions authority
(collectively, " <u>Sanctions</u> "), nor is the Company located, organized or resident in a country or territory that is the
subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the sale of the Securities, or lend, contribute
or otherwise make available such proceeds to any subsidiaries, joint venture partners or other Person, to fund or facilitate any activities
of or business with any Person, or in any country or territory, that, at the time of such funding or facilitating, is the subject of Sanctions
or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as
underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, the Company and its subsidiaries have not knowingly
engaged in and are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction
is or was the subject or the target of Sanctions or with country or territory that is the subject of Sanctions.

&nbsp;&nbsp;&nbsp;&nbsp;4.33. <u>Cybersecurity</u>. The Company and its subsidiaries' information technology assets and equipment, computers, systems, networks,
hardware, software, websites, applications, and databases (collectively, " <u>IT Systems</u> ") are adequate for, and operate
and perform in all material respects as required in connection with the operation of the business of the Company and the Subsidiaries
as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants.
The Company and its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards
to maintain and protect their material confidential information and the integrity, continuous operation, redundancy and security of all
IT Systems and data (including all personal, personally identifiable, sensitive, confidential or regulated data (" <u>Personal Data</u> "))
used in connection with their businesses, and, to the Company's Knowledge, there have been no breaches, violations, outages or unauthorized
uses of or accesses to same, except for those that have been remedied without material cost or liability or the duty to notify any other
person, nor any incidents under internal review or investigations relating to the same. The Company and its subsidiaries are presently
in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator
or governmental or regulatory authority, internal policies and contractual obligations, in each case relating to the privacy and security
of IT Systems and Personal Data and to the protection of such IT Systems and Personal Data from unauthorized use, access, misappropriation
or modification.

&nbsp;&nbsp;&nbsp;&nbsp;4.34. <u>Registration Rights</u>. Except as disclosed in the SEC Filings and other than the Investors, no Person has any right to cause
the Company or any subsidiary to effect the registration under the Securities Act of any securities of the Company or any subsidiary.

&nbsp;&nbsp;&nbsp;&nbsp;4.35. <u>Form S-3 Eligibility/WKSI Status</u>. The Company is eligible to register the Securities for resale by the Investors on Form S-3
promulgated under the Securities Act. The Company is a "well-known seasoned issuer" as defined under Rule 405.

&nbsp;&nbsp;&nbsp;&nbsp;4.36. <u>Acknowledgment Regarding Investors' Trading Activity</u>. Anything in this Agreement or elsewhere herein to the contrary
notwithstanding, it is understood and acknowledged by the Company that: (i) none of the Investors has been asked by the Company to agree,
nor has any Investor agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or "derivative"
securities based on securities issued by the Company or to hold the Purchased Shares for any specified term, (ii) past or future open
market or other transactions by any Investor, specifically including, without limitation, short sales or "derivative" transactions,
before or after the closing of this or future private placement transactions, may negatively impact the market price of the Company's
publicly-traded securities, (iii) any Investor, and counter-parties in "derivative" transactions to which any such Investor
is a party, directly or indirectly, presently may have a "short" position in the Common Stock and (iv) each Investor shall
not be deemed to have any affiliation with or control over any arm's length counter-party in any "derivative" transaction.
The Company further understands and acknowledges that (y) one or more Investors may engage in hedging activities at various times during
the period that the Purchased Shares are outstanding and (z) such hedging activities (if any) could reduce the value of the existing stockholders'
equity interests in the Company at and after the time that the hedging activities are being conducted. The Company acknowledges that such
aforementioned hedging activities do not constitute a breach of any of the Transaction Documents.

5. <u>Representations and Warranties of the Investors</u>. Each of the Investors hereby severally, and not jointly, represents and warrants
to the Company that:

&nbsp;&nbsp;&nbsp;&nbsp;5.1. <u>Organization and Existence</u>. If the Investor is an entity, such Investor is a duly incorporated or organized and validly existing
corporation, limited partnership or limited liability company and has all requisite corporate, partnership or limited liability company
power and authority to enter into and consummate the transactions contemplated by the Transaction Documents and to carry out its obligations
hereunder and thereunder, and to invest in the Securities pursuant to this Agreement, and is in good standing under the laws of the jurisdiction
of its incorporation or organization.

&nbsp;&nbsp;&nbsp;&nbsp;5.2. <u>Authorization</u>. The execution, delivery and performance by such Investor of the Transaction Documents to which such Investor
is a party have been duly authorized and each has been duly executed and when delivered will constitute the valid and legally binding
obligation of such Investor, enforceable against such Investor in accordance with their respective terms, subject to bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors' rights
generally.

&nbsp;&nbsp;&nbsp;&nbsp;5.3. <u>Purchase Entirely for Own Account</u>. The Securities to be received by such Investor hereunder will be acquired for such Investor's
own account, not as nominee or agent (although the Securities may be registered in the name of the Investor's custodian bank, or
a nominee of such custodian bank), for the purpose of investment and not with a view to the resale or distribution of any part thereof
in violation of the 1933 Act, and such Investor has no present intention of selling, granting any participation in, or otherwise distributing
the same in violation of the 1933 Act without prejudice, however, to such Investor's right at all times to sell or otherwise dispose
of all or any part of such Securities in compliance with applicable federal and state securities laws. The Securities are being purchased
by such Investor in the ordinary course of its business. Nothing contained herein shall be deemed a representation or warranty by such
Investor to hold the Securities for any period of time. Such Investor is not a broker-dealer registered with the SEC under the 1934 Act
or an entity engaged in a business that would require it to be so registered.

&nbsp;&nbsp;&nbsp;&nbsp;5.4. <u>Investment Experience</u>. Such Investor acknowledges that it can bear the economic risk and complete loss of its investment in
the Securities and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and
risks of the investment contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;5.5. <u>Disclosure of Information</u>. Such Investor has had an opportunity to receive, review and understand all information related to
the Company requested by such Investor and to ask questions of and receive answers from the Company regarding the Company, its business
and the terms and conditions of the offering of the Securities, and has conducted and completed such Investor's own independent
due diligence. Such Investor acknowledges that copies of the SEC Filings are available on the EDGAR system. Based on the information such
Investor has deemed appropriate, it has independently made its own analysis and decision to enter into the Transaction Documents. Such
Investor is relying exclusively on its own sources of information, investment analysis and due diligence (including professional advice
it deems appropriate) with respect to the execution, delivery and performance of the Transaction Documents and the business, condition
(financial and otherwise), management, operations, properties and prospects of the Company, including but not limited to all business,
legal, regulatory, accounting, credit and tax matters. Neither such inquiries nor any other due diligence investigation conducted by such
Investor shall modify, limit or otherwise affect such Investor's right to rely on the Company's representations and warranties
contained in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;5.6. <u>Restricted Securities</u>. Such Investor understands that the Securities are characterized as "restricted securities"
under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering
and that under such laws and applicable regulations such securities may be resold without registration under the 1933 Act only in certain
limited circumstances.

&nbsp;&nbsp;&nbsp;&nbsp;5.7. <u>Legends</u>. It is understood that, except as provided below, certificates or book-entry records evidencing the Securities may
bear the following or any similar legend:

"THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND, ACCORDINGLY, MAY NOT BE TRANSFERRED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, (II) SUCH SECURITIES MAY BE SOLD PURSUANT TO RULE 144, OR (III) THE COMPANY HAS RECEIVED AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED."

If required by the authorities of any state in connection with the issuance or sale of the Securities, the legend required by such state authority.

&nbsp;&nbsp;&nbsp;&nbsp;5.8. <u>Accredited Investor</u>. Such Investor is (i) an institutional "accredited investor" within the meaning of Rule 501
under the 1933 Act, (ii) is an "institutional account" as defined in FINRA Rule 4512(c) and (iii) has executed and delivered
to the Company a questionnaire in substantially the form attached hereto as <u>Exhibit D</u> (the " <u>Investor Questionnaire</u> "),
which such Investor represents and warrants is true, correct and complete. Such investor is a sophisticated institutional investor with
sufficient knowledge and experience in investing in private equity transactions to properly evaluate the risks and merits of its purchase
of the Securities. Such Investor has determined based on its own independent review and such professional advice as it deems appropriate
that its purchase of the Securities and participation in the transactions contemplated by the Transaction Documents (i) comply and are
consistent with all investment policies, guidelines and other restrictions applicable to such Investor, (ii) have been duly authorized
and approved by all necessary action, and (iii) do not and will not violate or constitute a default under such Investor's charter,
bylaws or other constituent document or under any law, rule, regulation, agreement or other obligation by which such Investor is bound.
Such Investor understands that the Securities are being offered and sold to it in reliance upon specific exemptions from the registration
requirements of the Securities Act and state securities laws, and that the Company is relying upon the truth and accuracy of, and such
Investor's compliance with, the representations, warranties, agreements, acknowledgments and understandings of such Investor set
forth herein in order to determine the availability of such exemptions and the eligibility of such Investor to acquire the Securities.

&nbsp;&nbsp;&nbsp;&nbsp;5.9. <u>Ownership of Capital Stock</u>. As of the date hereof, such Investor and its affiliates beneficially own such shares of capital
stock of the Company as set forth in the Investor Questionnaire.

&nbsp;&nbsp;&nbsp;&nbsp;5.10. <u>No General Solicitation</u>. Such Investor did not learn of the investment in the Securities as a result of any general or public
solicitation or general advertising, or publicly disseminated advertisements or sales literature, including (a) any advertisement, article,
notice or other communication published in any newspaper, magazine, website, or similar media, or broadcast over television or radio,
or (b) any seminar or meeting to which such Investor was invited by any of the foregoing means of communications.

&nbsp;&nbsp;&nbsp;&nbsp;5.11. <u>Brokers and Finders</u>. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid
right, interest or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement,
arrangement or understanding entered into by or on behalf of such Investor.

&nbsp;&nbsp;&nbsp;&nbsp;5.12. <u>Short Sales and Confidentiality Prior to the Date Hereof</u>. Other than consummating the transactions contemplated hereunder,
such Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with such Investor, directly or indirectly
executed any purchases or sales, including Short Sales, of the securities of the Company during the period commencing as of the time that
such Investor was first contacted by the Company or any other Person regarding the transactions contemplated hereby and ending immediately
prior to the date hereof. Notwithstanding the foregoing, in the case of an Investor that is a multi-managed investment vehicle whereby
separate portfolio managers manage separate portions of such Investor's assets and the portfolio managers have no direct knowledge
of the investment decisions made by the portfolio managers managing other portions of such Investor's assets, the representation
set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision
to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement and other than to such Person's
outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the
performance of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may
be required by law, such Investor has maintained the confidentiality of all disclosures made to it in connection with this transaction
(including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein
shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or
securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future.

&nbsp;&nbsp;&nbsp;&nbsp;5.13. <u>No Government Recommendation or Approval</u>. Such Investor understands that no United States federal or state agency, or similar
agency of any other country, has reviewed, approved, passed upon, or made any recommendation or endorsement of the Company or the purchase
of the Securities.

&nbsp;&nbsp;&nbsp;&nbsp;5.14. <u>No Conflicts</u>. The execution, delivery and performance by such Investor of the Transaction Documents and the consummation by
such Investor of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of
such Investor or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default)
under, or give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument
to which such Investor is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal
and state securities laws) applicable to such Investor, except in the case of clauses (ii) and (iii) above, for such conflicts, defaults,
rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the
ability of such Investor to perform its obligations hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;5.15. <u>Residency</u>. Such Investor is a resident of the jurisdiction specified below its address on the Schedule of Investors in <u>Exhibit A</u> hereto.

&nbsp;&nbsp;&nbsp;&nbsp;5.16. <u>No Legal, Tax or Investment Advice</u>. Such Investor understands that nothing in this Agreement or any other materials presented
by or on behalf of the Company to such Investor in connection with the purchase of the Securities constitutes legal, tax or investment
advice. Such Investor has consulted such legal, tax and investment advisors as it, in its sole discretion, has deemed necessary or appropriate
in connection with its purchase of the Securities.

6. <u>Conditions to Closing</u>.

&nbsp;&nbsp;&nbsp;&nbsp;6.1. <u>Conditions to the Investors' Obligations</u>. The obligation of each Investor to purchase Securities at the Closing is subject
to the fulfillment to such Investor's satisfaction, on or prior to the Closing Date, of the following conditions, any of which may
be waived by such Investor (as to itself only):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The representations and warranties made by the Company in Section 4 hereof shall be true and correct as of the date hereof and on
the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such
representation or warranty shall be true and correct as of such earlier date. The Company shall have performed in all respects all obligations
and covenants herein required to be performed by it on or prior to the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for consummation of
the purchase and sale of the Securities and the consummation of the other transactions contemplated by the Transaction Documents, all
of which shall be in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) The Company shall have executed and delivered the Registration Rights Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy
court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been
instituted by any governmental authority, enjoining or preventing the consummation of the transactions contemplated hereby or in the other
Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) The Company shall have delivered a Certificate, executed on behalf of the Company by its Chief Executive Officer or its Chief Financial
Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in subsections (a), (b), and (d) of this
Section 6.1.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) The Company shall have delivered a Certificate, executed on behalf of the Company by its Secretary, dated as of the Closing Date,
certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement
and the other Transaction Documents and the issuance of the Securities, certifying the current versions of the Certificate of Incorporation
and Bylaws of the Company and certifying as to the signatures and authority of persons signing the Transaction Documents and related documents
on behalf of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) The Investors shall have received from Fenwick & West LLP, legal counsel to the Company, an opinion dated as of the Closing Date
in a form reasonably acceptable to the Investors.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory body with
respect to public trading in the Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Company shall use its best efforts to cause the closing of the purchase of Securities by each Investor to occur substantially
simultaneously, subject to each Investor's performance of its obligations under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;6.2. <u>Conditions to Obligations of the Company</u>. The Company's obligation to sell and issue the Securities at the Closing is
subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which
may be waived by the Company:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The representations and warranties made by the Investors in Section 5 hereof shall be true and correct as of the date hereof and on
the Closing Date. The Investors shall have performed in all respects all obligations and covenants herein required to be performed by
them on or prior to the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The Investors shall have executed and delivered the Registration Rights Agreement and each Investor Questionnaire.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Any Investor purchasing Securities at the Closing shall have paid in full its Subscription Amount to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;6.3. <u>Termination of Obligations to Effect Closing; Effects</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall terminate as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Upon the mutual written consent of the Company and Investors that agreed to purchase a majority of the Securities to be issued and
sold pursuant to this Agreement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) By the Company if any of the conditions set forth in Section 6.2 shall have become incapable of fulfillment, and shall not have been
waived by the Company;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) By an Investor (with respect to itself only) if any of the conditions set forth in Section 6.1 shall have become incapable of fulfillment,
and shall not have been waived by the Investor; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) By either the Company or any Investor (with respect to itself only) if the Closing has not occurred on or prior to the fifth trading
day following the date of this Agreement; provided, however, that, except in the case of clause (i) above, the party seeking to terminate
its obligation to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained
in this Agreement or the other Transaction Documents if such breach has resulted in the circumstances giving rise to such party's
seeking to terminate its obligation to effect the Closing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) In the event of termination by the Company or any Investor of its obligations to effect the Closing pursuant to this Section 6.3,
written notice thereof shall be given to the other Investors by the Company and the other Investors shall have the right to terminate
their obligations to effect the Closing upon written notice to the Company and the other Investors. Nothing in this Section 6.3 shall
be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other
Transaction Documents or to impair the right of any party to compel specific performance by any other party of its obligations under this
Agreement or the other Transaction Documents.

7. <u>Covenants and Agreements of the Company and the Investors</u>.

&nbsp;&nbsp;&nbsp;&nbsp;7.1. <u>Nasdaq Listing</u>. The Company shall promptly secure the listing of all of the Shares and Warrant Shares on Nasdaq and shall pay
all fees and expenses in connection with satisfying its obligations under this Section 7.1. The Company will use commercially reasonable
efforts to continue the listing and trading of its Common Stock on Nasdaq and, in accordance, therewith, will use commercially reasonable
efforts to comply with the Company's reporting, filing and other obligations under the bylaws or rules of such market or exchange,
as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;7.2. <u>Removal of Legends</u>. In connection with any sale or disposition of the Securities by an Investor pursuant to Rule 144 or pursuant
to any other exemption under the 1933 Act such that the purchaser acquires freely tradable shares and upon compliance by the Investor
with the requirements of this Agreement, if requested by the Investor, the Company shall cause the transfer agent for the Common Stock
(the " <u>Transfer Agent</u> ") to remove any restrictive legends related to the book entry account holding such Securities
and make a new, unlegended entry for such book entry Securities sold or disposed of without restrictive legends within two trading days
of receipt of such request, provided that the Company has received customary representations and other documentation reasonably acceptable
to the Company in connection therewith (and in the case of clause 7.2(i) below, the representation letter agreed to by EcoR1 and the Company
in connection with the execution of this Agreement shall constitute customary representations and documentation reasonably acceptable
to the Company). Subject to receipt by the Company of customary representations and other documentation reasonably acceptable to the Company
in connection therewith, upon the earlier of such time as the Securities (i) have been registered for resale pursuant to an effective
registration statement, (ii) such time as the Securities have been or are about to be sold pursuant to Rule 144, or (iii) are eligible
for resale under Rule 144(b)(1) or any successor provision, the Company shall (A) deliver to the Transfer Agent irrevocable instructions
that the Transfer Agent shall make a new, unlegended entry for such book entry Securities, and (B) cause its counsel to deliver to the
Transfer Agent one or more opinions to the effect that the removal of such legends in such circumstances may be effected under the 1933
Act. If all or any portion of a Pre-Funded Warrant is exercised at a time when there is an effective registration statement to cover the
resale of the Warrant Shares, or if such Warrant Shares may be sold under Rule 144 and the Company is then in compliance with the current
public information required under Rule 144 (assuming cashless exercise of the Pre-Funded Warrants), or if the Warrant Shares may be sold
under Rule 144 without the requirement for the Company to be in compliance with the current public information required under Rule 144
as to such Warrant Shares or if such legend is not otherwise required under applicable requirements of the Securities Act, then such Warrant
Shares shall be issued free of all legends. The Company shall be responsible for the fees of its Transfer Agent and all DTC fees associated
with such issuance.

&nbsp;&nbsp;&nbsp;&nbsp;7.3. Each Investor, severally and not jointly with the other Investors, agrees with the Company (i) that such Investor will sell any Securities
only pursuant to either the registration requirements of the 1933 Act, including any applicable prospectus delivery requirements, or an
exemption therefrom, (ii) that if Securities are sold pursuant to a registration statement, they will be sold in compliance with the plan
of distribution set forth therein and (iii) that if, after the effective date of the registration statement covering the resale of the
Securities, such registration statement ceases to be effective and the Company has provided notice to such Investor to that effect, such
Investor will sell Securities only in compliance with an exemption from the registration requirements of the 1933 Act.

&nbsp;&nbsp;&nbsp;&nbsp;7.4. <u>Short Sales and Confidentiality After the Date Hereof</u>. Each Investor covenants that neither it nor any Affiliates acting on
its behalf or pursuant to any understanding with it will execute any Short Sales during the period from the date hereof until the earlier
of such time as (i) after the transactions contemplated by this Agreement are first publicly announced or (ii) this Agreement is terminated
in full. Each Investor covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the
Company, such Investor will maintain the confidentiality of all disclosures made to it in connection with this transaction (including
the existence and terms of this transaction). Each Investor understands and acknowledges that the SEC currently takes the position that
coverage of short sales of shares of the Common Stock "against the box" prior to effectiveness of a resale registration statement
with securities included in such registration statement would be a violation of Section 5 of the 1933 Act, as set forth in Item 239.10
of the 1933 Act Rules Compliance and Disclosure Interpretations compiled by the Office of Chief Counsel, Division of Corporation Finance.

8. <u>Survival and Indemnification</u>.

&nbsp;&nbsp;&nbsp;&nbsp;8.1. <u>Survival</u>. The representations, warranties, covenants and agreements contained in this Agreement shall survive the Closing of
the transactions contemplated by this Agreement for the applicable statute of limitations.

&nbsp;&nbsp;&nbsp;&nbsp;8.2. <u>Indemnification</u>. The Company agrees to indemnify and hold harmless each Investor and its Affiliates and their respective directors,
officers, trustees, members, managers, employees and agents, and their respective successors and assigns, from and against any and all
losses, claims, damages, liabilities and expenses (including without limitation reasonable and documented attorney fees and disbursements
and other documented out-of-pocket expenses reasonably incurred in connection with investigating, preparing or defending any action, claim
or proceeding, pending or threatened and the costs of enforcement thereof) (collectively, " <u>Losses</u> ") to which such Person
may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the part
of the Company under the Transaction Documents, and will reimburse any such Person for all such amounts as they are incurred by such Person
solely to the extent such amounts have been finally judicially determined not to have resulted from such Person's fraud or willful
misconduct.

&nbsp;&nbsp;&nbsp;&nbsp;8.3. <u>Conduct of Indemnification Proceedings</u>  *.*** Any person entitled to indemnification hereunder shall (i) give prompt
written notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying
party to assume the defense of such claim with counsel reasonably satisfactory to the indemnified party; <u>provided</u> that any person
entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim,
but the fees and expenses of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed in writing
to pay such fees or expenses, (b) the indemnifying party shall have failed to assume the defense of such claim and employ counsel reasonably
satisfactory to such person or (c) in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict
of interest exists between such person and the indemnifying party with respect to such claims (in which case, if the person notifies the
indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying
party shall not have the right to assume the defense of such claim on behalf of such person); and <u>provided</u>, <u>further</u>, that
the failure of any indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its obligations
hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense
of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same
jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties.
No indemnifying party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned
or delayed, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving
by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim or litigation. No indemnified
party will, except with the consent of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed,
consent to entry of any judgment or enter into any settlement.

9. <u>Miscellaneous</u>.

&nbsp;&nbsp;&nbsp;&nbsp;9.1. <u>Successors and Assigns</u>. This Agreement may not be assigned by a party hereto without the prior written consent of the Company
or the Investors, as applicable, provided, however, that an Investor may assign its rights and delegate its duties hereunder in whole
or in part to an Affiliate or to a third party acquiring some or all of its Securities in a transaction complying with applicable securities
laws without the prior written consent of the Company or the other Investors, provided such assignee agrees in writing to be bound by
the provisions hereof that apply to Investors. The provisions of this Agreement shall inure to the benefit of and be binding upon the
respective permitted successors and assigns of the parties. Without limiting the generality of the foregoing, in the event that the Company
is a party to a merger, consolidation, share exchange or similar business combination transaction in which the Common Stock is converted
into the equity securities of another Person, from and after the effective time of such transaction, such Person shall, by virtue of such
transaction, be deemed to have assumed the obligations of the Company hereunder, the term "Company" shall be deemed to refer
to such Person and the term "Securities" shall be deemed to refer to the securities received by the Investors in connection
with such transaction. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto
or their respective permitted successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement,
except as expressly provided in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;9.2. <u>Counterparts; Faxes; E-mail</u>. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original,
but all of which together shall constitute one and the same instrument. This Agreement may also be executed via facsimile or e-mail, which
shall be deemed an original.

&nbsp;&nbsp;&nbsp;&nbsp;9.3. <u>Titles and Subtitles</u>. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;9.4. <u>Notices</u>. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall
be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given upon such
delivery, (ii) if given by facsimile or e-mail, then such notice shall be deemed given upon receipt of confirmation of complete transmittal
or confirmation of receipt of an e-mail transmission, (iii) if given by mail, then such notice shall be deemed given upon the earlier
of (A) receipt of such notice by the recipient or (B) three days after such notice is deposited in first class mail, postage prepaid,
and (iv) if given by an internationally recognized overnight air courier, then such notice shall be deemed given one Business Day after
delivery to such carrier.

All notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten days' advance written notice to the other party:

If to the Company:

Morphic Holding, Inc.

35 Gatehouse Drive, A2

Waltham, Massachusetts 02451

Attention: Chief Financial Officer

Email:

With a copy (which shall not constitute notice) to:

Fenwick & West LLP

555 California Street, 12th Floor

San Francisco, California 94104

Attention: Effie Toshav, Robert Freedman, Julia Forbess

Email:

If to the Investors:

to the addresses set forth on the signature pages hereto.

&nbsp;&nbsp;&nbsp;&nbsp;9.5. <u>Expenses</u>. The parties hereto shall pay their own costs and expenses in connection herewith regardless of whether the transactions
contemplated hereby are consummated; it being understood that each of the Company and each Investor has relied on the advice of its own
respective counsel.

&nbsp;&nbsp;&nbsp;&nbsp;9.6. <u>Amendments and Waivers</u>. Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company
and each Investor. Any amendment or waiver effected in accordance with this paragraph shall be binding upon (i) prior to Closing, each
Investor and (ii) following the Closing, each holder of any Securities purchased under this Agreement, and in each case, each future holder
of all such Securities and the Company.

&nbsp;&nbsp;&nbsp;&nbsp;9.7. <u>Publicity</u>. Except as set forth below, no press release or, except to the extent required under applicable law (in which case
the disclosing party shall use reasonable efforts to give the other party hereto an opportunity to review and comment on such disclosure
in advance of its public release), other public announcement shall be made, directly or indirectly, by either party hereto concerning
the execution of this Agreement, the terms and conditions hereof or the consummation of the transactions contemplated hereby, in each
case without the prior written consent of the other party hereto, which consent shall not be unreasonably withheld, conditioned or delayed.
By 9:30 a.m. (New York City time) on the first trading day following the date of this Agreement, the Company shall issue a press release
or file a Current Report on Form 8-K disclosing all material terms of the sale of the Securities to the Investors pursuant to this Agreement.
In addition, by 9:30 a.m. (New York City time) on February 13, 2023 (the " <u>Disclosure Date</u> "), the Company will make
such other filings and notices in the manner and time required by the SEC or Nasdaq. The Company shall not include the name of EcoR1 in
the public disclosure or any other public announcement or publication (including without limitation, press releases, the Company website
or the Company "deck") without the prior written consent of EcoR1, except as required by law, rule, regulation or applicable
SEC guidance, provided however that the parties agree and understand that EcoR1 shall be listed in the selling stockholder section of
the resale registration statement(s) filed in connection with the Securities issued to EcoR1 pursuant to this Agreement. From and after
the Disclosure Date, the Company represents to the Investors that no Investor shall be in possession of any material non-public information
received from the Company or any of their respective officers, directors, employees or agents in connection with the transactions contemplated
by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;9.8. <u>Severability</u>. Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction,
be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be
interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition
or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the
extent permitted by applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable
in any respect.

&nbsp;&nbsp;&nbsp;&nbsp;9.9. <u>Entire Agreement</u>. This Agreement, including the signature pages, Exhibits, and the other Transaction Documents constitute the
entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements and
understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof.

&nbsp;&nbsp;&nbsp;&nbsp;9.10. <u>Further Assurances</u>. The parties shall execute and deliver all such further instruments and documents and take all such other
actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements
herein contained.

&nbsp;&nbsp;&nbsp;&nbsp;9.11. <u>Governing Law; Consent to Jurisdiction; Waiver of Jury Trial</u>. This Agreement shall be governed by, and construed in accordance
with, the internal laws of the State of New York without regard to the choice of law principles thereof. Each of the parties hereto irrevocably
submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States District
Court for the Southern District of New York for the purpose of any suit, action, proceeding or judgment relating to or arising out of
this Agreement and the transactions contemplated hereby. Service of process in connection with any such suit, action or proceeding may
be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement.
Each of the parties hereto irrevocably consents to the jurisdiction of any such court in any such suit, action or proceeding and to the
laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding
brought in such courts and irrevocably waives any claim that any such suit, action or proceeding brought in any such court has been brought
in an inconvenient forum. **EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER.** 

&nbsp;&nbsp;&nbsp;&nbsp;9.12. <u>Independent Nature of Investors' Obligations and Rights</u>. The obligations of each Investor under any Transaction Document
are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance
of the obligations of any other Investor under any Transaction Document. The decision of each Investor to purchase Securities pursuant
to the Transaction Documents has been made by such Investor independently of any other Investor. Nothing contained herein or in any Transaction
Document, and no action taken by any Investor pursuant thereto, shall be deemed to constitute the Investors as a partnership, an association,
a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group
with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Investor acknowledges that no other
Investor has acted as agent for such Investor in connection with making its investment hereunder and that no Investor will be acting as
agent of such Investor in connection with monitoring its investment in the Securities or enforcing its rights under the Transaction Documents.
Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out
of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Investor to be joined as an additional
party in any proceeding for such purpose. The Company acknowledges that each of the Investors has been provided with the same Transaction
Documents for the purpose of closing a transaction with multiple Investors and not because it was required or requested to do so by any
Investor.

&nbsp;&nbsp;&nbsp;&nbsp;9.13. <u>Limitation of Liability</u>. Notwithstanding anything herein to the contrary, the Company acknowledges and agrees that the liability
of an Investor arising directly or indirectly under any Transaction Document of any and every nature whatsoever shall be satisfied solely
out of the assets of such Investor and that no trustee, officer, other investment vehicle or any other Affiliate of such Investor or any
investor, shareholder or holder of shares of beneficial interest of such Investor shall be personally liable for any liabilities of such
Investor.

[Remainder of page intentionally left blank]

IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written.

---

| | | |
|:---|:---|:---|
| COMPANY: | MORPHIC HOLDING, INC.  | MORPHIC HOLDING, INC.  |
|  | By: | /s/ Marc Schegerin |
|  |  | Name: Marc Schegerin, M.D. |
|  |  | Title: Chief Financial Officer, Chief Operating Officer |

---

[*Signature page to Securities Purchase Agreement*]

---

| | | |
|:---|:---|:---|
| INVESTOR: | EcoR1 Capital Fund, L.P.<br> By: EcoR1 Capital, LLC, its General Partner  | EcoR1 Capital Fund, L.P.<br> By: EcoR1 Capital, LLC, its General Partner  |
|  | By: | /s/ Oleg Nodelman |
|  |  | Name: Oleg Nodelman |
|  |  | Title: Manager |

---

---

| | | |
|:---|:---|:---|
| INVESTOR: | EcoR1 Capital Fund Qualified, L.P.<br> By: EcoR1 Capital, LLC, its General Partner  | EcoR1 Capital Fund Qualified, L.P.<br> By: EcoR1 Capital, LLC, its General Partner  |
|  | By: | /s/ Oleg Nodelman |
|  |  | Name: Oleg Nodelman |
|  |  | Title: Manager |

---

[*Signature page to Securities Purchase Agreement*]

---

| | | |
|:---|:---|:---|
| INVESTOR: | Timothy A. Springer  | Timothy A. Springer  |
|  | By: | /s/ Timothy A. Springer |
|  |  | Name: Timothy A. Springer |

---

---

| | | |
|:---|:---|:---|
| INVESTOR: | TAS Partners, LLC  | TAS Partners, LLC  |
|  | By: | /s/ Timothy A. Springer |
|  |  | Name: Timothy A. Springer |
|  |  | Title: Manager |

---

[*Signature page to Securities Purchase Agreement*]

**EXHIBIT A** 

**Schedule of Investors** 

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Name of Investor and <br> Address/Contact <br> Information** | **Number of <br> Shares <br> Purchased** | **Aggregate <br> Share <br> Purchase Price** | **Number of <br> Pre-Funded <br> Warrants <br> Purchased** | **Aggregate**<br> **Purchase Price**<br> **of Pre-Funded**<br> **Warrants** | **Number of <br> Securities <br> Purchased** | **Aggregate <br> Purchase Price<br> of Securities <br> Purchased** |
| **EcoR1 Capital Fund, L.P.**<br> **Address:**<br> **Telephone:**<br> **Email:**<br> **Name:** | **-** | **-** | **112871** | $**3989978.56** | **112871** | $**3989978.56** |
| **EcoR1 Capital Fund Qualified, L.P.**<br> **Address:**<br> **Telephone:**<br> **Email:**<br> **Name:** | **-** | **-** | **1867327** | $**66009822.72** | **1867327** | $**66009822.72** |
| **Timothy A. Springer**<br> **Address:**<br> **Telephone:**<br> **Email:** | **42432** | $**1499971.20** | **-** | **-** | **42432** | $**1499971.20** |
| **TAS Partners, LLC**<br> **Address:**<br> **Telephone:**<br> **Email:**<br> **Name:** | **806223** | $**28499983.05** | **-** | **-** | **806223** | $**28499983.05** |

---

**EXHIBIT B**

**Form of Pre-Funded Warrant**

[*Form of Pre-Funded Warrant separately filed*]

**EXHIBIT C** 

**Registration Rights Agreement** 

[*Form of Registration Rights Agreement separately filed*]

**EXHIBIT D** 

**Form of Investor Questionnaire** 

**MORPHIC HOLDING, INC.**

## Exhibit 10.2

**Exhibit 10.2**

**<u>REGISTRATION RIGHTS AGREEMENT</u>**

This REGISTRATION RIGHTS AGREEMENT (this "<u>Agreement</u>") is made and entered into as of February 13, 2023 by and among Morphic Holding, Inc., a Delaware corporation (the "<u>Company</u>"), and the "<u>Investors</u>" named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of the date hereof (the "<u>Purchase Agreement</u>"). Capitalized terms used herein have the respective meanings ascribed thereto in the Purchase Agreement unless otherwise defined herein.

The parties hereby agree as follows:

1) <u>Certain Definitions</u>.

As used in this Agreement, the following terms shall have the following meanings:

"<u>Automatic Shelf Registration Statement</u>" means an "automatic shelf registration statement" as defined under Rule 405.

"<u>Effectiveness Deadline</u>" means, with respect to the Registration Statement, the 30th calendar day following the Closing Date; provided, however, that if the Effectiveness Deadline falls on a Saturday, Sunday or other day that the SEC is closed for business, the Effectiveness Deadline shall be extended to the next Business Day on which the SEC is open for business.

"<u>Investors</u>" means the Investors identified in the Purchase Agreement and any Affiliate or permitted transferee of any Investor who is a subsequent holder of Registrable Securities.

"<u>Prospectus</u>" means (i) the prospectus included in any Registration Statement, as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement and by all other amendments and supplements to the prospectus, including post-effective amendments and all material incorporated by reference in such prospectus and (ii) any "free writing prospectus" as defined in Rule 405 under the 1933 Act.

"<u>Register</u>," "<u>registered</u>" and "<u>registration</u>" refer to a registration made by preparing and filing a Registration Statement or similar document in compliance with the 1933 Act, and the declaration or ordering of effectiveness of such Registration Statement or document.

"<u>Registrable Securities</u>" means (i) the Shares, (ii) all Warrant Shares then issued or issuable upon exercise of the Pre-Funded Warrants (assuming on such date the Pre-Funded Warrants are exercised in full without regard to any exercise limitations therein) and (iii) any other securities issued or issuable with respect to or in exchange for Registrable Securities, whether by merger, charter amendment or otherwise; provided, that a security shall cease to be a Registrable Security upon (A) sale pursuant to a Registration Statement or Rule 144 under the 1933 Act, or (B) such security becoming eligible for sale without restriction by the Investor pursuant to Rule 144 (assuming that all Pre-Funded Warrants are exercised by "cashless exercise" as provided in each of the Pre-Funded Warrants).

"<u>Registration Statement</u>" means any registration statement of the Company under the 1933 Act that covers the resale of any of the Registrable Securities pursuant to the provisions of this Agreement, amendments and supplements to such Registration Statement, including post-effective amendments, all exhibits and all material incorporated by reference in such Registration Statement.

"<u>Required Investors</u>" means the Investors holding a majority of the Registrable Securities outstanding from time to time.

"<u>Rule 405</u>" means Rule 405 promulgated under the 1933 Act and any successor provision.

"<u>WKSI</u>" means a "well-known seasoned issuer" as defined under Rule 405.

2) <u>Registration</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <u>Registration Statements</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Promptly following the Closing Date but no later than 30 days after
 the Closing Date (the " <u>Filing Deadline</u> "), the Company shall prepare and
 file with the SEC one Registration Statement covering the resale of all of the Registrable
 Securities. Subject to any SEC comments, such Registration Statement shall include the plan
 of distribution attached hereto as <u>Exhibit A</u>. Such Registration Statement also
 shall cover, to the extent allowable under the 1933 Act and the rules promulgated thereunder
 (including Rule 416), such indeterminate number of additional shares of Common Stock
 resulting from stock splits, stock dividends or similar transactions with respect to the
 Registrable Securities. Such Registration Statement shall not include any shares of Common
 Stock or other securities for the account of any other holder without the prior written consent
 of the Required Investors. Such Registration Statement (and each amendment or supplement
 thereto, and each request for acceleration of effectiveness thereof) shall be provided in
 accordance with Section 3(c) to the Investors prior to its filing or other submission.
 If a Registration Statement covering the Registrable Securities is not filed with the SEC
 on or prior to the Filing Deadline, the Company will make pro rata payments to each Investor,
 as liquidated damages and not as a penalty, in an amount equal to 1.0% of the aggregate amount
 invested by such Investor for each 30-day period or pro rata for any portion thereof following
 the Filing Deadline for which no Registration Statement is filed with respect to the Registrable
 Securities. Such payments shall constitute the Investors' exclusive monetary remedy
 for such events, but shall not affect the right of the Investors to seek injunctive relief.
 Such payments shall be made to each Investor in cash no later than three Business Days after
 the end of each 30-day period (the " <u>Payment Date</u> "). Interest shall accrue
 at the rate of 1% per month on any such liquidated damages payments that shall not be paid
 by the Payment Date until such amount is paid in full. The parties agree that the maximum
 aggregate liquidated damages payable to a holder of Registrable Securities under this Agreement
 shall be 5.0% of the aggregate purchase price paid by such holder pursuant to the Purchase
 Agreement for the Registrable Securities then held by such holder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) The Registration Statement referred to in Section 2(a)(i) shall
 be on Form S-3 and if the Company is a WKSI as of the filing date, the Registration
 Statement shall consist of an Automatic Shelf Registration Statement, or a prospectus supplement
 to an effective Automatic Shelf Registration Statement, that shall become effective upon
 filing with the SEC pursuant to Rule 462(e). In the event that Form S-3 is not
 available for the registration of the resale of Registrable Securities hereunder, the Company
 shall (i) register the resale of the Registrable Securities on such other form as is
 available to the Company and (ii) so long as Registrable Securities remain outstanding,
 promptly following the date upon which the Company becomes eligible to use a registration
 statement on Form S-3 to register the Registrable Securities for resale (the " <u>Qualification Date</u> "), but in no event more than 30 days after the Qualification Date (the " <u>Qualification Deadline</u> "), the Company shall file a registration statement on Form S-3 covering
 the Registrable Securities (or a post-effective amendment on Form S-3 to a registration
 statement on Form S-1) (a " <u>Shelf Registration Statement</u> "); provided
 that the Company shall maintain the effectiveness of the Registration Statement then in effect
 until such time as a Shelf Registration Statement covering the Registrable Securities has
 been declared effective by the SEC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) If at any time following the filing of a Shelf Registration Statement
 when the Company is required to re-evaluate its Form S-3 eligibility or WKSI status,
 the Company determines that it is not eligible to register the Registrable Securities on
 Form S-3 or is not a WKSI, the Company shall use its reasonable best efforts to (i) as
 promptly as possible (A) if the Shelf Registration Statement is an Automatic Shelf Registration
 Statement, post-effectively amend the Shelf Registration Statement to a Shelf Registration
 Statement that is not automatically effective or file a new Shelf Registration Statement
 on Form S-3, or (B) if the Company is not eligible at such time to file a Shelf
 Registration Statement on Form S-3, post-effectively amend the Shelf Registration Statement
 to a Shelf Registration Statement on Form S-1 or file a new Shelf Registration Statement
 on Form S-1; (ii) have such post-effective amendment or Shelf Registration Statement
 declared effective by the SEC; and (iii) keep such Shelf Registration Statement effective
 during the period during which such Shelf Registration Statement is required to be kept effective
 in accordance with this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <u>Expenses</u>. The Company will pay all reasonable expenses associated
 with the filing of any Registration Statement, including filing and printing fees, the Company's
 counsel and accounting fees and expenses, costs associated with clearing the Registrable
 Securities for sale under applicable state securities laws and listing fees, but excluding
 discounts, commissions and fees of underwriters, selling brokers, dealer managers or similar
 securities industry professionals with respect to the Registrable Securities being sold.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <u>Effectiveness</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) The Company shall use commercially reasonable efforts to have the
 Registration Statement declared effective as soon as practicable, but no later than the Effectiveness
 Deadline (it being agreed that if the Company is a WKSI as of the filing date, the Registration
 Statement shall be an Automatic Shelf Registration Statement, or a prospectus supplement
 to an effective Automatic Shelf Registration Statement, that shall become effective upon
 filing with the SEC pursuant to Rule 462(e)). The Company shall notify the Investors
 by e-mail as promptly as practicable, and in any event, on the same Business Day that any
 Registration Statement is declared effective and shall simultaneously provide the Investors
 with copies of any related Prospectus to be used in connection with the sale or other disposition
 of the securities covered thereby. If (A) a Registration Statement covering the Registrable
 Securities is not declared effective by the SEC prior to the earlier of (i) five (5) Business
 Days after the SEC informs the Company that no review of such Registration Statement will
 be made or that the SEC has no further comments on such Registration Statement or (ii) the
 Effectiveness Deadline or (B) after a Registration Statement has been declared effective
 by the SEC, sales cannot be made pursuant to such Registration Statement for any reason (including
 without limitation by reason of a stop order, or the Company's failure to update such
 Registration Statement), but excluding any Allowed Delay (as defined below), then the Company
 will make pro rata payments to each Investor then holding Registrable Securities, as liquidated
 damages and not as a penalty, in an amount equal to 1% of the aggregate amount invested by
 such Investor for each 30-day period or pro rata for any portion thereof following the date
 by which such Registration Statement should have been effective (the " <u>Blackout Period</u> ").
 Such payments shall constitute the Investors' exclusive monetary remedy for such events,
 but shall not affect the right of the Investors to seek injunctive relief. The amounts payable
 as liquidated damages pursuant to this paragraph shall be paid monthly within three Business
 Days of the last day of each month following the commencement of the Blackout Period until
 the termination of the Blackout Period (the " <u>Blackout Period Payment Date</u> ").
 Such payments shall be made to each Investor in cash. Interest shall accrue at the rate of
 1% per month on any such liquidated damages payments that shall not be paid by the Blackout
 Payment Date until such amount is paid in full.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) For not more than 30 consecutive days or for a total of not more
 than 60 days in any 12 month period, the Company may suspend the use of any Prospectus included
 in any Registration Statement contemplated by this Section 2 in the event that the Company
 determines in good faith that such suspension is necessary to (A) delay the disclosure
 of material non-public information concerning the Company, the disclosure of which at the
 time is not, in the good faith opinion of the Company, in the best interests of the Company
 or (B) amend or supplement the affected Registration Statement or the related Prospectus
 so that such Registration Statement or Prospectus shall not include an untrue statement of
 a material fact or omit to state a material fact required to be stated therein or necessary
 to make the statements therein, in the case of the Prospectus in light of the circumstances
 under which they were made, not misleading (an " <u>Allowed Delay</u> "); provided,
 that the Company shall promptly (a) notify each Investor in writing of the commencement
 of an Allowed Delay, but shall not (without the prior written consent of an Investor) disclose
 to such Investor any material non-public information giving rise to an Allowed Delay, (b) advise
 the Investors in writing to cease all sales under such Registration Statement until the end
 of the Allowed Delay and (c) use commercially reasonable efforts to terminate an Allowed
 Delay as promptly as practicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <u>Rule 415; Cutback</u>. If at any time the SEC takes the position
 that the offering of some or all of the Registrable Securities in a Registration Statement
 is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415
 under the 1933 Act or requires any Investor to be named as an "underwriter,"
 the Company shall use commercially reasonable efforts to persuade the SEC that the offering
 contemplated by such Registration Statement is a valid secondary offering and not an offering
 "by or on behalf of the issuer" as defined in Rule 415 and that none of
 the Investors is an "underwriter." The Investors shall have the right to together
 select one legal counsel designated by the holders of a majority of the Registrable Securities
 to review and oversee any registration or matters pursuant to this Section 2(d), including
 participation in any meetings or discussions with the SEC regarding the SEC's position
 and to comment on any written submission made to the SEC with respect thereto. No such written
 submission with respect to this matter shall be made to the SEC to which the Investors'
 counsel reasonably objects. In the event that, despite the Company's commercially reasonable
 efforts and compliance with the terms of this Section 2(d), the SEC refuses to alter
 its position, the Company shall (i) remove from such Registration Statement such portion
 of the Registrable Securities (the " <u>Cut Back Shares</u> ") and/or (ii) agree
 to such restrictions and limitations on the registration and resale of the Registrable Securities
 as the SEC may require to assure the Company's compliance with the requirements of
 Rule 415 (collectively, the " <u>SEC Restrictions</u> "); provided, however,
 that the Company shall not agree to name any Investor as an "underwriter" in
 such Registration Statement without the prior written consent of such Investor. Any cut-back
 imposed on the Investors pursuant to this Section 2(d) shall be allocated among
 the Investors on a pro rata basis and shall be applied first to any of the Registrable Securities
 of such Investor as such Investor shall designate, unless the SEC Restrictions otherwise
 require or provide or the Investors otherwise agree. No liquidated damages shall accrue as
 to any Cut Back Shares until such date as the Company is able to effect the registration
 of such Cut Back Shares in accordance with any SEC Restrictions applicable to such Cut Back
 Shares (such date, the " <u>Restriction Termination Date</u> "). In furtherance
 of the foregoing, each Investor shall provide the Company with prompt written notice of its
 sale of substantially all of the Registrable Securities under such Registration Statement
 such that the Company will be able to file one or more additional Registration Statements
 covering the Cut Back Shares. From and after the Restriction Termination Date applicable
 to any Cut Back Shares, all of the provisions of this Section 2 (including the Company's
 obligations with respect to the filing of a Registration Statement and its obligations to
 use commercially reasonable efforts to have such Registration Statement declared effective
 within the time periods set forth herein and the liquidated damages provisions relating thereto)
 shall again be applicable to such Cut Back Shares; provided, however, that (i) the Filing
 Deadline and/or the Qualification Deadline, as applicable, for such Registration Statement
 including such Cut Back Shares shall be 10 Business Days after such Restriction Termination
 Date, and (ii) the date by which the Company is required to obtain effectiveness with
 respect to such Cut Back Shares shall be the 120th day immediately after the Restriction
 Termination Date.

3) <u>Company Obligations</u>. The Company will use commercially reasonable efforts to effect the registration of the Registrable Securities in accordance with the terms hereof, and pursuant thereto the Company will, as expeditiously as possible:

&nbsp;&nbsp;&nbsp;&nbsp;a) use commercially reasonable efforts to cause such Registration Statement
 to become effective and to remain continuously effective for a period that will terminate
 upon the earlier of (i) the date on which all Registrable Securities covered by such
 Registration Statement as amended from time to time, have been sold, and (ii) the date
 on which all Registrable Securities covered by such Registration Statement may be sold without
 restriction pursuant to Rule 144 (the " <u>Effectiveness Period</u> ") and
 advise the Investors promptly in writing when the Effectiveness Period has expired;

&nbsp;&nbsp;&nbsp;&nbsp;b) prepare and file with the SEC such amendments and post-effective
 amendments to such Registration Statement and the related Prospectus as may be necessary
 to keep such Registration Statement effective for the Effectiveness Period and to comply
 with the provisions of the 1933 Act and the 1934 Act, with respect to the distribution of
 all of the Registrable Securities covered thereby;

&nbsp;&nbsp;&nbsp;&nbsp;c) provide copies to and permit any counsel designated by the Investors
 to review each Registration Statement and all amendments and supplements thereto no fewer
 than two days prior to their filing with the SEC and not file any document to which such
 counsel reasonably objects;

&nbsp;&nbsp;&nbsp;&nbsp;d) furnish to each Investor whose Registrable Securities are included
 in any Registration Statement (i) promptly after the same is prepared and filed with
 the SEC, if requested by the Investor, one copy of any Registration Statement and any amendment
 thereto, each preliminary prospectus and Prospectus and each amendment or supplement thereto,
 and each letter written by or on behalf of the Company to the SEC or the staff of the SEC,
 and each item of correspondence from the SEC or the staff of the SEC, in each case relating
 to such Registration Statement (other than any portion of any thereof which contains information
 for which the Company has sought confidential treatment), and (ii) such number of copies
 of a Prospectus, including a preliminary prospectus, and all amendments and supplements thereto
 and such other documents as each Investor may reasonably request in order to facilitate the
 disposition of the Registrable Securities owned by such Investor;

&nbsp;&nbsp;&nbsp;&nbsp;e) use commercially reasonable efforts to (i) prevent the issuance
 of any stop order or other suspension of effectiveness and, (ii) if such order is issued,
 obtain the withdrawal of any such order at the earliest practical moment;

&nbsp;&nbsp;&nbsp;&nbsp;f) prior to any public offering of Registrable Securities, use commercially
 reasonable efforts to register or qualify or cooperate with the Investors and their counsel
 in connection with the registration or qualification of such Registrable Securities for the
 offer and sale under the securities or blue sky laws of such jurisdictions requested by the
 Investors and do any and all other commercially reasonable acts or things necessary or advisable
 to enable the distribution in such jurisdictions of the Registrable Securities covered by
 the Registration Statement; provided, however, that the Company shall not be required in
 connection therewith or as a condition thereto to (i) qualify to do business in any
 jurisdiction where it would not otherwise be required to qualify but for this Section 3(f),
 (ii) subject itself to general taxation in any jurisdiction where it would not otherwise
 be so subject but for this Section 3(f), or (iii) file a general consent to service
 of process in any such jurisdiction;

&nbsp;&nbsp;&nbsp;&nbsp;g) use commercially reasonable efforts to cause all Registrable Securities
 covered by a Registration Statement to be listed on each securities exchange, interdealer
 quotation system or other market on which similar securities issued by the Company are then
 listed;

&nbsp;&nbsp;&nbsp;&nbsp;h) promptly notify the Investors, at any time prior to the end of the
 Effectiveness Period, upon discovery that, or upon the happening of any event as a result
 of which, the Prospectus includes an untrue statement of a material fact or omits to state
 any material fact required to be stated therein or necessary to make the statements therein
 not misleading in light of the circumstances then existing, and promptly prepare, file with
 the SEC and furnish to such holder a supplement to or an amendment of such Prospectus as
 may be necessary so that such Prospectus shall not include an untrue statement of a material
 fact or omit to state a material fact required to be stated therein or necessary to make
 the statements therein not misleading in light of the circumstances then existing;

&nbsp;&nbsp;&nbsp;&nbsp;i) otherwise use commercially reasonable efforts to comply with all
 applicable rules and regulations of the SEC under the 1933 Act and the 1934 Act, including,
 without limitation, (i) Rule 172 under the 1933 Act, file any final Prospectus,
 including any supplement or amendment thereof, with the SEC pursuant to Rule 424 under
 the 1933 Act, (ii) promptly inform the Investors in writing if, at any time during the
 Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172
 and, as a result thereof, the Investors are required to deliver a Prospectus in connection
 with any disposition of Registrable Securities and take such other actions as may be reasonably
 necessary to facilitate the registration of the Registrable Securities hereunder, (iii) and
 make available to its security holders, as soon as reasonably practicable, but not later
 than the Availability Date (as defined below), an earnings statement covering a period of
 at least 12 months, beginning after the effective date of each Registration Statement, which
 earnings statement shall satisfy the provisions of Section 11(a) of the 1933 Act,
 including Rule 158 promulgated thereunder (for the purpose of this Section 3(i),
 " <u>Availability Date</u> " means the 45th day following the end of the fourth
 fiscal quarter that includes the effective date of such Registration Statement, except that,
 if such fourth fiscal quarter is the last quarter of the Company's fiscal year, " <u>Availability Date</u> " means the 90th day after the end of such fourth fiscal quarter); and

&nbsp;&nbsp;&nbsp;&nbsp;j) with a view to making available to the Investors the benefits of
 Rule 144 (or its successor rule) and any other rule or regulation of the SEC that
 may at any time permit the Investors to sell shares of Common Stock to the public without
 registration, the Company covenants and agrees to: (i) make and keep public information
 available, as those terms are understood and defined in Rule 144, until the earlier
 of (A) six months after such date as all of the Registrable Securities may be sold without
 restriction by the holders thereof pursuant to Rule 144 or any other rule of similar
 effect or (B) such date as all of the Registrable Securities shall have been resold;
 (ii) file with the SEC in a timely manner all reports and other documents required of
 the Company under the 1934 Act; and (iii) furnish to each Investor upon request, as
 long as such Investor owns any Registrable Securities, (A) a written statement by the
 Company that it has complied with the reporting requirements of the 1934 Act, (B) a
 copy of the Company's most recent Annual Report on Form 10-K or Quarterly Report
 on Form 10-Q, and (C) such other information as may be reasonably requested in
 order to avail such Investor of any rule or regulation of the SEC that permits the selling
 of any such Registrable Securities without registration.

4) <u>Obligations of the Investors</u>.

&nbsp;&nbsp;&nbsp;&nbsp;a) Each Investor shall furnish in writing to the Company such information
 regarding itself, the Registrable Securities held by it and the intended method of disposition
 of the Registrable Securities held by it, as shall be reasonably required to effect the registration
 of such Registrable Securities and shall execute such documents in connection with such registration
 as the Company may reasonably request. At least five Business Days prior to the first anticipated
 filing date of any Registration Statement, the Company shall notify each Investor of the
 information the Company requires from such Investor if such Investor elects to have any of
 the Registrable Securities included in such Registration Statement. An Investor shall provide
 such information to the Company at least two Business Days prior to the first anticipated
 filing date of such Registration Statement if such Investor elects to have any of the Registrable
 Securities included in such Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;b) Each Investor, by its acceptance of the Registrable Securities, agrees
 to cooperate with the Company as reasonably requested by the Company in connection with the
 preparation and filing of a Registration Statement hereunder, unless such Investor has notified
 the Company in writing of its election to exclude all of its Registrable Securities from
 such Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;c) Each Investor agrees that, upon receipt of any notice from the Company
 of either (i) the commencement of an Allowed Delay pursuant to Section 2(c)(ii) or
 (ii) the happening of an event pursuant to Section 3(h) hereof, such Investor
 will immediately discontinue disposition of Registrable Securities pursuant to any Registration
 Statement covering such Registrable Securities, until the Investor is advised by the Company
 that such dispositions may again be made, provided that each Investor may deliver shares
 to settle trades placed prior to receipt of such notice from the Company.

5) <u>Indemnification</u>.

&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Indemnification by the Company</u>. The Company will indemnify
 and hold harmless each Investor and its officers, directors, members, employees, investment
 advisers and agents, successors and assigns, and each other person, if any, who controls
 such Investor within the meaning of the 1933 Act, against any losses, claims, damages or
 liabilities, joint or several, or any other amounts, to which they may become subject under
 the 1933 Act or otherwise, insofar as such losses, claims, damages or liabilities (or actions
 in respect thereof) arise out of or are based upon: (x) any untrue statement or alleged
 untrue statement or omission or alleged omission of any material fact contained in any Registration
 Statement, any preliminary Prospectus or final Prospectus, or any amendment or supplement
 thereof or (y) any violation or alleged violation by the Company of the Securities Act,
 Exchange Act or any state securities law or any rule or regulation thereunder, in connection
 with the performance of its obligations under this Agreement and, in each case, will reimburse
 such Investor, and each such officer, director or member and each such controlling person
 for any legal or other documented, out-of-pocket expenses reasonably incurred by them in
 connection with investigating or defending any such loss, claim, damage, liability or action; <u>provided</u>, <u>however</u>, that the Company will not be liable in any such case if
 and to the extent that any such loss, claim, damage or liability arises out of or is based
 upon (i) an untrue statement or alleged untrue statement or omission or alleged omission
 so made in conformity with information furnished by such Investor or any such controlling
 person in writing specifically for use in such Registration Statement or Prospectus, or (ii) the
 use by an Investor of an outdated or defective Prospectus after the Company has notified
 such Investor in writing that such Prospectus is outdated or defective.

&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Indemnification by the Investors</u>. Each Investor agrees, severally
 but not jointly, to indemnify and hold harmless, to the fullest extent permitted by law,
 the Company, its directors, officers, employees, stockholders and each person who controls
 the Company (within the meaning of the 1933 Act) against any losses, claims, damages, liabilities
 and expense (including reasonable attorney fees) resulting from any untrue statement of a
 material fact or any omission of a material fact required to be stated in any Registration
 Statement or Prospectus or preliminary Prospectus or amendment or supplement thereto or necessary
 to make the statements therein not misleading, to the extent, but only to the extent that
 such untrue statement of material fact or omission is contained in any information furnished
 in writing by such Investor to the Company specifically for inclusion in such Registration
 Statement or Prospectus or amendment or supplement thereto. In no event shall the liability
 of an Investor be greater in amount than the dollar amount of the proceeds received by such
 Investor upon the sale of the Registrable Securities included in such Registration Statement
 giving rise to such indemnification obligation.

&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Conduct of Indemnification Proceedings</u>. Any person entitled
 to indemnification hereunder shall (i) give prompt written notice to the indemnifying
 party of any claim with respect to which it seeks indemnification and (ii) permit such
 indemnifying party to assume the defense of such claim with counsel reasonably satisfactory
 to the indemnified party; provided that any person entitled to indemnification hereunder
 shall have the right to employ separate counsel and to participate in the defense of such
 claim, but the fees and expenses of such counsel shall be at the expense of such person unless
 (a) the indemnifying party has agreed in writing to pay such fees or expenses, (b) the
 indemnifying party shall have failed to assume the defense of such claim and employ counsel
 reasonably satisfactory to such person or (c) in the reasonable judgment of any such
 person, based upon written advice of its counsel, a conflict of interest exists between such
 person and the indemnifying party with respect to such claims (in which case, if the person
 notifies the indemnifying party in writing that such person elects to employ separate counsel
 at the expense of the indemnifying party, the indemnifying party shall not have the right
 to assume the defense of such claim on behalf of such person); and provided, further that
 the failure of any indemnified party to give written notice as provided herein shall not
 relieve the indemnifying party of its obligations hereunder, except to the extent that such
 failure to give notice shall materially adversely affect the indemnifying party in the defense
 of any such claim or litigation. It is understood that the indemnifying party shall not,
 in connection with any proceeding in the same jurisdiction, be liable for fees or expenses
 of more than one separate firm of attorneys at any time for all such indemnified parties.
 No indemnifying party will, except with the consent of the indemnified party, consent to
 entry of any judgment or enter into any settlement that does not include as an unconditional
 term thereof the giving by the claimant or plaintiff to such indemnified party of a release
 from all liability in respect of such claim or litigation.

&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Contribution</u>. If for any reason the indemnification provided
 for in the preceding paragraphs (a) and (b) is unavailable to an indemnified party
 or insufficient to hold it harmless, other than as expressly specified therein, then the
 indemnifying party shall contribute to the amount paid or payable by the indemnified party
 as a result of such loss, claim, damage or liability in such proportion as is appropriate
 to reflect the relative fault of the indemnified party and the indemnifying party, as well
 as any other relevant equitable considerations. No person guilty of fraudulent misrepresentation
 within the meaning of Section 11(f) of the 1933 Act shall be entitled to contribution
 from any person not guilty of such fraudulent misrepresentation. In no event shall the aggregate
 liability a holder of Registrable Securities under this Section 5(d) and Section 5(b) be
 greater in amount than the dollar amount of the net proceeds received by it upon the sale
 of the Registrable Securities giving rise to such contribution obligation. The amount paid
 or payable by a party as a result of the losses or other liabilities referred to above shall
 be deemed to include, subject to the limitations set forth in Section 5(a), 5(b) and
 5(c), any legal or other fees, charges or expenses reasonably incurred by such party in connection
 with any investigation or proceeding. The parties agree that it would not be just and equitable
 if contribution pursuant to this Section 5(d) were determined by pro rata allocation
 or by any other method of allocation, which does not take account of the equitable considerations
 referred to in this Section 5(d).

6) <u>Miscellaneous</u>.

&nbsp;&nbsp;&nbsp;&nbsp;a) <u>Effective Date</u>. This Agreement shall be effective as of the
 Closing Date, and if the Closing Date has not occurred on or prior to the fifth trading day
 following the date of the Purchase Agreement, unless otherwise mutually agreed, then this
 Agreement shall be null and void.

&nbsp;&nbsp;&nbsp;&nbsp;b) <u>Amendments and Waivers</u>. This Agreement may be amended only
 by a writing signed by the Company and each Investor then holding Registrable Securities;
 provided that any such amendment treats all Investors equally. The Company may take any action
 herein prohibited, or omit to perform any act herein required to be performed by it, only
 if the Company shall have obtained the written consent to such amendment, action or omission
 to act, of each Investor then holding Registrable Securities.

&nbsp;&nbsp;&nbsp;&nbsp;c) <u>Notices</u>. All notices and other communications provided for
 or permitted hereunder shall be made as set forth in Section 9.4 of the Purchase Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;d) <u>Assignments and Transfers by Investors</u>. The provisions of
 this Agreement shall be binding upon and inure to the benefit of the Investors and their
 respective successors and assigns. An Investor may transfer or assign, in whole or from time
 to time in part, to one or more persons its rights hereunder in connection with the transfer
 of Registrable Securities by such Investor to such person, provided that such Investor complies
 with all laws applicable thereto, and the provisions of the Purchase Agreement, and provides
 written notice of assignment to the Company promptly after such assignment is effected, and
 such person agrees in writing to be bound by all of the provisions contained herein.

&nbsp;&nbsp;&nbsp;&nbsp;e) <u>Assignments and Transfers by the Company</u>. This Agreement may
 not be assigned by the Company (whether by operation of law or otherwise) without the prior
 written consent of the Required Investors, provided, however, that in the event that the
 Company is a party to a merger, consolidation, share exchange or similar business combination
 transaction in which the Common Stock is converted into the equity securities of another
 Person, from and after the effective time of such transaction, such Person shall, by virtue
 of such transaction, be deemed to have assumed the obligations of the Company hereunder,
 the term "Company" shall be deemed to refer to such Person and the term "Registrable
 Securities" shall be deemed to include the securities received by the Investors in
 connection with such transaction unless such securities are otherwise freely tradable by
 the Investors after giving effect to such transaction.

&nbsp;&nbsp;&nbsp;&nbsp;f) <u>Benefits of the Agreement</u>. The terms and conditions of this
 Agreement shall inure to the benefit of and be binding upon the respective permitted successors
 and assigns of the parties. Nothing in this Agreement, express or implied, is intended to
 confer upon any party other than the parties hereto or their respective successors and assigns
 any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except
 as expressly provided in this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;g) <u>Counterparts; Faxes</u>. This Agreement may be executed in two
 or more counterparts, each of which shall be deemed an original, but all of which together
 shall constitute one and the same instrument. This Agreement may also be executed electronically,
 which shall be deemed an original.

&nbsp;&nbsp;&nbsp;&nbsp;h) <u>Titles and Subtitles</u>. The titles and subtitles used in this
 Agreement are used for convenience only and are not to be considered in construing or interpreting
 this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;i) <u>Severability</u>. Any provision of this Agreement that is prohibited
 or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the
 extent of such prohibition or unenforceability without invalidating the remaining provisions
 hereof but shall be interpreted as if it were written so as to be enforceable to the maximum
 extent permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction
 shall not invalidate or render unenforceable such provision in any other jurisdiction. To
 the extent permitted by applicable law, the parties hereby waive any provision of law which
 renders any provisions hereof prohibited or unenforceable in any respect.

&nbsp;&nbsp;&nbsp;&nbsp;j) <u>Further Assurances</u>. The parties shall execute and deliver
 all such further instruments and documents and take all such other actions as may reasonably
 be required to carry out the transactions contemplated hereby and to evidence the fulfillment
 of the agreements herein contained.

&nbsp;&nbsp;&nbsp;&nbsp;k) <u>Entire Agreement</u>. This Agreement is intended by the parties
 as a final expression of their agreement and intended to be a complete and exclusive statement
 of the agreement and understanding of the parties hereto in respect of the subject matter
 contained herein. This Agreement supersedes all prior agreements and understandings between
 the parties with respect to such subject matter.

&nbsp;&nbsp;&nbsp;&nbsp;l) <u>Governing Law; Consent to Jurisdiction; Waiver of Jury Trial</u>.
 This Agreement shall be governed by, and construed in accordance with, the internal laws
 of the State of New York without regard to the choice of law principles thereof. Each of
 the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the
 State of New York located in New York County and the United States District Court for the
 Southern District of New York for the purpose of any suit, action, proceeding or judgment
 relating to or arising out of this Agreement and the transactions contemplated hereby. Service
 of process in connection with any such suit, action or proceeding may be served on each party
 hereto anywhere in the world by the same methods as are specified for the giving of notices
 under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction
 of any such court in any such suit, action or proceeding and to the laying of venue in such
 court. Each party hereto irrevocably waives any objection to the laying of venue of any such
 suit, action or proceeding brought in such courts and irrevocably waives any claim that any
 such suit, action or proceeding brought in any such court has been brought in an inconvenient
 forum. EACH OF THE PARTIES HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION
 WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY
 AS TO THIS WAIVER.

[remainder of page intentionally left blank]

IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written.

---

| | | |
|:---|:---|:---|
| COMPANY: | Morphic Holding, Inc. | Morphic Holding, Inc. |
|  | By: | /s/ Marc Schegerin |
|  |  | Name: Marc Schegerin, M.D. |
|  |  | Title: Chief Financial Officer, Chief Accounting Officer |

---

[*Signature page to Registration Rights Agreement*]

---

| | | |
|:---|:---|:---|
| INVESTOR: | EcoR1 Capital Fund, L.P.<br> By: EcoR1 Capital, LLC, its General Partner | EcoR1 Capital Fund, L.P.<br> By: EcoR1 Capital, LLC, its General Partner |
|  | By: | /s/ Oleg Nodelman |
|  |  | Name: Oleg Nodelman |
|  |  | Title: Manager |
| INVESTOR: | EcoR1 Capital Fund Qualified, L.P.<br> By: EcoR1 Capital, LLC, its General Partner | EcoR1 Capital Fund Qualified, L.P.<br> By: EcoR1 Capital, LLC, its General Partner |
|  | By: | /s/ Oleg Nodelman |
|  |  | Name: Oleg Nodelman |
|  |  | Title: Manager |

---

[*Signature page to Registration Rights Agreement*]

---

| | | |
|:---|:---|:---|
| INVESTOR: | Timothy A. Springer | Timothy A. Springer |
|  | By: | /s/ Timothy A. Springer |
|  |  | Name: Timothy A. Springer |
| INVESTOR: | TAS Partners, LLC | TAS Partners, LLC |
|  | By: | /s/ Timothy A. Springer |
|  |  | Name: Timothy A. Springer |
|  |  | Title: Manager |

---

[*Signature page to Registration Rights Agreement*]

**<u>Exhibit A</u>**

**Plan of Distribution**

We are registering the shares of common stock to permit the resale of these shares of common stock by the holders of the common stock from time to time after the date of this prospectus. We will not receive any of the proceeds from the sale by the selling stockholders of the shares of common stock. We will bear all fees and expenses incident to our obligation to register the shares of common stock, except that, if the shares of common stock are sold through underwriters or broker-dealers, the selling stockholders will be responsible for underwriting discounts or commissions or agent's commissions.

The selling stockholders may sell all or a portion of the shares of our common stock beneficially owned by them and offered hereby from time to time directly or through one or more underwriters, broker-dealers or agents. The shares of common stock may be sold in one or more transactions at fixed prices, at prevailing market prices at the time of the sale, at varying prices determined at the time of sale, or at negotiated prices. These sales may be effected in transactions, which may involve crosses or block transactions,

· on any
 national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale;

· in the
 over-the-counter market;

· in transactions
 otherwise than on these exchanges or systems or in the over-the-counter market;

· through
 the writing of options, whether such options are listed on an options exchange or otherwise;

· ordinary
 brokerage transactions and transactions in which the broker-dealer solicits purchasers;

· block
 trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as
 principal to facilitate the transaction;

· purchases
 by a broker-dealer as principal and resale by the broker-dealer for its account;

· distributions
 to members, partners, stockholders or other equityholders of the selling stockholders;

· an exchange
 distribution in accordance with the rules of the applicable exchange;

· privately
 negotiated transactions;

· short
 sales;

· sales
 pursuant to Rule 144 of the Securities Act;

· broker-dealers
 may agree with the selling stockholder to sell a specified number of such shares at a stipulated price per share;

· a combination
 of any such methods of sale; and

· any other
 method permitted pursuant to applicable law.

If the selling stockholders effect such transactions by selling shares of our common stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or agents may receive commissions in the form of discounts, concessions or commissions from the selling stockholders or commissions from purchasers of the shares of our common stock for whom they may act as agent or to whom they may sell as principal (which discounts, concessions or commissions as to particular underwriters, broker-dealers or agents may be in excess of those customary in the types of transactions involved). In connection with sales of the shares of our common stock or otherwise, the selling stockholders may enter into hedging transactions with broker-dealers, which may in turn engage in short sales of the shares of our common stock in the course of hedging in positions they assume. The selling stockholders may also sell shares of our common stock short and deliver shares of our common stock covered by this prospectus to close out short positions and to return borrowed shares in connection with such short sales. The selling stockholders may also loan or pledge shares of our common stock to broker-dealers that in turn may sell such shares.

The selling stockholders may pledge or grant a security interest in some or all of the shares of our common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time pursuant to this prospectus or other applicable provisions of the Securities Act, amending, if necessary, the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer and donate the shares of our common stock in other circumstances in which case the transferees, donees, pledgees or other successors in interest will be the selling beneficial owners for purposes of this prospectus.

The selling stockholders and any broker-dealer participating in the distribution of the shares of our common stock may be deemed to be "underwriters" within the meaning of the Securities Act, and any commission paid, or any discounts or concessions allowed to, any such broker-dealer may be deemed to be underwriting commissions or discounts under the Securities Act. At the time a particular offering of the shares of our common stock is made, a prospectus supplement, if required, will be distributed which will set forth the aggregate amount of shares of our common stock being offered and the terms of the offering, including the name or names of any broker-dealers or agents, any discounts, commissions and other terms constituting compensation from the selling stockholders and any discounts, commissions or concessions allowed or reallowed or paid to broker-dealers.

Under the securities laws of some states, the shares of our common stock may be sold in such states only through registered or licensed brokers or dealers. In addition, in some states the shares of our common stock may not be sold unless such shares have been registered or qualified for sale in such state or an exemption from registration or qualification is available and is complied with.

There can be no assurance that any selling stockholder will sell any or all of the shares of our common stock registered pursuant to the registration statement, of which this prospectus forms a part.

The selling stockholders and any other person participating in such distribution will be subject to applicable provisions of the Exchange Act, and the rules and regulations thereunder, including, without limitation, Regulation M of the Exchange Act, which may limit the timing of purchases and sales of any of the shares of our common stock by the selling stockholders and any other participating person. Regulation M may also restrict the ability of any person engaged in the distribution of the shares of our common stock to engage in market-making activities with respect to the shares of our common stock. All of the foregoing may affect the marketability of the shares of our common stock and the ability of any person or entity to engage in market-making activities with respect to the shares of our common stock.

We will pay all expenses of the registration of the shares of our common stock pursuant to the registration statement of which this prospectus forms a part, including, without limitation, SEC filing fees and expenses of compliance with state securities or "blue sky" laws; provided, however, that the selling stockholders will pay all underwriting discounts and selling commissions, if any. We will indemnify the selling stockholders against liabilities, including some liabilities under the Securities Act, or the selling stockholders will be entitled to contribution. We may be indemnified by the selling stockholders against civil liabilities, including liabilities under the Securities Act, that may arise from any written information furnished to us by the selling stockholder specifically for use in this prospectus or we may be entitled to contribution.

Once sold under the registration statement of which this prospectus forms a part, the shares of our common stock will be freely tradable in the hands of persons other than our affiliates.